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Abstract 
Serum autoantibodies directed towards a wide range of single glycosphingolipids, 
especially gangliosides, in humans with autoimmune peripheral neuropathies 
have been extensively investigated since the 1980s and these are widely 
measured both in clinical practice and research. It has been recently 
appreciated that glycosphingolipid and lipid complexes, formed from 2 or more 
individual components, can interact to create molecular shapes capable of being 
recognised by autoantibodies that do not bind the individual components. 
Conversely, 2 glycosphingolipids may interact to form a heteromeric complex 
that inhibits binding of an antibody known to bind one of the partners. As a 
result of this, previously undiscovered autoantibodies have been identified, 
providing substantial new insights into disease pathogenesis and diagnostic 
testing. In particular, this newly-termed ‘combinatorial glycomic’ approach has 
provided the impetus to redesigning the assay methodologies traditionally used 
in the neuropathy-associated autoantibody field. Combinatorial glycoarrays can 
be readily constructed in house using any lipids and glycosphingolipids of 
interest, and as a result many new antibody specificities to gangliosides and 
other glycosphingolipid complexes are being discovered in neuropathy subjects. 
Herein we also highlight the role of the neutral lipids cholesterol and 
galactocerebroside in modifying glycosphingolipid orientation as two critical 
components of the molecular topography of target membranes in nerves that 
might favour or inhibit autoantibody binding. 
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1 Chapter 1. Introduction 
1.1 Lipids 
Lipids were first identified in 1673 by Tachenius Otto who suggested that an acid 
compound was hidden in fat since the strength of alkali disappeared when 
making soap. Lipids were then defined as fatty acids and their derivatives, and 
substances related biosynthetically or functionally to these compounds. 
We now know that lipids are crucial elements of the eukaryotic cell, 
approximately 5% of their genes being occupied directly or indirectly in lipid 
synthesis (van et al. 2008), making them capable of generating more than 9,000 
different molecular species that actively contribute to crucial cellular activities 
(van, Voelker, & Feigenson 2008). Lipids can be sub-divided into different groups 
including: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol 
lipids, prenol lipids, saccharolipids and polyketides (Degroote et al. 2004). Each 
of these groups will fulfil a different general function in the eukaryotic cell for 
example triacylglycerols and steryl esters act in energy storage due to their 
relatively reduced state, whereas polar lipids are involved in conformation of 
cellular membranes or acting as first and second messengers in signal 
transduction (Spiegel et al. 1996).  
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Table 1.1. Milestones in lipid research. 
From the first description of lipids to the fluid mosaic model. 
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1.1.1 Lipids and cell activity 
From the expanding list of cellular activities in which lipids are involved signal 
transduction and receptor modulation are possibly the main ones.  
Lipids have been described as first and secondary messengers in several studies 
(Carlson et al. 1994;Spiegel, Foster, & Kolesnick 1996). The process of lipid 
degradation is involved in signalling within the cell membrane by the action of 
hydrophobic lipid portions or in the case of soluble portions of the lipid molecule 
through the cytosol (van, Voelker, & Feigenson 2008). As first and secondary 
messengers lipids can regulate cellular activities and modulate receptor 
activation. An example of lipid-mediated receptor modulation is the close 
interaction of sphingolipids and cholesterol with ligand-gated ion channels and G 
protein-coupled receptors (eg. acetylcholine and serotonin receptors) which can 
lead to a major change in the receptor conformation therefore directly 
regulating its functionality (Fantini and Barrantes 2009). These receptors in the 
form of integral membrane proteins would be directly affected by the lipid 
environment serving as a receptor regulatory system. 
1.1.2 Lipids and cell membrane structure 
Although the content of lipids and variety of lipid species in cells can vary from 
tissue to tissue the major structural lipids in eukaryotic membranes are the 
glycerophospholipids including phosphatidylcholine (pc), 
phosphatidylethanolamine (pe), phosphatidylserine (ps), phosphatidylinositol (pi) 
and phosphatidic acid (pa). 
Another less abundant class of structural lipids are the sphingolipids. These lipids 
are composed of a common backbone of ceramide (cer) which by addition of a 
sugar based head group forms glycosphingolipids (GSLs) the most common being 
galactose (galactosylceramide), sulphated galactose (sulfatide) or glucose 
(glucosylceramide).  
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Figure 1.1. Structure of representative sterols and GSLs. 
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1.1.3 Gangliosides 
Another highly relevant group of GSLs are the gangliosides. Gangliosides firstly 
described and named by Ernst Klenk in 1942 (Klenk 1970) are GSLs with terminal 
sialic acids and are mainly found in vertebrate peripheral nervous system (PNS) 
and central nervous system (CNS) tissue. The content and quantification of 
gangliosides in brain was first reported by Svennerholm and co-workers in 1956 
establishing the relevance of these GSLs (Svennerholm 1956a;Svennerholm 
1956b). In later studies the amount of ganglioside in both PNS and CNS tissue 
was established as 10% to 12% of the overall lipid content (Gong et al. 
2002;Tettamanti et al. 1973a;Tettamanti et al. 1973b).  
Chemically, gangliosides are defined as amphipathic molecules containing both a 
hydrophobic and a hydrophilic fraction. This ambivalent nature determines the 
way they are displayed within the lipid membrane. The carbohydrate moiety of 
the molecule protrudes into the exoplasmic surface of the cell membrane with 
the ceramide tail anchored within the membrane bilayer (Sonnino et al. 2007). 
Gangliosides are classified according to the profile of sugars attached to the 
ceramide tail (Figure 1.2 A) a system of nomenclature first described by 
Svennerholm. This nomenclature designates an initial G indicating gangliosides, 
followed by the number of sialic acid residues (M=1, D=2, T=3 and Q=4) and the 
length of the carbohydrate sequence expressed as five minus the number of 
residues. The final part corresponded to the isomeric form of the sialic acid 
residues as a, b or c (svennerholm 1994). So, as an example, GM1b (Figure 1.2 B) 
would refer to a ganglioside , containing one sialic acid molecule, with 4 carbon 
residues and the sialic acid in conformation b. 
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A 
 
B 
 
 
 
Figure 1.2. Structure and biosynthetic pathway of gangliosides. 
A. Ganglioside biosynthetic pathway (adapted from (Rinaldi and Willison 2008)). B. GM1 
ganglioside structure containing Galactose (Gal), Glucose (Glc), N-Acetylgalactosamine (GalNAc) 
and Neuraminic acid (NeuNAc).  
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The synthesis of gangliosides within the Golgi apparatus consists of the 
sequential addition of sialic acids and saccharide polymers. The addition of 
these molecules is catalysed by and dependent on a series of specific 
glycotransferases listed in Table 1.2. 
Table 1.2. Enzymes involved in the biosynthetic pathway of gangliosides 
 
 
1.2 Domain organization and Membrane Rafts 
The lateral organization of biomembranes has become a recurrent topic of 
discussion since the fluid mosaic model postulated by Singer and Nicolson in 1972 
(Singer and Nicolson 1972) was challenged by the “lipid rafts” model. However, 
due to the heterogeneity and diversity of the field of lipid research, a clear and 
common definition for “lipid raft” was still the main challenge. It was not until 
the Keystone symposium on lipid rafts and cell function which took place on 
March 2006 that the research community agreed on one consistent definition for 
“lipid raft”. First the terminology “lipid raft” was discarded in favour of the 
term “membrane raft” due to the fact that the formation of these domains was 
not exclusively determined by lipids but by a cooperative contribution of lipids 
and proteins. These “membrane rafts” were then defined as “small (10-200 nm), 
heterogeneous, highly dynamic, sterol- and sphingolipid-enriched domains that 
compartmentalize cellular processes. Small rafts can sometimes be stabilized to 
form larger platforms through protein-protein and protein-lipid interactions” 
(Munro 2003). This definition introduced the necessity of establishing the key 
molecules intervening in raft formation, trying to elucidate the nature of their 
lateral organization and interactions within the domain thus opening a new line 
of research, lipidomics.  
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The road to defining membrane rafts and realising their implications has been a 
long one. The first studies in the early 1970s served as preliminary evidences of 
the existence of membrane rafts and their composition; some of these described 
the tendency of cholesterol (Chol) and sphingolipids to preferentially interact 
with each other (Oldfield and Chapman 1971;Oldfield and Chapman 1972). These 
results complemented data obtained from x-ray diffraction and polarized light 
studies of the myelin sheath of nerve suggesting that chol molecules complex 
with phospholipids and/or cerebrosides (Finean 1954a;Finean 1954b). However, 
it was not until later that the presence and composition of these platforms in 
cell membranes was confirmed; the results of the study showed that the 
solubilisation of cell membranes at 4ºC by non-ionic detergents such as Triton X-
100 results in two clearly defined fractions: a detergent-resistant membrane 
fraction (DRM) rich in sphingolipids and chol and a detergent-soluble fraction, 
suggesting the DRM as a membrane raft domain (Simons and Ikonen 1997). 
Although the conclusions extracted from the “detergent-based” studies have 
been widely criticized and finally defeated, for being a highly artificial and 
subjective approach which could even induce the formation of membrane 
domains (Fastenberg et al. 2003;Shogomori and Brown 2003), it was these results 
and some others (Kenworthy and Edidin 1998) which first suggested the 
existence of small dynamic entities in cell membranes controlled and regulated 
by the presence of chol and sm (sphingomyelin). Therefore, it was assumed that 
lipids were structural building elements involved in maintaining cell membrane 
consistency. Although this definition for the purpose of the lipid presence in cell 
membranes explained their relevance in cellular physiology it did not suggest the 
direct intervention of lipids in cellular activities. However, we now know that 
lipids can act as functional entities in cellular functions. Evidence suggested that 
lipids can play a major role as cell surface receptors (Fishman et al. 
1980;Fishman and Atikkan 1980), precursors of bioactive molecules (Koumanov 
et al. 2002) or function as secondary messengers (Hakomori and Igarashi 1995).  
One example of membrane rafts are the glycosphingolipid (GSL) enriched 
microdomains. GSLs due to their high melting temperature tend to cluster 
forming ordered subcellular domains (Fantini et al. 2000;Fantini 2003). The 
possible functional implications of these GSL platforms and their role as surface 
receptors in cell recognition has been widely studied. A good example is the 
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characterization in the early 80s of a GSL domain as a binding site for cholera 
toxin; the study described the affinity of this bacterial toxin for GM1 
(monosialotetrahexosylganglioside) ganglioside included in the membrane raft 
(Fishman, Pacuszka, Hom, & Moss 1980;Fishman & Atikkan 1980). 
In order to exert any of the biological functions specified above lipids need to be 
organized in dynamic microdomains. These subcellular domains are created by 
the association of particular molecular species of membrane lipids, more 
ordered than the surrounding lipids composing the cell membrane. This specific 
domain composition will consist of lipids acting as stabilizer components of the 
membrane raft and lipids directly intervening in biological processes such as cell 
to cell recognition. Initial studies pointed to the role of chol and sm acting as a 
raft stabilizer (Wolf et al. 2001). Wolf and co-workers described in their work 
how a hydrogen bond network was established between the 3ß-OH group of chol 
and the amide-linkage in sm. These results supported those of Bittman and co-
workers (Bittman et al. 1994). This work used the substitution of the amide-
linked fatty acid in sm for a carbonyl ester-linked acyl chain in a chol/sm 
subdomain to confirm the looseness of domain integrity. In addition to this, data 
indicating that chol interacted favourably with all the physiologically relevant 
forms of sm (eg. 16:0, 18:0, 24:0 as well as 24:1 fatty acids in the N-linked 
position) implied that other forces other than Van der Waals attractive forces 
and hydrophobic interactions were involved in the formation of a chol:sm 
dynamic interaction within the raft (Ramstedt and Slotte 1999). The hydrogen 
bond network was then elucidated as the most plausible explanation for the 
domain stability and dynamics.  
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Figure 1.3. Top view of cell membrane bilayers  
including different Chol (violet)/sm (18:0) (green) molar ratios (a) 20/80, (b) 35/65, and (c) 40/60. 
(d) Side view of (b) (Zidar et al. 2009). 
Although the interaction between chol and sm was accepted by some in the 
formation and long-term maintenance of subcellular raft domains, several 
studies argued with the hypothetical involvement of chol in the formation of sm 
domains highlighting a possible lateral demixing effect exerted by chol within 
the raft (Radhakrishnan 2010). Therefore, chol would be having an attenuating 
effect on domain formation; this chol-induced negative effect on raft formation 
was observed by Milhiet and co-workers on domain formation for renal brush 
border membranes (Milhiet et al. 2001;Milhiet et al. 2002). Other studies tried to 
define the role of chol in raft formation by extracting it from the domains. 
Veatch & Keller found that chol exclusion from the domain instead of disrupting 
the raft structure tended to increase its size, demonstrating that the generation 
of functional domains is possible in the absence of high concentrations of chol 
(Veatch and Keller 2005a;Veatch and Keller 2005b).  
After shifting from the idea of Chol as an essential building block in the sm 
containing microdomains, the majority of the research then focussed on finding 
another element which could stabilize the rafts by establishing a partnership 
with sm. The generation of membrane domains was finally observed in lipid 
bilayer models containing different ratios of sm and phosphatydilcholine (pc) 
even without the presence of chol (Prenner et al. 2007). Furthemore, this study 
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reiterated the importance of Sm:pc molar ratios within the domain as a critical 
factor in defining the formation and functional properties of the subcellular 
domain. The molar threshold for domain formation in a liquid ordered phase (l0) 
was then established for lipid mixtures containing sm and pc molar % above 30 
mol % (Prenner, Honsek, Honig, Mobius, & Lohner 2007) and mixtures including 
sm and/or chol molar % above 30 mol % (Zidar, Merzel, Hodoscek, Rebolj, 
Sepcic, Macek, & Janezic 2009). It would seem that the studies so far had not 
managed to give a conclusive answer to the minimum requirements to form a 
functional GSL raft. A deeper insight into the chol role in GSL domains was 
achieved when the cytolytic activity of a protein, Ostreolysin, isolated from the 
fruiting bodies of the mushroom Pleurotus ostreatus was found to be directly 
affected by the content and accessibility of chol in a sm:chol membrane domain 
(Rebolj et al. 2006). Overall, it would seem that cholesterol instead of directly 
regulating the formation of sm domains could be regulating the raft functionality 
and influencing the physical state and packing density of phospholipids 
(Bjorkbom et al. 2007;Bjorkbom et al. 2010). In terms of internal raft 
networking and lipid-lipid interactions it could be concluded that Van der Waals’ 
forces could be established between the saturated acyl-chains of the 
sphingolipids and possible hydrogen bonding in the head group between 
sphingolipids and/or chol (Dobrowsky 2000;Dobrowsky and Gazula 2000). 
So far the composition and distribution of lipids within the rafts has been 
discussed with the understanding that the membrane domains are three-
dimensional entities. Although membrane domains are relatively stable, 
evidence has shown that they are dynamic structures (Pike 2006). Taking into 
account the dynamic nature of membrane rafts some research groups pointed 
out the necessity to introduce a fourth dimension in the domain’s composition, 
time. This fourth dimension would define rafts not as static functional entities 
localized on a specific cell fraction but as dynamic domains whose appearance 
would be subjected to cell membrane composition and lipid fluctuations (Pike 
2006). 
I have described what it is known about the formation and stability of the rafts 
and how critical they are in the raft-dependent cellular activities and tissue 
integrity, but what would happen if the membrane microdomain architecture 
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was somehow disrupted, what would be the implications of losing membrane raft 
consistency in terms of cellular activity and homeostasis? 
1.3 Lipids and disease 
Lipids belonging to the same group can have internal subtle variation in 
structure and composition. This variation can be due to changes following lipid 
synthesis, for example differential hydroxylation patterns on the fatty acid chain 
forming the ceramide (cer) in glycolipids (Sandhoff and Kolter 2003). It is known 
that in the case of galactosylceramide (galC), hydroxylation is a highly recurrent 
modification. The most abundant form of hydroxylation in galC occurs at the α-
Carbon atom of the fatty acid moiety (Degroote, Wolthoorn, & van 2004). The 
enzyme responsible for the formation of α-hydroxylated galc is called fatty acid 
2-hydroxylase (FA2H) (Eckhardt et al. 2005). Research in mice lacking 2-
hydroxylated sphingolipids has shown that up to 5 months the presence of 
hydroxylated sphingolipids is not necessary for the development of normal 
compacted myelin. However, mice up to 18 months old lacking 2-hydroxylated 
sphingolipids presented severe myelin sheath degeneration in the spinal cord and 
a pronounced loss of consistency of myelin in sciatic nerve (Zoller et al. 2008). In 
addition to this, Dick and co-workers associated severe neurodegeneration in 
patients suffering a progressive spasticity and weakness of the lower limbs 
included in the diagnostic group of Hereditary spastic paraplegia (HSP) to a 
mutation in the gene encoding FA2H (Dick et al. 2010). These results together 
suggested that the hydrogen bonding network created by lateral interaction of 
hydroxylated lipids is a key mediator of long term maintenance of domain 
stability (Zoller, Meixner, Hartmann, Bussow, Meyer, Gieselmann, & Eckhardt 
2008). 
Although lipid accumulation in motor and sensory nerve cell membranes has 
been identified as an important mechanism in the cause and progression of 
several neurodegenerative diseases such as Niemann-Pick and metachromatic 
leukodystrophy (MLD) (Gieselmann et al. 2003) there are other mechanisms 
which dramatically disrupt membrane domain architecture causing 
disorganization of myelin components and causing demyelination and 
neurodegeneration. One of these demyelinating mechanisms is based on auto-
antibody recognition of lipid-based structures localized in membrane domains of 
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peripheral nerves; this mechanism seems to be involved in the progression of a 
particular group of disorders known as Guillain-Barré syndrome (GBS) and 
another neuropathy known as Multifocal Motor Neuropathy (MMN). In the case of 
neurons, the antibody targeting of lipids causes cell death via the complement-
induced formation of MAC (membrane attack complex) pores causing a wide 
range of neuropathies. The involvement of antibodies targeting lipids in some 
neuropathies was described more than 20 years ago (Ilyas et al. 1988b). 
However, the way in which lipids behave in the cellular membrane was poorly 
understood. Lipids were still considered as individual entities forming an 
exclusive individual epitope. It was not until 2004 that Kaida and co-workers 
described lipid complexes originating from cis-interactions of two different lipid 
species as novel targets for antibodies involved in neural injury (Kaida et al. 
2004). The definition of antibody lipid targets as possible heteromeric complexes 
was an important breakthrough in understanding a group of neuropathies which 
are more closely aligned to the complex arrangement of lipids found in the cell 
membrane.  
1.3.1 Guillain-Barré syndrome (GBS) 
1.3.1.1 Introduction 
The characteristic phenotype of this neuropathy consists of: peripheral sensory 
symptoms and ascending motor weakness with loss of tendon reflexes. 
It has been reported that approximately two thirds of GBS patients develop the 
disease following an infection with a pathogen, the most common being 
Campylobacter jejuni enteritis (Ang et al. 2004;van Doorn et al. 2008). 
GBS has been characterised as presenting a wide variety of clinical subtypes. All 
these subtypes are defined according to their differential clinical phenotypes 
and pathology. These include: acute inflammatory demyelinating polyneuropathy 
(AIDP), acute motor and axonal neuropathy (AMSAN), acute motor axonal 
neuropathy (AMAN) and Miller-Fisher Syndrome (MFS) (Kaida and Kusunoki 
2010;Plomp and Willison 2009).  
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1.3.1.2 GBS phenotypes and anti-ganglioside antibodies 
Clinically, the presentation of different GBS phenotypes correlates with 
differential antibody profiling in patient sera (Kaida & Kusunoki 2010). It has 
been suggested that this is due to ganglioside distribution across the PNS and the 
specific site of injury which then leads to a specific disease phenotype. One well 
defined example would be that of MFS. MFS which has been associated with IgG 
antibodies against GQ1b ganglioside is clinically characterised by ataxia, 
areflexia and opthalmoplegia (Chiba et al. 1993). Lipid profiling of cranial nerves 
and spinal nerve roots revealed that GQ1b was characteristically enriched in the 
oculomotor, trochlear and abducens nerves. This lipid profiling correlates with 
the specific sites of injury required for the development of MFS. In addition to 
this, anti-GQ1b mAb binding revealed specific localised binding to the paranodes 
of these nerves (Chiba, Kusunoki, Obata, Machinami, & Kanazawa 1993;Chiba et 
al. 1997). Subsequent work by Halstead and co-workers (Halstead et al. 2004) 
demonstrated anti-GQ1b binding to motor nerve terminals in tissue preparations 
and the capability of these antibodies to fix complement. Other studies 
confirmed the existing link of IgG antibodies against GM1, GD1a or GalNAc GD1a 
and their combinations with the motor axonal forms of GBS (AMAN and AMSAN) 
(Hadden and Hughes 1998). 
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Figure 1.4. Antibody screening of MFS patient sera. 
Combinatorial glycoarray demonstrating the anti-GQ1b IgG reactivity of patient serum (1:100) in 
the acute and convalescent phase of the illness. Combinatorial glycoarrays are designed to identify 
antibody reactivity to single glycolipids (duplicated in top row and left-hand row) and 1:1 glycolipid 
complexes (remainder of grid). A line of symmetry runs top left to bottom right, representing 
analysis in duplicate. In the acute phase serum, strong reactivity to GQ1b is seen that is not 
substantially enhanced or inhibited when in complex with other glycolipids. In the convalescent 
serum, anti-GQ1b antibody activity is no longer detectable, except for a low antibody signal for the 
complex of GQ1b with GD1a. 
This evidence, in addition to the recovery after IVIG and/or plasma exchange 
(PE) treatment, would suggest the direct implication of antibodies in the 
development of the disease. 
Among the different variants of GBS, AIDP is the only one which has not been 
associated with a significant anti-ganglioside antibody reactivity (Kusunoki et al. 
2008;Plomp & Willison 2009). 
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1.3.1.3 Antibodies against heterodimeric complexes 
In an attempt to elucidate the antibody profile of GBS patients negative for Abs 
binding to single ganglioside epitopes, Kaida and co-workers explored the 
existence of heterodimeric complexes of gangliosides as targets for neuropathy 
related antibodies. 
The screening of a population consisting of 100 GBS patients revealed 8% of 
cases presenting IgG antibodies directed against a ganglioside complex formed 
by GD1a and GD1b but not to the gangliosides alone (Kaida, Morita, Kanzaki, 
Kamakura, Motoyoshi, Hirakawa, & Kusunoki 2004). This study helped to redefine 
GBS cases thought to be antibody negative, and strengthened the idea of GBS as 
an Ab driven disease. 
A subsequent study on a cohort of 234 GBS patients found 17% of patients with a 
detectable IgG reactivity against GSL complexes such as GD1:GD1b, GM1:GD1a, 
GD1b:GT1b, GM1:GT1b and GM1:GD1b. Among these complexes, GD1a:GD1b and 
GD1b:GT1b were associated with a characteristic disease phenotype consisting 
of disability and the requirement for mechanical ventilation (Kaida et al. 2007). 
1.3.2 Multifocal Motor Neuropathy (MMN) 
MMN was first described by three different research groups (Parry and Clarke 
1988) (Roth et al. 1986) (Chad et al. 1986). These groups reported the existence 
of a cohort of patients presenting a pure motor neuropathy, 
electrophysiologically characterized by the presence of multifocal persistent 
conduction blocks on motor but not sensory nerves.  
Antibodies to GM1 ganglioside were first identified in multifocal motor 
neuropathy (MMN) sera by Pestronk and colleagues almost 25 years ago (Pestronk 
et al. 1988). Since then, extensive studies have examined the sensitivity and 
specificity of anti-GM1 IgM antibody detection in MMN in contrast to related 
neurological disorders and healthy control populations (Adams et al. 
1991;Kornberg and Pestronk 1994;Pestronk and Li 1991), using a wide range of 
different assay methodologies (Alaedini and Latov 2000;Bech et al. 1994;Carpo 
et al. 1999;Chabraoui et al. 1993;Willison et al. 1999). Studies including MMN 
diagnosed patients have found variable proportions of patients with anti-GM1 
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antibodies ranging from 31% (Kinsella et al. 1994;Sadiq et al. 1990) to 78% 
(Chaudhry 1998). Although no uniform consensus on methodology has been 
achieved, in part due to differences in defining patient populations and the lack 
of standardised assay guidelines, it is widely accepted that IgM antibodies to 
GM1 do occur in a significantly higher proportion of MMN cases compared with 
control groups (Baumann et al. 1998;Nobile-Orazio et al. 2005). Therefore, due 
to the potential implication of antibodies in the development of the disease, 
patients diagnosed with MMN were first successfully treated with immune 
therapy (Pestronk, Cornblath, Ilyas, Baba, Quarles, Griffin, Alderson, & Adams 
1988;van Asseldonk et al. 2005). 
However, the clinical utility of antibody testing and its predictive value in 
clinical course and treatment responsiveness remain debated. In the case of 
MMN, the lack of a definitive antibody marker, defining the majority of disease 
cases, and the absence of a differential disease phenotype between antibody-
positive and negative cases has fed this debate.  
One long-standing consideration in assay design has been varying the antigen 
composition to include ‘accessory’ lipids that might enhance or attenuate the 
detection of anti-GM1 antibody binding revealing a new binding ‘fingerprint’. 
Many studies have shown that accessory lipids or liposomal GM1 preparations 
markedly affect anti-GM1 antibody detection exerting an epitope unmasking 
effect (Willison et al. 1994). Pestronk previously detected enhanced MMN 
antibody binding to GM1 in the presence of galactocerebroside (GalC) (Pestronk 
et al. 1997), results recently validated by two independent laboratories (Galban-
Horcajo et al. 2013;Nobile-Orazio et al. 2013), and Greenshields observed 
inhibition of anti-GM1 binding to GM1 in the presence of GD1a using MMN-
derived human monoclonal antibodies (Greenshields et al. 2009;Paterson et al. 
1995), a finding subsequently confirmed using MMN patient sera (Nobile-Orazio 
et al. 2010). In addition to previous findings by Pestronk, the recent observations 
by Kaida on ganglioside complexes has led to renewed interest in the roles of 
accessory lipids and glycolipids in influencing antibody binding to GM1 (Kaida, 
Morita, Kanzaki, Kamakura, Motoyoshi, Hirakawa, & Kusunoki 2004;Kaida & 
Kusunoki 2010). 
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Figure 1.5. MMN Ab binding fingerprint. 
Two potential Ab-GSL binding scenarios characteristic of MMN patients. A. In the first example, the 
anti-GM1Abs bind GM1 as a single GSL (green ticks), binding to GM1 is affected by the presence 
of a second GSL (red ticks for the GM1:GD1a complex) and thus exhibits complex-inhibition. In 
contrast, in the presence of GalC, binding to GM1 is cis-enhanced (green ticks). B. In the second 
example, binding to GM1 solely occurs in the presence of GalC but not when presented as a single 
epitope (GM1:GalC green tick). 
These data suggest the potentially cryptic nature of glycolipid epitopes bound by 
anti-GM1 antibodies, thus offering a new line of investigation attempting to re-
define the presence of anti-glycolipid antibodies in the ‘antibody-negative’ MMN 
cases. 
1.3.3 Chronic Inflammatory demyelinating polyneuropathy (CIDP) 
CIDP is an acquired disease affecting the PNS characterised by demyelination. 
The disease phenotype consists of progressive or relapsing weakness and 
impaired sensory function in the upper and lower limbs (McCombe et al. 1987). 
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To a significant extent CIDP patients respond well to immunotherapies. Among 
these therapies the most efficient are intravenous immunoglobulin (IVIG) and 
plasma exchange (PE) (Dyck et al. 1986;Lunn and Willison 2009). These empirical 
observations give support to the idea that CIDP is an autoimmune condition with 
myelin as the likely antibody target. 
Another indication of the antibody-mediated nature of CIDP was the generation 
of a chronic experimental autoimmune neuritis CIDP (CIDP-EAN) model after 
immunising rabbits with bovine galactocerebrosides (Saida et al. 1979). After 
localised injection of the resulting anti-galactosylcerebroside sera, 
demyelinating lesions localised within the PNS started appearing in rabbit sciatic 
nerve (Saida, Saida, Brown, & Silberberg 1979). These observations were further 
supported by the inhibition of the demyelinating process in the CIDP-EAN model 
following complement inactivation (Sumner et al. 1982). Antibodies against 
galactosylcerebrosides have not been found in serology studies in CIDP patients, 
however an early study suggested the presence of antibodies against sulphated 
galactosylcerebrosides in a significant proportion (Fredman et al. 1991). Other 
major GSL antibody targets have been found in serology studies LM1, GD1a and 
SGPG (Fredman, Vedeler, Nyland, Aarli, & Svennerholm 1991;Ilyas et al. 
1992;Willison and Yuki 2002). 
1.4 The application of glycosphingolipid arrays to 
autoantibody detection in neuroimmunological 
disorders  
1.4.1 Introduction 
A significant number of human subjects with autoimmune peripheral neuropathy 
harbour serum IgG and IgM autoantibodies (neuropathy-associated antibodies, N-
Abs) to glycosphingolipids (GSLs) which are present in peripheral nerves (Kaida & 
Kusunoki 2010;Rinaldi 2013;Rinaldi & Willison 2008;Willison & Yuki 2002). In the 
acute disorder termed Guillain-Barré syndrome (GBS), the anti-GSL antibodies 
cause patterns of paralysis that can be recapitulated in animal models, attesting 
to their clinical and pathological significance(Plomp & Willison 2009). Over 20 
individual GSL species have been reported as antigens in GBS and allied chronic 
disorders; for example the GBS variant termed acute motor axonal neuropathy is 
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highly associated with anti-GM1 and -GD1a N-Abs, and the Miller Fisher syndrome 
variant with anti-GQ1b and -GT1a N-Abs. Despite this major advance in 
knowledge, in many neuropathy cases anti-GSL autoantibodies remain 
undiscovered, although there are strong hypothetical grounds for assuming their 
presence. Measuring N-Abs is widespread for diagnostic purposes, 
notwithstanding methodological shortcomings. Conventionally, in house or 
commercially available enzyme linked immunosorbent assays (ELISAs, usually 96 
well plate format) or nitrocellulose dot blots or strip assays are used, in which a 
small range of 6-10 purified GSLs as the adhered antigens are probed with 
neuropathy sera. Until recently, the emphasis has been on analyzing N-Ab 
reactivity to highly purified, single species of GSLs. Although longstanding 
studies have highlighted the importance of accessory lipids and liposomal 
environments in influencing GSL antibody binding, incorporating the necessary 
modifications to achieve multimeric composition in routine assays has not been 
widely implemented in reproducible protocols (Rinaldi et al. 2012). Recent 
observations have led to a renaissance of interest in this area of multimeric lipid 
complexes as N-Ab targets (Kaida and Kusunoki 2013). Firstly, it was discovered 
that pairs of GSL can interact in 1:1 molar ratios to form heteromeric complexes 
that enhance binding of N-Abs (Kaida, Morita, Kanzaki, Kamakura, Motoyoshi, 
Hirakawa, & Kusunoki 2004;Kaida et al. 2008;Mauri et al. 2012). Secondly, it was 
discovered that GSL complexes that form naturally in live nerve membranes can 
inhibit binding of certain N-Abs to single GSLs, rendering them pathologically 
harmless, as summarised in Figure 1.6 (Greenshields, Halstead, Zitman, Rinaldi, 
Brennan, O'Leary, Chamberlain, Easton, Roxburgh, Pediani, Furukawa, 
Furukawa, Goodyear, Plomp, & Willison 2009). These enhancing and inhibiting 
GSL complexes form on solid phase matrices such as microtitre wells, thin layer 
chromatography plates and nitrocellulose or polyvinyldifluoride (PVDF) 
membranes, and can thereby be analysed using modified immunoassay 
techniques (Kusunoki et al. 2007). When considering the potentially vast 
combinatorial diversity of heteromeric or multimeric GSL and lipid targets, these 
new perspectives open up substantial challenges that impact on the design and 
detection methodologies for N-Abs, on which this thesis is focussed.  
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Figure 1.6 Anti-glycolipid antibody binding to glycolipid complexes analysed by 
combinatorial glycoarray and in live tissue.  
Combinatorial glycoarray grids are printed in duplicate with single GSLs and their 1:1 heteromeric 
complexes. In each 6x6 grid, a diagonal line of symmetry runs from top left to bottom right, with the 
single GSLs printed in the outermost left hand column and uppermost row and the complexes 
duplicated at two unique XY coordinates within the grid. The mouse anti-GM1 mAbs, DG1 and 
DG2 both bind GM1 as a single GSL (green circles in outermost rows/columns). DG2 binding to 
GM1 is unaffected by the presence of a second GSL (circled in green for the GM1:GD1a complex) 
and thus exhibits complex-independent binding. In contrast, DG1 is inhibited from binding GM1 by 
the presence of GD1a (circled in red) and all other GSLs depicted. 
In live nerve-muscle tissue preparations (bottom row, 4 panels), fluorescently conjugated 
bungarotoxin (BTx, red) was used to delineate the region of the neuromuscular synapse and the 
presence of DG1 or DG2 antibody binding was detected with fluorescently conjugated anti-mouse 
IgG antibody (green). DG2 readily binds to GM1-containing membranes in the synaptic region, 
whereas DG1 does not. These data indicate that although both DG1 and DG2 bind GM1 as a 
single GSL, cis-interactions between GM1 and other GSLs are capable of masking the target 
epitope within GM1 for DG1, but do not interfere with the epitope for DG2 (adapted from 
(Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, Easton, Roxburgh, 
Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 2009)). Epitope masking by GSL cis-
interactions thus occurs for DG1 both in solid phase assay and biologically intact membranes. 
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1.4.2 The use of covalent carbohydrate arrays for autoantibody 
detection 
Many carbohydrate arrays have been developed for high-throughput screening 
(HTS) of autoantibody responses in recent decades. Each approach is 
methodologically varied to achieve array designs that are tailored to specific 
research field perspectives, including immune response profiling (Oyelaran et al. 
2009b), drug development (Kaufmann et al. 2011) and detection of viral (de 
Geus et al. 2013) and parasite (Aranzamendi et al. 2011) infection in sera. A key 
distinguishing feature of assay platforms has been the application of covalent or 
non-covalent binding methodology for glycan immobilisation. Covalent 
immobilisation arrays employ a derivatized solid surface, either containing 
hydrophobic linkers or photo-labile groups, to achieve the immobilisation of 
modified (Harris et al. 2009) or unmodified (Wang et al. 2007) glycans. These 
arrays have the advantage of probing a fixed amount of glycan at pre-
determined, variable density (Disney and Seeberger 2004). This approach is 
highly applicable to areas such as IgM antibody and toxin profiling where 
multivalent binding plays a major role in amplifying the avidity of interaction 
(Godula and Bertozzi 2012;Wehner et al. 2013). The binding of lectins is also 
dependent upon the density and molecular distribution of their glycan ligand, 
lending them well to analysis by covalent glycan arrays where density of binding 
to protein supports such as BSA can be controlled (Narla and Sun 2012;Oyelaran 
et al. 2009a;Zhang et al. 2010). With respect to N-Abs, covalent linkage of GM1 
to ELISA plates has been used to detect anti-GM1 IgM antibodies, but with 
conflicting data on improvements in sensitivity and specificity achieved in 
comparison with conventional non-covalent ELISA methods (Carpo, Allaria, 
Scarlato, & Nobile-Orazio 1999;Pestronk and Choksi 1997). GM1-sepharose and 
disialylgalactose-sepharose (NeuAc(α2–8)NeuAc(α2–3)Gal-sepharose) conjugates 
have also been shown to bind anti-GM1 and GQ1b IgG and IgM N-Abs 
respectively, although some N-Abs that bind the native GSL appear unable to 
bind the glycan-sepharose conjugate, indicating that the display of the 
sepahrose-conjugated glycan may not be optimal in comparison with non-
covalently adhered GSLs (Townson et al. 2007;Willison et al. 2004). 
Chapter 1  35 
 
1.4.3 The biophysical basis for arrays of heteromeric lipid 
complexes 
When considering how one might apply array design to detecting heteromeric 
lipid complexes as N-Ab targets, the issue of scale requires foremost 
consideration. In excess of 300 different species of glycosphingolipids (GSLs) 
have been identified, based on their carbohydrate chain structure (Degroote, 
Wolthoorn, & van 2004). An array of all heteromeric complex permutations of 
these 300 GSLs in an equimolar ratio would generate almost 45,000 (300x299/2) 
targets for screening. Even a simple screen of 20 GSLs generates 190 unique 
heteromeric complex targets. Inclusion of additional accessory lipids (e.g. 
cholesterol or sphingomyelin), or introducing a range of molar ratios massively 
expands the target size to unmanageable proportions using conventional ELISAs. 
In addition, heterogeneity is also present in the ceramide chain length, degree 
of unsaturation and hydroxylation of both the sphingoid base and the fatty acid 
moieties (Fantini, Maresca, Hammache, Yahi, & Delezay 2000;Fantini & 
Barrantes 2009). These physicochemical properties have the potential to 
influence cis interactions between neighbouring GSLs as well as cholesterol in 
the plasma membrane and therefore influence the shape of an antigenic 
determinant that might be a target for N-Abs. GSLs are enriched in the 
exoplasmic leaflet of neural cell membranes, and concentrated in nanoscale 
domains known as membrane rafts. The core components of these rafts are 
cholesterol and sphingomyelin, which together with GSLs form densely packed 
domains of variable size, composition and lifespan (Pike 2006). The transient 
nature of these platforms, as well as the lateral diffusion of molecules within 
the plasma membrane, allow for a myriad of potential cis interactions, resulting 
in either preferential presentation (complex-enhancement) or masking (complex 
inhibition) of constituent molecules through conformational modulation, steric 
hindrance and the generation of neoepitopes. It is this local microenvironment 
that has the potential to dramatically influence N-Ab/GSL interactions, as the 
molecular topography of the exofacial membrane leaflet visible to circulating 
ligands is the result not only of the properties of the single components but also 
of the interactions among them. 
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1.4.4 Conformational modulation of GSLs  
One accessory lipid that we have identified as a modulator of N-Ab binding to 
GM1 is cholesterol (see Figure 1.7 A). In other contexts, there has been intense 
interest in the modulating effects of cholesterol on GSLs including GM1 within 
the cell membrane (Fantini et al. 2013a;Fantini and Yahi 2010;Fantini and Yahi 
2013;Lingwood et al. 2011;Mahfoud et al. 2010;Yahi et al. 2010). Cholesterol 
contains a rigid four ring hydrophobic structure with a short flexible chain and a 
polar hydroxyl headgroup (Bloom et al. 1991). It resides, almost completely 
submerged, in the plasma membrane and is a key component of the liquid 
ordered lipid raft domain in the exofacial leaflet. The rigid structure of 
cholesterol allows for the tight packing and orientational ordering of GSLs within 
the lipid raft. Only the hydroxylated polar headgroup is free to interact with the 
hydrophilic carbohydrate moieties of GSLs, through the formation of a hydrogen 
bond (H-bond) network (Hall et al. 2010). This series of interactions induces a 
tilt in the orientation of the carbohydrate headgroup from perpendicular to 
parallel to the membrane surface, thereby either enhancing or inhibiting ligand 
binding (Lingwood, Binnington, Rog, Vattulainen, Grzybek, Coskun, Lingwood, & 
Simons 2011). In liposomes, cholesterol interactions with the carbohydrate 
headgroup of neighbouring GM1 and globotriose (Gb3) reduces the binding of 
cholera toxin and verotoxin respectively. This inhibitory effect was also 
determined to be biologically relevant in toxin binding studies to human tissues 
(kidney, erythrocytes, sperm) and reversed under conditions of cholesterol 
depletion with methyl-β cyclodextrin (Lingwood, Binnington, Rog, Vattulainen, 
Grzybek, Coskun, Lingwood, & Simons 2011). Interestingly, when the 
cerebrosides, galactocerebroside (GalC) or glucocerebroside (GlcC) were 
incorporated into detergent resistant membrane vesicles containing Gb3 and 
abundant cholesterol, verotoxin binding occurred. Gb3 was seen to bind GalC 
and GlcC on TLC overlay, however, cleavage or substitution of the fatty acid 
moiety of the ceramide tail, rendered this interaction void, indicating a pivotal 
role for this component in the interaction with Gb3 (Mahfoud, Manis, Binnington, 
Ackerley, & Lingwood 2010). 
This scenario is reported to be reversed in models of Alzheimer’s disease, where 
an increase in cholesterol enhances β-amyloid binding to GM1. In a description of 
this situation, cholesterol presents a hydroxyl group to form a H-bond with the 
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glycosidic bond of GM1 at the junction of the apolar ceramide tail and the polar 
headgroup. This induces a downwards tilt in the glycan orientation of GM1, 
allowing it to form homodimers in which both sugar headgroups are parallel to 
the membrane and orientated in opposite directions, thereby creating a 
‘chalice-shaped’ receptacle for beta-amyloid binding (Fantini et al. 2013b).  
The impact of cholesterol on the conformational modulation of GSLs is thought 
to be highly dependent upon the hydroxylation status of the C2 of the fatty acid 
chain of the GSL ceramide moiety (i.e. non hydroxylated/hydroxlyated fatty 
acid, NFA/HFA). Whilst the hydroxylation status of the fatty acid C2 and its 
functional effect in neural gangliosides is debated (Hama 2010), this has been 
well documented for GalC. Since NFA and HFA GalC as a single antigen (see 
Figure 1.7 B) and in heteromeric complex with other GSLs (see Figure 1.7 C), are 
a target for N-Abs and highly abundant in myelin, this also requires consideration 
in combinatorial array design. It has been demonstrated that the galactose group 
of the HFA-GalC forms an intramolecular H-bond network which restricts the 
headgroup to the parallel conformation, whereas NFA-GalC is free to adopt a 
conformation perpendicular to the membrane surface (Nyholm et al. 1990). In 
this latter situation, cholesterol is able to fine tune the orientation of the NFA-
GalC headgroup to the parallel conformation through the formation of 
intermolecular H-bonds (Fantini & Yahi 2010;Yahi, Aulas, & Fantini 2010), which 
has the potential to either enhance or reduce interactions with N-Abs. In 
addition to interacting with cholesterol, the galactose residue of GalC can form 
multiple H-bonds (4.5-5 H-bonds) (Hall, Rog, Karttunen, & Vattulainen 2010) 
with other GSL components, and in doing so mould the local membrane 
architecture. By inference, one might predict that other GSLs, whether in HFA or 
NFA forms (Hama 2010) and containing variable numbers of H-bond, 
donor/acceptor groups, to a greater or lesser extent, can form both intra- and 
inter-molecular H-bonds in a similar fashion. 
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Figure 1.7. Inter- and intra-molecular modulation of GSL conformation. 
Glycoarray grids are presented in one dimension of each lipid and complex.  
Panel A. The upper row contains cholesterol or GM1 as single lipids, and the lower row contains 
heteromeric complexes of cholesterol with GM1. The molar ratio of cholesterol relative to GM1 
increases from left (0.5:1) to right (40:1). The grid was overlaid with a N-Ab serum that 
demonstrated heterodimer-dependent binding at molecular ratios equal to or greater than 5:1 
cholesterol:GM1, in the absence of binding to either single component. Cholesterol can modulate 
the orientation of the glycan headgroup of GM1, from perpendicular to parallel to the membrane 
surface through the formation of intermolecular hydrogen bond (H-bonds) networks. By inference, 
this also appears to occur on the glycoarray platform, herein creating a GM1 conformation 
favourable to N-Ab binding.  
Panel B. One N-Ab serum is profiled on a glycoarray comprising either hydroxylated or non-
hydroxylated galactocerebroside (GalC-HFA or NFA). This sample showed preferential binding to 
GalC-HFA, with absence of binding to GalC-NFA. The presence of a hydroxyl group on the C2 of 
the ceramide moiety of GalC, is capable of forming intramolecular H-bonds networks, causing the 
galactose headgroup to tilt parallel towards the membrane surface. In comparison, the galactose 
headgroup of GalC-NFA (in the absence of any additional modulating GSLs or cholesterol), exists 
perpendicular to the membrane, creating unfavourable conditions for this N-Ab binding. 
Panel C. Two different N-Ab sera were evaluated on combinatorial glycoarray. One N-Ab (left) 
bound exclusively to the GM1:GalC-HFA complex, in the absence of binding to GM1 GalC-NFA or 
GalC -NFA/HFA mixtures, or any single lipids. The second (right) indiscriminately bound to GalC-
HFA, GalC-NFA and mixtures of both when in complex with GM1. The conformational modulation 
of GM1 by GalC, through both intra- and inter-molecular H-bond partnerships, can be recapitulated 
on a glycoarray platform, and different N-Abs possess varied preferences towards these glycan 
orientations. 
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1.4.5 Cis-interactions between GSLs result in the formation of 
neoepitopes or introduce steric hindrance 
The concept of N-Abs that bind preferentially to heteromeric GSL complexes is 
now well established (Rinaldi 2013). After the initial demonstration of N-Abs that 
bound a GD1a/GD1b complex (Kaida, Morita, Kanzaki, Kamakura, Motoyoshi, 
Hirakawa, & Kusunoki 2004;Willison 2005) many other heteromeric pairings (e.g. 
GM1/GD1a, GM1/GQ1b, LM1/GM1) have now been identified (Kaida & Kusunoki 
2010;Ogawa et al. 2013;Rinaldi 2013). N-Abs are defined as having undetectable 
or very low reactivity against either single species of GSL, but greatly enhanced 
reactivity in the presence of the heteromeric complex of both GSLs in equimolar 
amounts (Brennan et al. 2011;Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Kaida, Morita, Kanzaki, 
Kamakura, Motoyoshi, Hirakawa, & Kusunoki 2004;Kaida, Sonoo, Ogawa, 
Kamakura, Ueda-Sada, Arita, Motoyoshi, & Kusunoki 2008;Kaida & Kusunoki 
2010;Rinaldi et al. 2009). For GM1/GD1a N-Abs, conformation of the 
requirement for both GSLs has been confirmed using a GM1-GD1a hybrid 
ganglioside derivative (Mauri, Casellato, Ciampa, Uekusa, Kato, Kaida, 
Motoyama, Kusunoki, & Sonnino 2012). In another context a monoclonal antibody 
(mAb) that reacts with the heteromeric GM2/GM3 dimer, but not to either 
partner, has been characterised (Todeschini et al. 2008). IgM N-Abs to 
heteromeric complexes of GM1/GalC and GM2/GalC are extensively found in 
multifocal motor neuropathy sera, including in samples negative for 
conventional anti-GM1 antibodies (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, 
Kalna, Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Nobile-Orazio, 
Giannotta, Musset, Messina, & Leger 2013;Pestronk, Choksi, Blume, & Lopate 
1997). However it has yet to be experimentally demonstrated at the structural 
level that the GSL interactions form new molecular shapes i.e. ‘neoepitopes’ 
identifiable by N-Abs that contain glycan elements of both GSL components 
within the antibody binding site. 
Of equal importance is the reverse phenomenon of steric hindrance which 
appears prominent amongst N-Abs, having long been observed amongst other 
anti-GSL antibodies (Lloyd et al. 1992;Shichijo and Alving 1986). Herein, this is 
defined as the process in which the binding of an N-Ab to a single GSL is 
prevented by the spatial structure of a second GSL in near proximity. In lipid 
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rafts in which molecules are tightly packed in the liquid ordered phase, it is 
likely that the numerous interactions occurring at any given time will give rise to 
inhibitory partnerships, resulting in the masking of various membrane 
components. Indeed, Greenshields et al found that when examining the 
properties of mouse monoclonal anti-GM1 IgG antibodies with similar GM1 
binding affinities that only one was able to bind to live plasma membranes, as 
was also the case for human anti-GM1 N-Abs. Further investigations revealed 
that this was due to steric hindrance resulting from the adjacent presence of 
GD1a in the neuronal membrane, which masked the specific GM1 epitope for one 
antibody but not the other (Figure 1) (Greenshields, Halstead, Zitman, Rinaldi, 
Brennan, O'Leary, Chamberlain, Easton, Roxburgh, Pediani, Furukawa, 
Furukawa, Goodyear, Plomp, & Willison 2009). Similar findings have been 
observed for anti-GD1b N-Abs that bind dorsal root ganglion neurons (Kusunoki et 
al. 1999). 
Issues surrounding GSL packing and density are thus critical to N-Ab target 
binding. Monovalent interactions of anti-GSL antibodies or lectins with their 
target are typically very weak, even undetectable. Most ligands rely on engaging 
multiple binding sites and/or the formation of multivalent immune complexes to 
increase the avidity of the interaction. The density of GSL targets on any glycan 
array platform is thus fundamental to ensuring simultaneous binding of two or 
more epitopes, resulting in a net avidity enhancement. In addition to avidity, 
density can also influence antibody selectivity (Oyelaran, Li, Farnsworth, & 
Gildersleeve 2009a) and antigen presentation through an increased frequency of 
neoepitope formation, or steric hinderance of target epitopes. When screening 
polyreactive serum samples in which multiple antibodies may be directed against 
the same molecule, but with different epitope specificities, this becomes 
complex. A balance of these enhancing and inhibitory factors thus needs to be 
achieved that maximises N-Ab detection rates, which may not be achievable in a 
single array design.  
1.4.6 Methodological developments of combinatorial glycoarrays 
Traditional ELISA based methodologies for N-Ab detection are inappropriate for 
large scale screening of GSL complexes owing to impractical increases in 
requirement for volumes of sera and scarce lipid reagents (Bech, Jakobsen, & 
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Orntoft 1994;Carpo, Allaria, Scarlato, & Nobile-Orazio 1999;Cats et al. 
2010b;Willison, Veitch, Swan, Baumann, Comi, Gregson, Illa, Zielasek, & Hughes 
1999). This heightened the need for a HTS combinatorial array platform capable 
of screening single and complex epitopes simultaneously without an increase in 
sera and lipid usage. In 2006, adapting the principles of dot-blot assays 
(Chabraoui, Derrington, Mallie-Didier, Confavreux, Quincy, & Caudie 1993), a 
polyvinylidene difluoride (PVDF)-based non-covalent array comprising 200 lipids 
spotted using an automated TLC dispenser was used to probe multiple sclerosis 
(MS) sera for autoantibodies (Kanter et al. 2006). We further adapted this 
method to generate combinatorial arrays to screen single and complex lipid 
epitopes for MS-associated autoantibodies and N-Abs (Brennan, Galban-Horcajo, 
Rinaldi, O'Leary, Goodyear, Kalna, Arthur, Elliot, Barnett, Linington, Bennett, 
Owens, & Willison 2011;Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Rinaldi, Brennan, Goodyear, 
O'Leary, Schiavo, Crocker, & Willison 2009). The method has been described in 
detail (Rinaldi, Brennan, & Willison 2012), and multiple examples shown in 
Figures 1-3. Unmodified single lipids and complexes in methanol are spotted in 
duplicate onto a PVDF substrate via non-covalent, hydrophobic interactions and 
dried by evaporation. For complexes, GSLs and other lipids are pre-mixed in 
appropriate ratios prior to spotting. Arrays generally comprising 10 to 20 lipids 
and their heteromeric permutations are probed with neuropathy and control 
sera for N-Ab identification. For detection, we have extensively used HRP-
labelled secondary antibodies and enhanced chemiluminescence (ECL plus). 
Although very sensitive, ECL plus suffers from a low dynamic range and is 
currently being replaced by fluorescently labelled secondary antibodies that 
generate a more dynamic intensity measurement with higher saturation 
threshold (Figure 3). This requires low fluorescence PVDF (PVDF-FL), to reduce 
the intrinsic auto-fluorescence of PVDF (Zhang and Zhou 2011). Furthermore, 
fluorescence based secondary antibodies labelled with different fluorophores 
(e.g anti-IgG-Alexafluor 647 and anti-IgM-Alexafluor 555) allow the simultaneous 
detection of different classes of antibodies in the same serum sample. Data 
readout is numerical and analysed using iterative cluster analysis, heat maps and 
graphical representation. 
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1.5 Summary 
High throughput screening of human serum cohorts for N-Abs directed to 
heteromeric lipid complexes that approximate their native state in neural 
membranes has necessitated the development of new methodologies specifically 
tailored to this need. Herein we have described some theoretical issues 
underpinning this field and its practical application, illustrating the sensitivity, 
specificity and versatility of the methodology developed to date. Further 
automation and increases in scale to include a wider range of lipids admixed in 
greater complexity with variations in components and ratios are currently being 
developed. The major long-term goal for clinical diagnostics is to recapitulate 
the natural lipid landscape of neural membranes that might act as targets for N-
Abs in their full molecular diversity; in doing so we expect that previously 
unidentified lipid complex targets for N-Abs will be discovered. The major gap in 
fundamental knowledge concerns the theoretical basis underpinning lipid 
complex formation resulting from cis-interaction in the lateral plane of the 
membrane which requires the application of advanced biophysical and imaging 
techniques. 
The aims of this thesis were therefore: 
1. Investigate the diversity and cryptic behaviour of anti-GM1 Abs in patient 
sera using non-immobilised artificial membranes and Ab affinity purification 
(Chapter 3). 
2. Characterize anti-ganglioside complex antibodies in Multifocal Motor 
Neuropathy (MMN) (Chapter 4). 
2.1. Compare the diagnostic efficiency of Glycoarray and ELISA. 
2.2. Validate preliminary findings by the use of an external, double-blinded 
cohort including patients and controls. 
3. Explore the existence of anti-ganglioside complex antibodies against targets 
containing three different GSL in Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) (Chapter 5). 
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3.1. Pattern recognition antibodies. 
3.2. Antibodies against heterotrimeric GSL complexes. 
44 
 
2 Chapter 2. Materials and Methods 
Table 2.1. Lipids used in ELISA, Array and liposome experiments. 
Lipid Supplier 
GM1 Sigma (UK) 
GM2 Sigma (UK) 
GM3 Sigma (UK) 
GA1 Sigma (UK) 
GD1a Sigma (UK) 
GD1b Sigma (UK) 
GQ1b Matreya (Pennsylvania, USA) 
GD3 Avanti Polar Lipids (Alabama, USA) 
LM1 Professor RK Yu (Augusta, USA) 
SGPG Professor RK Yu (Augusta, USA) 
Galactosylcerebroside (GalC) Sigma (UK) 
Phrenosin (Phre) Matreya (Pennsylvania, USA) 
Kerasin (Ker) Matreya (Pennsylvania, USA) 
Sulphatide (Sulph) Sigma (UK) 
Sphingomyelin (SM) Sigma (UK) 
Cholesterol (Chol) Avanti Polar Lipids (Alabama, USA) 
Phosphatidylcholine (PC) Avanti Polar Lipids (Alabama, USA) 
Coprostanol (Copr) Avanti Polar Lipids (Alabama, USA) 
Lanosterol (Lano) Avanti Polar Lipids (Alabama, USA) 
Cholestenol (Stan) Avanti Polar Lipids (Alabama, USA) 
Ergosterol (Ergo) Avanti Polar Lipids (Alabama, USA) 
Sitosterol (Sitos) Avanti Polar Lipids (Alabama, USA) 
Zymosterol (Zym) Avanti Polar Lipids (Alabama, USA) 
Diosgenin (Dios) Avanti Polar Lipids (Alabama, USA) 
Cholesterol sulphate (Chs) Avanti Polar Lipids (Alabama, USA) 
Dicetylphosphate Sigma (UK) 
 
2.1 Monoclonal antibody production from existing cell 
lines 
SM1, BO3, DO1 and BR1 cell lines from MMN patients producing human anti-GM1 
antibodies were cultured (O'Hanlon et al. 1996). Cell culture procedures were all 
conducted under sterile conditions using a class II hood and the cells were 
incubated at 37ºC in 5%CO2. 
Previously cloned cells were retrieved from liquid nitrogen and thawed on a 
sterile water bath set at 37ºC. Cells were then resuspended in 50 ml of RPMI 
(Invitrogen, UK) containing 10% Foetal Bovine Serum (FBS) (Invitrogen, UK) and 
spun down for 5 minutes at 200 g using a centaur 2 bench-top centrifuge (MSE, 
UK). The supernatant was removed and the cell pellet resuspended in 15 ml 
RPMI-FBS put into a T25 tissue culture flask (Corning, Netherlands) and 
transferred to a 3100 Forma Series II incubator at 37ºC (Thermo Scientific, UK). 
Cells were subjected to regular viability assessment and expanded into larger 
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flasks when reaching confluence. Cells were removed from a confluent T25 
culture flask, pelleted down as described previously resuspended in RPMI-FBS 
and split between several T175 flasks containing 50 ml fresh RPMI-FBS media. In 
order to assess the antibody production rate of the growing cell lines, regular 
supernatant aliquots were taken and tested on ELISA (see Methods 2.5) on a 
ganglioside panel containing GM1. 
2.1.1 Antibody purification 
When a minimum of 1 litre of supernatant was available, the monoclonal 
antibodies were purified using a HiTrap Protein M column (GE Healthcare, UK). 
Supernatants were removed from the flasks transferred to sorval RC5C 
centrifuge bottles (Fisher scientific, UK) and spun for 30 minutes at 10000 rpm 
at 4ºC to remove particulate matter contained in the media on a Beckman 
(Beckman Coulter, UK). The supernatant was transferred to dialysis tubing of 
molecular weight cut-off <900,000 Daltons and placed in 10x the volume of 
antibody binding buffer (see appendices 1) to dialyse overnight at 4ºC. 
Following dialysis the supernatant was filtered through a 0.2 µm bottle top 
filtration unit (Milipore, UK) before loading onto the HiTrap protein M column 
using a peristaltic pump at 50 rpm. The flow through was kept to ensure no 
protein remained in it and for quantification purposes. Once the supernatant 
was loaded, the column was washed with 10x the column volume of binding 
buffer and the wash through collected in 10 fractions. The bound protein was 
eluted with 10x column volumes of 0.1M glycine at pH 2.7 (see appendices 1) 
into 10 fractions containing a precalculated volume of 1M Tris-HCL at pH 9 (see 
appendices 1) to neutralise the low pH. All fractions, including starting 
supernatant, flow through, wash and elution fractions were tested by ELISA and 
glycoarray for anti-GM1 IgM binding (see Methods 2.5 and 2.6). 
Fractions showing antibody binding to GM1 were pooled and desalted using a 
Sephadex PD-10 column (Amersham Biosciences, Sweden) and eluted in 
phosphate buffered saline (PBS) (see appendices 7.1). Antibody concentration 
was calculated using spectrophotometric absorbance (Eppendorf, Germany) as 
follows: 
Chapter 2  46 
 
Antibody concentration (mg/ml) = A280/1.43 
Antibodies were then aliquoted and stored at -80ºC. 
2.2 Preparation of liposomes 
Liposomes were prepared using a mole to mole 5:4:1:1 ratio of Cholesterol 
(Chol), Sphingomyelin (SM), dicetylphosphate and ganglioside respectively to a 
final ganglioside concentration of 2mM. 
Lipid components dissolved in 1:1 chloroform:methanol were added to a 15 ml 
plastic tube (Corning, Netherlands) and dried under oxygen free nitrogen (BOC, 
UK) in order to form a thin lipid film. Five times the lipid volume of PBS was 
added to the falcon, rehydrating the thin lipid layers and allowing the formation 
of cave-like lipid structures which will finally fuse to generate multilamelar 
vesicles (MLVs). The size of the MLVs was then reduced by sonication (Ultrawave 
Ltd, UK) for 15 minutes at room temperature. After sonication, liposome 
preparations underwent five freeze-thaw cycles by submerging in liquid nitrogen 
and then thawing at 37ºC in a water bath. Larger vesicles and aggregates were 
removed by centrifugation at 600 g in a B4 centrifuge (Jouan, France) at room 
temperature for 20 minutes. To create unilamelar vesicles, the supernatant 
underwent 11 cycles of extrusion using a Mini-extruder (Avanti Polar Lipids, USA) 
with supports and filters of 0.4 µm pore size (Whatman, UK). The unilamelar 
vesicles were then isolated by centrifugation in a Beckman at 38500 rpm 
(Beckman Coulter, UK) and 22ºC for 1 hour. The resulting pellet was resuspended 
in 2.5 ml of PBS pH 7.4. 
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Figure 2.1. Diagram illustrating the formation of GM1-containing multilamelar vesicles 
(MLVs). 
 
2.3 Quantification of antibody binding to liposomes 
using flow cytometry 
A flow cytometry based assay was adapted to detect antibody binding to 
liposomes containing single gangliosides or heteromeric ganglioside complexes 
(Temmerman and Nickel 2009). 
Liposomes were prepared as previously described with the exception of BODIPY 
labelled Cholesteryl FLC12 (Invitrogen, UK) substituting Cholesterol (see Methods 
2.2). Alternatively, for liposomes labelled with OVA albumin tagged with Alexa 
488 (OVA488), during liposome preparation, the thin layer of lipid obtained after 
the application of nitrogen was reconstituted with a PBS solution containing 
OVA488.Liposome preparations were blocked for 1 hour at room temperature 
using 3% BSA (see appendices 7.1). Liposomes were then spun down (10 minutes 
at 16000g) and resuspended in 2 ml of PBS 1X. The suspensions were split in five 
different aliquots containing 300μl and spun down again under the same 
conditions. Pellets were reconstituted on a solution containing the primary 
antibody diluted in 0.1% BSA and incubated at 4°C for 30 minutes. Every 
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liposome aliquot will have a different antibody treatment including a negative 
control containing 0.1% BSA. After the incubation, liposomes solutions were 
pellet down as previously described and resuspended with 600 µl of PBS 1X. This 
process was repeated twice before adding the Alexa647 labelled secondary 
antibody. The secondary antibody was diluted 1:100 in PBS 1X containing 0.1% 
BSA and incubated with the liposomes for 30 minutes at 4ºC. The unbound 
secondary antibody was washed using three sequential PBS 1X washes spinning 
down the liposomes after every wash. After finalising the washes, liposomes 
were resuspended in PBS 1X and transferred onto flow cytometry tubes (Corning, 
Netherlands). 
Latex beads ranging from 0.1 to 0.6 µm (LB1-6, Sigma, UK) were used as size 
controls to set the gates on the flow cytometer and establish the compensation. 
2.4 Affinity Purification using liposomes 
Liposomes prepared at a ganglioside concentration of 2 mM (see Methods 2.2) 
were blocked overnight with 2.5 ml of 2% bovine serum albumin (Europa 
Bioproducts, UK) in PBS (BSA/PBS). The liposomes were then split between three 
microtubes and centrifuged for 15 minutes at 16000g at room temperature. After 
centrifugation the pellets were resuspended in 900µl PBS and the process 
repeated in order to eliminate the remaining BSA. Following the final 
centrifugation step, the first liposome pellet was resuspended with 70% patient 
sera diluted with 0.2% BSA/PBS and the mix incubated for 30 minutes at 4 ºC. 
After incubation the sera/liposome mix was centrifuged for 15 minutes at 16000g 
at room temperature and the supernatant transferred to the second then third 
aliquot of liposomes and the process repeated each time. Two washes were 
performed on the pellets from each stage, comprising resuspension of the pellet 
in PBS and recentrifugation. The three pellets, containing the affinity purified 
antibodies from patient sera, were incubated with 0.83 ml glycine buffer (0.1M 
pH 2.5) for 2 minutes to elute them from the liposomes before neutralising the 
pH with 0.083 ml of Tris HCl (1mM pH9). Samples were then centrifuged for 15 
minutes at 16000g and the supernatants containing the purified antibodies 
stored for further analysis. 
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Figure 2.2. Diagramme ilustrating the liposome-based methodology for antibody affinity 
purification from patient sera. 
 
2.5 Enzyme linked immunosorbant assay (ELISA) 
The enzyme linked immunosorbant assay (ELISA) method from the Glasgow 
Diagnostic Neuroimmunology Laboratory was used (Willison, Veitch, Swan, 
Baumann, Comi, Gregson, Illa, Zielasek, & Hughes 1999). Polystyrene plates 
(Immulon 2HB microtitre plates, Dynatech, UK) were coated with 200ng per well 
of glycolipid dissolved in methanol and allowed to dry leaving the glycolipid 
adhering to the ELISA plate. For preparation of heteromeric complexes 
comprising a 50:50 ratio of two glycolipids, 100ng of each glycolipid was 
admixed in methanol by sonication (3 min), and a total of 200ng of glycolipid 
mixture was applied per well. Following complete evaporation of the methanol 
the plates were stored at 4ºC for a minimum of one hour before blocking with 
150 µl per well of 2% BSA/PBS for one hour at 4ºC. The blocking reagent was 
then discarded followed by five consecutive PBS washes before 100μl sera, 
diluted in 0.1% BSA/PBS, was applied to duplicate wells at 1:100, 1:500, 1:2500, 
1:12500 dilutions and incubated for twelve hours at 4ºC. After washing 5 times 
with PBS, 100µl per well of horse radish peroxidase-labelled secondary antibody 
(DakoCytomation, Denmark) diluted 1:3000 in 0.1% BSA/PBS was applied for one 
hour at 4ºC. Detection was performed using 100 µl of substrate solution (see 
appendices 7.1) per well for 15 minutes at room temperature in the dark and the 
reaction terminated with 50 μl of 4 M H2SO4 (see appendices 1). Optical density 
(OD) was read at 492 nm using an automated plate reader (SunriseTM, Tecan 
Group Ltd, Männedorf, Switzerland). Background (methanol only coated wells) 
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OD values were subtracted to give final OD values. OD values >0.1 at 1:500 
dilution were considered positive, based on previous assay validation data 
(Willison, Veitch, Swan, Baumann, Comi, Gregson, Illa, Zielasek, & Hughes 
1999). 
2.6 Glycoarray 
2.6.1 Slide preparation 
2.6.1.1 Slides for Chemiluminescence 
For a lipid lay out containing 10 lipids and their corresponding heteromeric 
combinations, 0.2 µm polyvinylidene difluoride (PVDF) membranes (Invitrogen, 
UK) (2.8cm wide x 2.5 cm height) were fixed onto glass slides using UHU glue 
(UHU, UK). The dimensions of the PVDF were proportionally adapted to the 
dimensions of the lipid grid. After the membrane had fully adhered and the 
slides were fully dry (15-30 minutes) a hydrophobic sealing pen was applied on 
the border of the PVDF with the glass. 
2.6.1.2 Slides for fluorescence 
PVDF-FL (Immobilon®PVDF-FL, Milipore, UK) was affixed fully covering the glass 
slide (7.5cm wide x 2.5cm height) using a low fluorescence spray glue (3M photo 
mount, 3M, UK) (See Appendices 7.2.1). Any PVDF-FL outside the limits of the 
slide area was shaved off using a scalpel. The area containing lipids was then 
delimited using a hydrophobic sealing pen applied directly onto the PVDF-FL 
membrane. 
2.6.2 Lipid preparation 
2.6.2.1 For complexes containing two lipids 
Screening of antibody binding by combinatorial array using chemiluminescence 
as a detection method was performed as follows. Individual glycolipid solutions 
were prepared at a concentration of 100µg/ml in methanol and added to 
chromacol vials (maximum capacity 300µl) (Chromacol, UK). In order to generate 
the 1:1 heteromeric glycolipid complexes, equal volumes of the individual 
glycolipid solutions were mixed in a chromacol vial the total volume of the mix 
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being equal to the individual glycolipid preparations. The final glycolipid density 
in the vials remained constant between single and complex lipid mixtures. 
Following preparation, samples were sonicated for 3minutes (Ultrawave Ltd, 
UK). 
 
Figure 2.3. Chromacol vials illustrating the different lipid preparations. 
 
2.6.2.2 For Complexes containing three lipids 
In order to generate the 1:1:1 or 1:1:10 heteromeric glycolipid complexes, equal 
volumes of the individual glycolipid solutions were mixed in a chromacol vial the 
total volume of the mix being equal to the 1:1, 1:10 and individual glycolipid 
preparations. The final glycolipid density in the vials remained constant between 
single, dimeric and trimeric lipid mixtures. Following preparation, samples were 
sonicated for 3minutes (Ultrawave Ltd, UK). 
2.6.3 TLC Printing and program preparation 
2.6.3.1 Program preparation 
In order to print individual spots using the ATS4 TLC autosampler (Camag, 
Muttenz, Switzerland) it was necessary to write programs were the individual 
spots were defined by specific X and Y coordinates. Glycolipid singles and 
complexes were printed in duplicate in a grid formation. The first data point 
corresponding to the first single glycolipid on the initial slide was (15mm,36mm) 
and its duplicate (17mm,34mm). In order to complete print run of 6 PVDF slides, 
31.4mm were sequentially added to all X coordinates while the Y coordinates 
remained the same. For programs containing 12 slides, 92mm were added to all 
the Y coordinates while X coordinates remained unchanged.  
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All PVDF printed slides contain a diagonal line composed of methanol only spots 
that are used as negative background controls. The initial coordinates for the 
first two methanol spots were (17mm,36mm) and (19mm,38mm). The same rule 
described above applies for methanol in printings containing 6 or 12 slides. 
Spot number Position x Position y Type Width (x) Height (y) Volume (µl) Content
1 17 36 Band 0.4 0.4 0.1 metOH
2 19 38 Band 0.4 0.4 0.1 metOH
3 21 40 Band 0.4 0.4 0.1 metOH
4 23 42 Band 0.4 0.4 0.1 metOH
5 25 44 Band 0.4 0.4 0.1 metOH
6 27 46 Band 0.4 0.4 0.1 metOH
7 29 48 Band 0.4 0.4 0.1 metOH
8 31 50 Band 0.4 0.4 0.1 metOH
9 33 52 Band 0.4 0.4 0.1 metOH
10 35 54 Band 0.4 0.4 0.1 metOH
121 15 36 Band 0.4 0.4 0.1 GM1
122 17 34 Band 0.4 0.4 0.1 GM1
145 15 38 Band 0.4 0.4 0.1 GM2
146 19 34 Band 0.4 0.4 0.1 GM2
169 15 40 Band 0.4 0.4 0.1 GA1
170 21 34 Band 0.4 0.4 0.1 GA1
193 15 42 Band 0.4 0.4 0.1 GD1a
194 23 34 Band 0.4 0.4 0.1 GD1a
217 15 44 Band 0.4 0.4 0.1 GD1b
218 25 34 Band 0.4 0.4 0.1 GD1b
241 15 46 Band 0.4 0.4 0.1 LM1
242 27 34 Band 0.4 0.4 0.1 LM1
265 15 48 Band 0.4 0.4 0.1 SGPG
266 29 34 Band 0.4 0.4 0.1 SGPG
289 15 50 Band 0.4 0.4 0.1 GQ1b
290 31 34 Band 0.4 0.4 0.1 GQ1b
313 15 52 Band 0.4 0.4 0.1 Sulph
314 33 34 Band 0.4 0.4 0.1 Sulph
337 15 54 Band 0.4 0.4 0.1 GalC
338 35 34 Band 0.4 0.4 0.1 GalC  
 
Figure 2.4. Example of a programme listing the coordinates for 10 single lipids and 
methanol only controls on the first slide. 
 
2.6.3.2 TLC printing and settings 
The ATS4 TLC autosampler (Camag, Muttenz, Switzerland) was used to apply 0.1 
μl per spot of single glycolipid or glycolipid complex at 100 μg/ml in methanol to 
PVDF membranes affixed to glass slides. From 10 individual lipids, a total of 45 
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heteromeric lipid complexes were achieved, each duplicated in a mirror image 
against a diagonal control line of methanol. 
Oxygen free Nitrogen (BOC, UK) was used for the spraying system within the 
ATS4 TLC, at an optimum pressure of 5 bars. Both 25 µl and 10 µl syringes were 
used with an optimized filling speed of 15 µl/s, a rinsing vacuum speed of 4 
seconds and a general vacuum pressure of 1.2 MPa. 
 
Figure 2.5. Glycoarray slide holder for TLC dispensing  
Presenting four PVDF slides for an array dimension of 11x11. 
2.6.4 Array probing and Analysis 
The protocols described below have been adapted assuming an array area of 
2.8cm x 2.5cm corresponding to a symmetrical lipid layout of 10 lipids by 10 
lipids. The volumes of sera, secondary antibody and chemiluminescent reagents 
need to be proportionally adjusted to the dimension of the array. 
2.6.4.1 Array probing using Chemiluminescence 
Slides of the printed arrays were blocked for 1 hour in 2% BSA/PBS at room 
temperature in a staining dish on an orbital shaker, slides were then placed in a 
slide box containing moist paper and 250 µl of sera diluted 1 in 100 in was added 
and the slides incubated for 1 hour at 4ºC. Slides were then washed twice for 15 
minutes in 1% BSA/PBS with agitation before again transferring to the slide box 
and 250 µl of horseradish peroxidase conjugated secondary antibody 
(DakoCytomation, Denmark) prepared in 1% BSA/PBS at 1:25000 was applied and 
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the slides incubated for 30 minutes at 4ºC. The slides were then tapped dry and 
washed twice for 30 minutes in 1% BSA/PBS and subsequently for 5 minutes in 
distilled water. Binding was detected by enhanced chemiluminescence, (ECL+; 
Amersham/GE Healthcare, UK) following application of 450 µl of ECL (40:1 
Reagent A and B respectively) for 3 minutes slides were taped into an x-ray 
cassette and x-ray film (Kodak, UK) applied in the darkroom and the radiographs 
exposed for various times. Radiographs were then digitized by flatbed scanning 
(Epson DX 6000), and spot intensity calculated using TotalLab image analysis 
software (Nonlinear Dynamics Ltd, Newcastle upon Tyne, UK), and expressed as 
pixel intensity units of individual spots (IU). 
 
Figure 2.6. TotalLab software lay out depicting the measurement of a 9x9 lipid grid. 
 
2.6.4.2 Array probing using fluorescent tags 
Arrays were blocked in 2% BSA/PBS at room temperature on an orbital shaker. 
After one hour, slides were placed on a slides box containing moist paper and 
250 µl of sera diluted 1 in 100 in 1% BSA/PBS added, leaving the slides to 
incubate for 1hour at 4ºC. Slides were then washed twice for 15 minutes in 1% 
BSA/PBS before application of 250 µl of fluorescently labelled secondary 
antibody (α-IgG Alexa 555 and/or α-IgM Alexa 647, Invitrogen, UK) prepared in 
1% BSA/PBS at 1:1000 and incubation for 1hour at 4ºC. The slides were then 
tapped dry and washed twice for 30 minutes in 1% BSA/PBS and for 5minutes in 
distilled water. Binding was detected by fluorescent reading of the slides using a 
flatbed scanner (ScanArray Express imaging system, Perkin Elmer, UK). Intensity 
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was measured as mean fluorescence intensity minus background using the 
software provided with the scanner. (See Appendices 7.2.22) 
2.7 Microarray 
2.7.1 Microarray generation 
A sciFLEXARRAYER (Scienion, Germany) non-contact piezoelectric array was used 
to generate combinatorial lipid arrays. Lipids stocks were prepared at 30 µg/ml 
in a 70:30 methanol/water mixture and sonicated for 2 min prior to loading onto 
the 384 well plate for dispensing. Unless indicated, the microarrays containing 
heteromeric complexes were produced over-spotting the two single lipid samples 
forming the complex. In order to increase the molarity of lipid spotted, each 
spot was generated by the addition of 6 droplets, adding up to a total of 0.003 
µl, of lipid solution. Lipids were dispensed onto PVDF-FL membranes 
(Immobilon®PVDF-FL, Milipore, UK) affixed to glass slides (see Methods 2.6.1.2). 
The layout of the lipid grid, assuming spacing between spots of 390 µm and 10 
single lipids and their correspondent heteromeric complexes, allowed the 
generation of eight sub-arrays per slide. After printing, the arrays were left to 
dry overnight at 4ºC. 
2.7.2 Microarray probing 
Slides were first blocked for 1 hour at room temperature in 2% BSA/PBS in a 
50ml Falcon tube on a rocker. Slides were then washed in 45 ml of PBS 1 for 20 
minutes at room temperature. Following the wash step the slides were arranged 
and the FAST Frame multi slide plate (Whatman, UK) was placed on top of the 
slides in order to delineate the 8 sub-arrays generated per slide. Each sub-array 
was incubated with patient sera (1:100 dilution), monoclonal antibody or 0.2% 
BSA/PBS for 1 hour at 4ºC. After incubation, the solution within each FAST frame 
was carefully removed by aspiration using a Gilson pipette, the frame removed 
and the slides washed four times (15 minutes per wash) with 45 ml of PBS in a 
50ml falcon tube placed on a rocker. The slides were then transferred to the 
Fast frame and fluorescently labelled secondary antibody (diluted 1:500 in 0.2% 
BSA/PBS) added and incubated for 1 hour at 4ºC. The secondary antibody 
solution was carefully aspirated by pipetting and the Fast frame removed. The 
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slides were then washed four times with PBS in a falcon tube with agitation. 
Following the final wash cycle the slides were left to dry overnight at room 
temperature in the dark before scanning using the ScanArray Express imaging 
system (Perkin Elmer, UK). Detection was carried out using the 633nm laser 
excitation wavelength corresponding to AlexFluor647. Slides were scanned at 10 
µm resolution using 35% PMT with 90% laser power. 
 
Figure 2.7. Diagram illustrating the process of printing, probing with the FAST Frame and 
scanning the arrays. 
 
2.8 Mass spectrometry 
The matrix assisted desorption/ionization (MALDI) in Silica P254 (Merck, 
Darmstadt, Germany) TLC plates (20 cm x10 cm) was performed as follows. 
The TLC plate containing the combinatorial lipid arrays were attached to a 
MALDI sample plate with double-sided adhesive tape and coated with 40 layers 
of a matrix containing 2,5-dihydroxybenzoic acid (DHB) at 20 mg/ml dissolved in 
50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). The layers were 
applied at speeds of 5, 10, 15, 30 µl/min. The matrix, added in excess, was 
intended for maximising the absorption of the MALDI UV laser light. 
The analysis was performed using a Bruker Ultraflex Extreme MALDI Tandem TOF 
Mass Spectrometer (Bruker, USA) with 50 Hz nitrogen laser. The extraction 
voltage was 20 KV. The calibration of the MALDI-TOF-MS’s spectra was made by 
the use of a standard lipid mixture on DHB (positive ion mode).For calibration 
(negative ion mode) the signals originated from the DHB matrix were used. 
TLC spot imaging and scanning was done using an ultraflex MALDI-TOF/TOF. 
Imaging settings were as follows: laser in reflector mode at 200 Hz, 25 KV 
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extraction voltage and matrix suppression m/z<200. Spot images were taken at 
200x200 µm resolution using flexImaging. 
2.9 Statistical methodologies 
All data presented from serology studies was originated in the course of three 
independent studies containing a minimum of two internal duplicates. 
Throughout these studies the intra and inter-assay variability was monitored 
using sera samples of known reactivity and accepted as valid if the fluctuation of 
intensity was within 10-15% variation (Murray and Lawrence 1993). This variation 
was calculated as a coefficient of variation (CV) measured as follows: 
CV = (Standard Deviation (SD)/Mean)*100 
2.9.1 Normality test 
Descriptive statistics were used to determine the goodness of fit of our data to a 
normal distribution. Kolmogorov-Smirnov (KS) test and quantile-quantile plots 
(QQ) were the methodologies of choice to elucidate deviation from Gaussian 
distribution. (GRAPHPAD PRISM 5 software (GraphPad Software Inc., USA)). 
2.9.2 Receiver Operator Characteristic (ROC) analysis 
MEDCALC software using the Hanley & McNeil (Chapter 4.3) or DeLong (Chapter 
4.7) approach with 95% confidence intervals was used to perform ROC analysis. 
The areas under the curve were analysed assuming a likelihood ratio of LR+2.0 
and LR-0.5, corresponding to an area under the curve (AUC) of 0.75, as the 
accepted cut-off value for a clinically useful biomarker (Jones and Athanasiou 
2005). AUC values from Jones and co-workers (Jones & Athanasiou 2005) were 
used for reference purposes, being as follows: ≥0.97 excellent, 0.93-0.96 very 
good and 0.75-0.92 good. Although these guidelines were followed, every study 
needs to be assessed individually, in a clinical context, and the AUC values are 
not to be taken as an absolute indicator of a biomarker’s strength. 
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2.9.3 Heat map analysis 
Raw intensity unit values or Log10 transformed data from glycoarrays and 
microarrays were used to generate heat maps, which underwent hierarchical 
clustering (HCL) and Pearson correlation for distance metric selection (MEV 
software; Dana-Farber Cancer Institute, Boston, MA, USA). 
2.9.4 Clinical correlation studies 
Correlation studies for upper limit of normal (ULN) calculation including 
Wilcoxon signed rank test for non-parametric data and box and whisker plots set 
within 5-95% intervals were calculated using MINITAB 15 software (Minitab 15 
software, State College, PA,USA) and GRAPHPAD PRISM 5 software (GraphPad 
Software Inc., San Diego, CA, USA). 
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3 Chapter 3. Anti-GM1 antibody diversity. 
3.1 Introduction 
In 1976 GM1 ganglioside was first described to induce and/or mediate an 
experimental autoimmune neurologic disorder after being injected into rabbits 
(Nagai et al. 1976). A few years later, various studies finally associated GM1 as 
an antibody target in patients with motor neuron disease (Freddo et al. 
1986;Latov et al. 1988) and Guillain–Barré syndrome (Ilyas, Willison, Quarles, 
Jungalwala, Cornblath, Trapp, Griffin, Griffin, & McKhann 1988b). Since then, 
anti-GM1 antibodies have not escaped controversy. 
The inconsistency in anti-GM1 antibodies detection in patients has been pointed 
out as a major limitation in identifying these antibodies as causing agents of 
some neurological disorders (Parry 1994). Percentages of antibody positive 
patients have been found to be extremely diverse, depending on the technique 
used and disease evaluated, ranging from 30% to 60% (Adams, Kuntzer, Burger, 
Chofflon, Magistris, Regli, & Steck 1991;Pestronk 2000;Sadiq, Thomas, Kilidireas, 
Protopsaltis, Hays, Lee, Romas, Kumar, Van den Berg, Santoro, & . 1990). In the 
remainder antibodies are undetectable, although expected to be present as 
there is no clear distinction in phenotype characteristics or treatment 
responsiveness between antibody-positive and –negative cases amongst the 
distinct neurological disorders. 
The single most striking observation to emerge from the study of anti-GM1 
antibody mediated neuropathies is the existence of a clearly differentiated 
motor phenotype (Pestronk, Cornblath, Ilyas, Baba, Quarles, Griffin, Alderson, & 
Adams 1988). However, existing accounts fail to resolve the apparent 
contradiction between GM1 ganglioside location in both motor and sensory 
peripheral nerves and the distinct disease phenotype (Ogawa-Goto and Abe 
1998).  
Studies in tissue and solid-phase immunoassays have revealed that the GM1-
epitope can be inaccessible for antibody binding due to a masking effect exerted 
by neighbouring gangliosides such as GD1a (complex mediated cis-inhibition). 
The most striking conclusion to emerge from the data is that unless GM1-epitope 
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is topologically available for antibody binding no axonal damage or conduction 
block would be induced due to a lack of antibody bound complement activation 
(Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, 
Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 
2009).  
It can thus be suggested that heteromeric lipid complexes containing GM1 can be 
modulators, either enhancing or inhibiting antibody binding, thereby explaining 
the diversity found within anti-GM1 antibodies. For example, the presence of 
antibodies which exclusively bind lipid complexes formed by GM1 and GalC in 
the absence of antibody binding to the single components, highlights the 
importance of the neighbouring lipid environment in the formation of 
neoepitopes or the conformational modulation of the target epitope (Galban-
Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & 
Willison 2013;Nobile-Orazio, Giannotta, Musset, Messina, & Leger 2013;Pestronk, 
Choksi, Blume, & Lopate 1997). 
3.2 Aims 
The aims of this study are: 
 Evaluate lipid complex formation in a non-immobilised artificial 
membrane environment using a liposome-based model and Flow 
Cytometry analysis. 
 Use the developed liposome model to affinity purify anti-GM1 antibodies 
from neuropathy patient sera. 
 Characterise, through array technology, anti-GM1 antibody binding 
diversity in a complex lipid environment. 
3.3 Results 
3.3.1 Antibody binding to liposomes containing gangliosides 
Two mouse anti-GM1 IgG monoclonal antibodies (mAb), DG1 and DG2, were used 
to model lipid complex formation in liposome membranes. These two mAb have 
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similar GM1 binding affinities, but have been described to exert a differential 
GM1 binding in the presence of GD1a ganglioside; DG1 binding was cis-inhibited 
in the presence of GD1a and binding of DG2 remained unaltered (Greenshields, 
Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, Easton, Roxburgh, 
Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 2009).  
Liposomes were prepared as stated in Materials and Methods section 2.2. Prior to 
commencing the study, liposome staining with mAb was optimised. 
All the studies presented here comprise three internal replicates per sample and 
were repeated three consecutive times. 
3.3.1.1 Assessment of liposome labelling 
In initial experiments, liposomes were labelled by inclusion of OVA conjugated 
Alexa-488 (OVA-488) during the preparation of MLVs (see Methods Preparation of 
Liposomes 2.2). This protocol was adapted from a mouse immunisation regime 
utilising liposomes incorporating OVA as a T-Cell response adjuvant (Habjanec et 
al. 2006). 
Four different molarities of OVA-488, (0.05 µmols , 0.1 µmols, 0.5 µmols and 1 
µmol) were tested and compared against unlabelled liposomes, which were used 
as an indication of  background autofluorescence. Flow cytometry data (Figure 
3.1) revealed a disappointingly weak fluorescence emission signal for all the 
concentrations of OVA employed when excited at 488nm. The low signal could 
be due to a poor incorporation efficiency of OVA by the liposomes or the use of 
an insufficient quantity of labelled OVA. Examination of the literature suggests 
that the low incorporation rate of OVA into MLVs may result from the hydration 
of the thin lipid layers with a PBS containing OVA solution (Taneichi et al. 2010). 
An alternative method for OVA incorporation would consist of coupling via 
disuccinimidyl suberate on the surface of the liposome (Taneichi et al. 2006). 
Although proven more efficient, this methodology was discarded due to the 
potential disruption that OVA presented on the surface of the liposome could 
cause to antibody binding to gangliosides contained on the outer membrane of 
the vesicles. 
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Figure 3.1. Histogram representing OVA-488 positive liposomes. 
Flow cytometry data, plotted as a histogram. Data points represent fluorescent intensity from 
different liposome preparations. The liposome preparations included different quantities of Ova-488 
introduced during the synthesis of liposome. The different preparations were as follows: 1 µmol of 
OVA-488 (Dark green), 0.5 µmol of OVA-488 (light green), 0.1 µmol of OVA-488 (orange), 0.05 
µmol of OVA-488 (blue) and liposomes without including OVA as a test for liposome auto 
fluorescence (red). The X axis represents the size of the OVA-488 population and the Y axis 
represent the fluorescence intensity normalize to 100 using the highest intensity value. 
Subsequently, BODIPY labelled Cholesteryl (a non-hydroxylated cholesterol 
molecule) was assessed for liposome labelling. In this scenario, liposome 
cholesterol was substituted for either 0.30 mg, 0.60mg or 0.90mg fluorescently 
conjugated cholesteryl. Due to the integral role of cholesterol/cholestreryl, 0.30 
mg was the minimum amount of required for liposome formation.  
Flow cytometry data showed a significant difference between all the cholesteryl 
labelled liposomes and the unlabelled liposomes (Figure 3.2B) revealing a 
successful labelling protocol. However, no significant difference was observed 
between liposomes containing different amounts of labelled cholesteryl, 
suggesting that the labelling already reached saturation with the inclusion of 
0.30 mg. 
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Figure 3.2. Cholesteryl BODIPY and liposome’s fluorescence intensity. 
Panel A shows the overlapped histograms of flow cytometry data for unlabelled liposomes (blank 
liposomes) (blue) and liposomes containing 0.30 mg (red), 0.60 mg (orange) and 0.90 mg (green) 
of cholesteryl. Blank liposomes were an indication of autofluorescence. Panel B. illustrates the 
median fluorescence intensity of all the liposome populations. Significance was analysed using 
Kolmogorov-Smirnov (K-S) test (Young 1977) (*p value≤0.05 and **p value≤0.01). 
Much has been speculated as to how fluorescent labels might affect the way 
lipids diffuse across the membrane and interact with the neighbouring 
environment (Marks et al. 2008). In the case of antibody binding to glycolipid 
domains present on liposomes, the membrane lateral interactions could play a 
key role with the formation of glycolipid complexes. In this experiment the 
hydroxylated headgroup of naturally occurring cholesterol, is substitute by 
BODIPY in the cholesteryl molecule. It has recently been shown that the 
hydoxylated headgroup of cholesterol modulates the presentation of 
neighbouring glycolipid through the formation of hydrogen bonds. Therefore it 
could result in the disruption of lipid lateral flow within the membrane and alter 
the presentation of glycolipids. However, a study comparing the diffusion and 
sterol trafficking of natural radiolabelled [3H]cholesterol and BODIPY cholesteryl 
in membranes of Chinese hamster ovary (CHO) cells demonstrated that both 
molecules exerted a similar behaviour, and no anomaly due to labelling was 
reported (Holtta-Vuori et al. 2008). However, it is currently unknown what 
affect fluorescently conjugated cholesteryl may have on glycolipid presentation 
and antibody binding. 
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In the light of these results, further flow cytometry experiments will be 
conducted using 0.30 mg of BODIPY-cholesteryl per liposome preparation. 
3.3.1.2 Titration of DG2 mAb using GM1 liposomes 
Increasing concentrations of DG2 (10, 20, 40, 60, 80 µg/ml) were applied to 
blank liposomes and liposomes containing GM1 ganglioside. Antibody binding was 
detected using Alexa647 conjugated anti-mouse IgG antibody, and the positive 
liposome subsets were selected as BODIPY/Alexa647 double positive (Figure 
3.3.B). 
DG2 binding to GM1 liposomes was significantly increased between 10 µg/ml to 
20 µg/ml after which the fluorescent intensity plateaued. These data suggests 
that the antibody binding reached saturation at a concentration between 10-20 
µg/ml. 
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Figure 3.3. Flow Cytometry data corresponding to stained GM1-liposomes.  
A. Stained with increasing concentrations of DG2 mAb and secondary Ab only (negative) and B. 
selected as BODIPY+/Alexa647+ liposome subset. The MFI data for these concentrations was: 10 
µg/ml 397, 20 µg/ml 414, 40 µg/ml 454, 60 µg/ml 423 and 80 µg/ml 387. 
Therefore, the mAb concentration used for the subsequent liposome studies was 
40 µg/ml to ensure saturation. 
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3.3.1.3 Assesment of lipid complex formation in liposomes using DG1 and 
DG2 mAb 
The GM1:GD1a ratio used in liposomes for Flow Cytometry studies was 
elucidated using the sera of a GBS patient (JK) which contained IgG antibodies 
against GM1:GD1a but no antibodies directed against the single epitopes (Figure 
3.4 A). 
For this study, GM1 was kept constant at 100 µg/ml and increasing 
concentrations of GD1a were premixed with GM1 in order to obtain nine 
different weight:weight ratios on a single array. Arrays probed with different 
dilutions of JK serum revealed that the highest peak of binding intensity was 
found when both GM1 and GD1a were at 100 µg/ml (1:1, w:w). The binding 
profile of this antibody acquired a Gaussian shape, progressively decreasing its 
binding intensity as GD1a concentration was increased (Figure 3.4 B). 
The molecular weight of GM1 and GD1a are 1547 g/mol and 1838 g/mol 
respectively, therefore 100 µg are equivalent to 6.46.10-8 moles of GM1 and 
5.44.10-8 moles of GD1a. The existence of an optimum molecular ratio of 1:1 
GM1:GD1a, has been previously demonstrated by the construction of a dimeric 
GM1:GD1a hybrid ganglioside. In this study, a chemical construct formed by a 1:1 
dimerisation of GM1 with GD1a was seen to be an optimum epitope for complex 
specific IgG antibodies contained in patient sera (Mauri, Casellato, Ciampa, 
Uekusa, Kato, Kaida, Motoyama, Kusunoki, & Sonnino 2012). 
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Figure 3.4. Analysis of GM1:GD1a IgG antibodies in the patient JK. 
Panel A. Blot demonstrating JK’s IgG antibody binding profile when diluted at 1:100. Combinatorial 
glycoarrays are designed to identity antibody reactivity to single glycolipids (duplicated in top row 
and left-hand row) and 1:1 glycolipid complexes (w/w) (remainder of grid). A line of symmetry runs 
top left to bottom right, representing analysis in duplicate. Panel B. Illustrates data from arrays 
containing GM1 ganglioside at a constant concentration (100µg/ml), forming heteromeric 
complexes with increasing concentrations of GD1a in blots probed with JK sera at various dilutions. 
It is therefore likely, that the GM1:GD1a complexes will exist as 1:1 dimers on a 
liposome membrane and that the composition of these vesicles will contain a 
molecular ratio of 1:1 GM1:GD1a. As a result of this, all the subsequent studies 
were conducted including a 1:1 (mole to mole) ratio of both gangliosdies. 
Liposomes containing GM1, GD1a, GM1:GD1a and without gangliosides (blank 
liposomes) were prepared and stained with DG1, DG2, MOG35 (a GD1a specific 
mouse IgG mAb) and MOG1 (a GD1b specific mouse IgG mAb)  
As shown in Figure 3.5, binding of DG1 to GM1 was cis-inhibited in the presence 
of equal moles of GD1a (A) , while the binding of DG2 was unaltered (B). Neither 
DG1 nor DG2 bound to liposomes containing GD1a only (data not shown). There 
was very weak nonspecific binding of these mouse mAb to the liposomes, as 
tested using liposomes containing no ganglioside, therefore the difference in 
binding profiles between the antibodies was due to the presence of GD1a (Figure 
3.5 C). 
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Figure 3.5. Histograms depicting DG1 and DG2 binding to liposomes. 
A. Shows DG1 binding to GM1 (red) and GM1:GD1a (blue) liposomes. The scale has been 
automatically normalized up to 200. B. Shows DG2 binding to GM1 (red) and GM1:GD1a (blue). 
The scale has been automatically normalized up to 200. C. shows weak binding of ganglioside 
specific mAbs to liposomes containing no gangliosides. The scale has been automatically 
normalized up to 100. D. Graph bar representing the significance of difference in mAb binding to 
both GM1 and GM1:GD1a liposomes, expressed as mean fluorescence intensity (MFI). Analysis of 
histogram data was conducted using the Kolmogorov-Smirnov (K-S) test (Young 1977) (***p 
value≤0.001). 
From the data above we can see that the observations of Greenshields and co-
workers (Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, 
Chamberlain, Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, 
Plomp, & Willison 2009) were successfully reproduced using a liposome-based 
format. Therefore, the decrease in DG1 binding intensity to GM1 in the presence 
of GD1a, indicated the formation of GM1:GD1a complexes in the liposomes. 
Chapter 3  68 
 
3.3.2 Affinity purification of anti-GM1 antibodies from a GBS 
patient (BTN) serum  
The affinity purification was performed as stated in Materials and Methods 2.4. 
Due to the scarcity of sera availability, the following affinity purification studies 
were conducted using a GBS patient BTN, in which I explored GM1:Cholesterol 
IgG antibody binding. 
Prior to commencing the study, the optimum molecular ratio of GM1:Cholesterol 
was determined. For this, an array containing nine different GM1:Cholesterol 
ratios were probed with BTN serum and stained using an anti-Human IgG 
antibody HRP labelled (Figure 3.6)  
 
Figure 3.6. Array illustrating the IgG antibody binding profile of BTN serum. 
The molarity of GM1 was kept constant while Cholesterol was increased from 1:0.5 to 1:40 
(GM1:Cholesterol, M/M). Single glycolipids are duplicated in top row and left-hand row and 
GM1:Cholesterol complexes (M/M) are duplicated in second top row and second left-hand row. The 
array was probed with unpurified BTN serum at 1:100 dilution and detected using HRP conjugated 
anti-human IgG secondary antibody. 
From the data in Figure 3.6 it is apparent that antibody binding intensity to GM1 
increased with increasing amounts of cholesterol before reaching an intensity 
maximum at 1:8 GM1:Cholesterol. 
These finding, while preliminary, suggests that a molecular ratio of 1:8 
GM1:Cholesterol would be the optimum in order to affinity purify this antibodies 
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using liposomes. Therefore, further studies were conducted using liposomes 
containing this ratio. 
GM1:Chol, GM1 and Cholesterol liposomes were prepared and used to isolate the 
anti-GM1 and/or Cholesterol antibody component of the serum. (Figure 3.7). For 
isolation of complex dependent antibody, three consecutive purifications of BTN 
serum with GM1:Chol liposomes was performed, to maximise antibody retrieval, 
as it was anticipated that the liposome antigen would be readily saturated with 
antibodies. Glycoarray analysis of the affinity purified fraction revealed the 
presence of a complex specific GM1:Chol IgG antibody. This affinity purified 
antibody did not bind GM1 or cholesterol single epitopes but a only complex of 
both (Figure 3.7 purification 1, 2 and 3). When a batch of the same serum was 
applied to liposomes containing only cholesterol, no antibodies were retrieved, 
confirming the absence of anti-cholesterol antibodies in this patient’s serum. 
The supernatant fraction (not bound by the liposomes) was analysed by 
glycoarray following the first and final round of liposome affinity purification. 
The results reveal the presence of anti-GM1/GM1:Chol antibodies, albeit at a 
reduced intensity, indicating that the efficiency of the affinity purification could 
be further improved (Figure 3.7 supernatant step 1 and 3). 
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Figure 3.7. Affinity purification process. 
GM1:Chol IgG antibodies from BTN serum were purified using a three steps purification as 
specified in Chapter 2 (Materials and methods 1.4). In every purification step an array was probed 
to qualitatively analyse antibody reactivity present in the eluted material and in the supernatant.  
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To establish whether antibody fractions remained attached to the liposomes 
after pH driven elution, liposomes from the last purification step were spotted 
onto PVDF-FL coated microscope slides using a piezoelectric driven, non-contact 
microarray spotter. The arrays were then stained using an anti-Human IgG 
antibody labelled with Alexa555. 
The results obtained from the preliminary analysis of liposomes suggest that a 
significant amount of unknown specificity IgG antibodies remained bound to the 
liposomes (Figure 3.8).  
 
Figure 3.8. Liposomes spotted using microarray. 
GM1:Chol liposomes were spotted onto PVDF-FL slides after being used for affinity purification of 
Abs with BTN serum. Liposomes were then probed using fluorescently labelled anti-human IgG 
secondary antibody to detect IgG antibodies still attached to the liposomes. 
This finding has important implications for future development of a more 
efficient method to detach antibodies bound to liposomes and to improve any 
potential nonspecific binding. 
To determine the binding profile of the antibody purified using GM1:Cholesterol 
liposomes, arrays identical to that presented in Figure 3.6 were probed with the 
affinity purified, eluted antibody. As anticipated, the GM1:Chol isolated 
antibody followed a similar enhancement pattern to that previously seen in 
whole patient serum (Figure 3.6), in which no antibody binding was detected at 
ratios of 1:0.5 up to 1:2 , despite binding at a molecular ratio, at or greater than 
1:5 (Figure 3.9 A). The antibody binding intensity was significantly increased at 
ratio 1:8 and greater (Figure 3.9 B). This data suggests the presence of one or 
more antibodies species, present in human serum, highly sensitive to specific 
molecular ratios which can be isolated using liposome model membranes and can 
be readily detected on array platforms. 
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Figure 3.9. Glycoarray blots depicting GM1:Cholesterol mole to mole heteromeric 
complexes and singles lipids. 
The molarity of GM1 was kept constant and the molarity of Cholesterol increased gradually up to 
40 times higher the molarity of GM1. Single glycolipids are duplicated in top row and left-hand row 
and GM1:Cholesterol complexes (M/M) are duplicated in second top row and second left-hand row. 
A. the array was probed using GM1:Cholesterol antibodies affinity purified from BTN serum and 
detected using anti-human IgG HRP labelled secondary antibody. B. Intensity readout ± SEM (n=3) 
of panel A. 
The nature of the heteromeric partnership between GM1 and cholesterol, and its 
ability to be detected by GM1:Cholesterol liposome isolated antibodies was 
further investigated by substituting cholesterol for various different sterol 
molecules on an array platform. A direct comparison was made between anti- 
GM1:Cholesterol antibody binding under these conditions. 
Antibody binding to GM1 in the presence of Ergosterol (Ergo), Lanosterol (Lano), 
Cholesterol Sulphate (Chs) or Diosgenin (Dios) was very weak or absent when 
compared to GM1:Cholesterol binding intensity(Figure 3.10 B). Whereas, both 
Cholestenol (Stan) and Coprostanol (Copr) demonstrated equivalent binding 
intensities to GM1:Cholesterol complexes (Figure 3.10 C).  
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Figure 3.10. Arrays containing GM1 complexes with cholesterol variants probed with 
purified IgG GM1:Cholesterol antibody. 
A. Antibody detection on glycoarrays using an HRP labelled secondary antibody. B. Intensity 
readout corresponding to arrays developed using ECL. Analysis was conducted with a one way 
anova using Tukey’s multiple comparison test (*p value≤0.05, **p value≤0.01, ***p value≤0.001 and 
****p value≤ 0.0001).C. Intensity readout corresponding to arrays developed using fluorescence. D. 
Structure of four of the different sterols examined in this study. 
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3.4 Discussion 
3.4.1 Future technical improvements 
There is considerable room for further progress in affinity purification of 
antibodies from patient sera. Firstly, a considerable amount of IgG antibodies 
remained bound to the liposomes after the final elution step (Figure 3.8). This 
result might be explained by a number of different factors. The most important 
factor which would require further analysis is the extraction/elution buffer 
composition. Alving and Richards demonstrated that glycine-HCl buffer was 
amongst the less efficient solutions for antibody-lipid dissociation (Alving and 
Richards 1977a;Alving and Richards 1977b). Instead, this study recommended 
CHCl3/Saline followed by elution using 1M NaI as the most effective methods of 
extraction. The method was proven so effective that the time for incubation 
with extraction buffer could be reduced down to 10 minutes. It could be 
expected then that a new extraction/elution buffer would reduce the 
concentration of antibody bound to the liposomes after final elution and 
increase antibody recovery. 
3.4.2 Future prospectives 
 Evaluation of the antibody binding diversity to GM1:Cholesterol epitope by 
assessing the polyclonality of the purified antibody using isoelectic 
focusing (IEF). 
 Assess the effect of antibody binding to increasing concentrations of 
cholestenol complexed to GM1 compared to Cholesterol (Figure 3.9). 
 Use 5-alpha-colestane, a cholesterol derivative lacking the A ring β-OH 
group. 
 Test the potential tissue binding of the purified antibody in order to 
locate cholesterol-enriched GM1 domains in nerve preparations. 
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3.4.3 Conceptual development 
The single most striking observation to emerge from the antibody isolation 
studies is the presence of an anti-GM1 antibody which solely binds GM1 in the 
presence of a high molar ratio of Cholesterol. However, the initial 
interpretation, derived from Figure 3.6, was that IgG antibodies binding GM1 
single epitope are cis-enhanced by the presence of cholesterol. These studies to 
our knowledge are the first to demonstrate the existence of GM1:Cholesterol 
ratio-dependent, complex-specific antibodies. These findings stress the 
complexities of working with polyclonal serum samples in which multiple 
competing reactivities can mask individual binding patterns. Therefore it is 
essential to constantly re-evaluate the concept of cis-enhancement. The 
GM1:Cholesterol enhancement observed in the array using whole, unpurified BTN 
serum (Figure 3.6) was due to the presence of a different subset of antibodies all 
of which were complex specific. These observations highlight the polyclonality 
of the antibody repertoire and suggest an alternative interpretation of antibody 
binding cis-enhancements in the context of glycoarray analysis. 
Having concluded that anti-GM1:Cholesterol antibodies are a different subset of 
antibodies from the single reactive anti-GM1 antibodies found in whole BTN 
serum, the question which arises is what makes the partnership between 
cholesterol and GM1 so different from GM1 alone clusters. Lingwood and co-
workers described the structural modulation of GM1 by cholesterol enriched 
domains (Lingwood, Binnington, Rog, Vattulainen, Grzybek, Coskun, Lingwood, & 
Simons 2011). This article suggests that cholesterol is capable of altering the 
structure of GM1 by tilting its sugar headgroup orientation from perpendicular to 
parallel the membrane surface. This sterol induced structural change of GM1 
made the glycolipid unavailable for cholera toxin binding. In addition to this, the 
necessary molar ratio of cholesterol to induce structural changes to GM1 was 
50:1. This data demonstrates how heteromeric complexes may influence the 
presentation of antigen by either favouring or inhibiting ligand binding. In 
contrast to Lingwoods findings, BTN isolated antibody, exclusively binds GM1 
epitopes containing abundant cholesterol, suggesting that this Ab binding would 
favour a specific structural orientation of the glycan epitope (Figure 3.9 and 
Figure 3.11). A more recent study using molecular dynamics simulation, has 
established that cholesterol may alter the structure of GM1 and GalC by creating 
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hydrogen bond networks between its donor OH group and GM1’s glycosidic bond 
which links the ceramide to the glycan fraction (Figure 3.11 B). In addition, 
other stabilisation interactions were found between GM1 and cholesterol which 
were mediated by Van der Waals forces, interacting with the ganglioside’s 
ceramide moiety (Di et al. 2013). This evidence support previous studies 
suggesting that the structure of cholesterol is relatively specific for an optimum 
formation of glycolipid complexes (Niedieck 1975a;Niedieck 1975b;Yahi, Aulas, & 
Fantini 2010). One of these studies, using anti-GalC sera which precipitated GalC 
micelles solely in the presence of cholesterol but not but not in its absence, 
reported a differential behaviour of these antibodies after substituting 
cholesterol by other sterols. However, molecules such as cholestanol and 
coprostanol exerted the same effect on the antibody binding to micelles as 
cholesterol. On the other hand, antibody binding did not occur in the presence 
of sterols in which the OH group at the 3 position of the A ring had been 
substituted (Niedieck and Kuck 1976). Our data suggests a similar behaviour of 
coprostanol and Cholestenol, showing a comparable effect to that of cholesterol 
in forming complexes with GM1 (Figure 3.10 B and C). Moreover, Cholesterol 
Sulphate (Chs) in which the OH group of the A ring is substituted by a sulphatide 
group, does not induce antibody binding in the presence of GM1. There is, 
however, a discrepancy; Diosgenin (Dios) and Lanostherol (Lan), sterol 
containing OH groups in the A ring, do not facilitate antibody binding when in 
complex with GM1 as seen our glycoarrays (Figure 3.10 C). According to Niedieck 
and Kuck (Niedieck & Kuck 1976), the nature of the domains formed by 
cholesterol is mainly conferred by the presence of an unaltered aliphatic side 
chain and an A ring OH group in β position. Therefore it could be hypothesised 
that our GM1:Cholesterol IgG antibody has other structural requirements apart 
from the OH group for optimum binding. Some of these requirements could 
include the presence of a planar ring system or the α and β position of the OH 
group in the A ring (Niedieck & Kuck 1976). 
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Figure 3.11. Diagram illustrating the Hypothesis of “GM1 structure change”. 
A. Absence of antibody binding to GM1 in the presence of low cholesterol ratios (indicated by a red 
cross). High cholesterol ratios inducing a structural change to GM1 facilitating glycolipid-antibody 
recognition (indicated by a green tick). B. GM1 backbone structures illustrating the conformation 
change. Red dotted line represents hydrogen bonding and blue line around the cholesterol depicts 
the prescence of Van der Waals forces.  
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Another plausible explanation for how cholesterol impacts on antibody binding 
to GM1 could be explained by considering high density GM1 clusters. In the case 
of Cholera Toxin, binding to GM1 in a liposome model membrane (MacKenzie et 
al. 1997) or on immobilised bilayers (Shi et al. 2007), it has been demonstrated 
that binding strength was almost exclusively dependent on ligand density, such 
that toxin binding was found to be weakened on high density domains of GM1.  
Monovalent interactions of most anti-carbohydrate antibody and lectins with 
their target are known to be very weak. To compensate they rely on engaging 
multiple binding arms to increase the avidity of the interaction and so, density 
of the antigen is crucial to ensure simultaneous binding event may occur. It is 
possible that cholesterol may act as a spacing molecule in which GM1 is 
dispersed at optimum distances to allow such interaction to occur. 
This antibody screening approach could open up a hitherto unexplored and 
entirely novel area of biomarker discovery, were epitope structure and 
clustering could be tailored by using sterols and other highly abundant 
membrane molecules at different molecular ratios (Figure 3.12). 
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Figure 3.12. Two hypothesis for multivalent binding molecules. 
A. Illustration highlighting the possibility of “spacing” as a key player for antibody binding 
stabilisation. B. “Spacing and structural change” as the factors potentially involved in multivalent 
binding stabilisation. 
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4 Chapter 4. Antibodies to heteromeric glycolipid 
complexes in Multifocal Motor Neuropathy. 
4.1 Introduction 
As outlined in Chapter 3, the interaction of GM1 with neighbouring GSLs can play 
a major role in modulating Ab binding. Recent observations (Nobile-Orazio, 
Giannotta, Musset, Messina, & Leger 2013) on an MMN cohort have confirmed the 
Ab binding enhancing effect of GalC over GM1 Ab binding (Pestronk, Choksi, 
Blume, & Lopate 1997). In contrast, other GSLs can inhibit Ab binding to GM1. A 
good example is GD1a which has been reported as cis-inhibitory when in complex 
with GM1 after sera profiling of MMN patients (Nobile-Orazio, Giannotta, & 
Briani 2010). 
This chapter will attempt to describe the anti-GSL profile found in MMN patient 
sera, with particular emphasis on the enhancing or inhibitory effect of adjacent 
molecules to antibody binding. 
4.2 Chapter aims 
 Establish glycoarray as a robust method for routine diagnostic use in MMN. 
 Identify new GM1 ganglioside complexes in MMN which might unmask 
previously undetected antibody reactivities. 
 Investigate and characterise pattern recognition antibodies in MMN 
 Validate the findings on an external, double blinded cohort containing 
equal number of patients and controls. 
4.3 Southern General Hospital serology study 
4.3.1 Study aims 
 To investigate the antibody fingerprint of MMN sera using a recently 
developed combinatorial glycoarray, in which highly diverse repertoires of 
heteromeric complexes of lipids and glycolipids can be readily examined 
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for enhanced or attenuated antibody binding(Brennan, Galban-Horcajo, 
Rinaldi, O'Leary, Goodyear, Kalna, Arthur, Elliot, Barnett, Linington, 
Bennett, Owens, & Willison 2011;Rinaldi, Brennan, Goodyear, O'Leary, 
Schiavo, Crocker, & Willison 2009). 
 Compare the performance of Glycoarray screening with conventional 
ELISA methodology.  
 Using the same patient samples and MMN-derived monoclonal antibodies, 
further investigate antibody binding to epitopes consisting of specific 
molecular patterns, as described in the previous chapter. 
4.3.2 Study design 
Sera of 33 patients fulfilling diagnostic criteria for MMN were collected from the 
Southern General Hospital Glasgow, mostly undergoing treatment in our local 
clinical centre. 22 of these patients had undergone screening for a clinical trial 
of a complement inhibitor (Fitzpatrick et al. 2011). 
Other neurological disease (OND) sera (n=30) comprised other neuropathies 
(n=6), multiple sclerosis (n=4), motor neurone disease (n=3), chronic fatigue 
syndrome (n=2), non-organic or undiagnosed neurological disorder (n=6), 
encephalopathy (n=1), cerebrovascular disease (n=1), optic neuritis (n=1), viral 
meningitis (n=1), migraine (n=2), headache (n=1), idiopathic intracranial 
hypertension (n=2). 
Sera from healthy controls (HC) were obtained from 27 volunteers. 
Sera was screened by glycoarray against an initial panel comprising the following 
lipids and glycolipids and their 1:1 (weight to weight) heteromeric complexes: 
GM1, GM2, GD1a, GT1b, GA1, galactocerebroside (GalC), 3-sulphated 
galactosylceramide (sulphatide, sulph), sulphated glucuronyl paragloboside 
(SGPG), sialosyl-lactoneotetraosylceramide (LM1) and phosphatidylserine (PS). 
The same sera was then screened using ELISA against GM1, GalC and GM1:GalC. 
All sera were screened a minimum of three times (n=3). 
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4.3.3 Results 
All MMN and control samples were screened by glycoarray comprising 10 single 
lipids and their 45 possible 1:1 complexes. Preliminary results showed 9 
characteristic antibody binding fingerprints being shown in Figure 4.1, alongside 
2 controls. 
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Figure 4.1. Representative blots from glycoarray. 
Examples of glycoarrays from 9 MMN (2-10) and 2 control (11-12) cases, illustrating the different 
patterns of binding to individual glycolipids and their 1:1 complexes. Glycoarrays are printed in a 
grid, with the topmost row and far left hand column containing spots of 10 individual glycolipids, 
and the remaining spots comprising the complex formed from the combination of the glycolipids in 
the corresponding row and column. The template is shown in Array 1 as follows: 0, methanol; 1, 
GM1; 2, GM2, 3, GD1a; 4, GT1b; 5, GA1; 6, GalC; 7, SGPG; 8, sulphatide; 9, LM1; 10, PS. Each 
glycolipid and complex is thus printed in duplicate per array. A line of symmetry runs lop left to 
bottom right, in which no antigen is spotted (marked with X). The intricacy of antibody binding 
patterns to single glycolipids and complexes can be readily appreciated. 
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4.3.3.1 Determining a cut-off value for positivity 
As the glycoarray had not previously been systematically applied to an MMN 
population, there was no pre-determined upper limit of normal range (ULN) prior 
to the start of this study. Two proposed methods for determining ULN were 
compared. Firstly, the median and 95% confidence interval of GM1 spot intensity 
signal in the healthy control population was calculated by Wilcoxon signed rank 
test (as data were not normally distributed) giving an estimated median of 460 
intensity units (IU), with a 95% confidence interval of 341 to 654 IU. Secondly, as 
the correlation coefficient for ELISA and glycoarray was high (0.78) (Figure 4.6 
A), the regression equation was used to directly calculate the glycoarray value 
equivalent to 0.1 OD units on ELISA, yielding an ULN for the glycoarray of 4365 
IU. This latter, more restrictive, value (4365 IU) was used as the cut-off value 
for positivity for GM1 and all other single lipids and heteromeric complexes 
studied in the glycoarray. 
Using this cut-off value, 19/33 MMN samples were positive for anti-GM1 IgM by 
glycoarray. 3 of the samples positive for anti-GM1 IgM by ELISA were negative 
when screened by glycoarray (Figure 4.6 A). 
4.3.3.2 Analysis of combinatorial glycoarray data 
Array data from all MMN cases, OND and healthy controls were subjected to 
cluster analysis that yielded a heat map comprising spot intensities for 40/55 
glycolipids and glycolipid complexes amongst cases and controls (Figure 4.2 A). 
For the remaining 15 targets, no detectable array signal was obtained from any 
of the samples (cases or controls), and these were excluded from further 
analysis. Spot intensities were categorised as either positive (>4365 AU) or 
negative (<4365 AU) and each of the 40 remaining glycolipid and glycolipid 
complexes were then individually subjected to ROC analysis, comparing MMN 
cases (n=33) with the combined OND and healthy control groups (n=57). The 
areas under the ROC curve (AUC, used as a summary measure of diagnostic 
accuracy) were ranked according to value (Figure 4.2 B). Through this process, 
the best performing glycolipid complex combinations for diagnostic accuracy 
were identified as GM1, GA1 and GM2, all in complex with GalC. Another high 
performing complex was GM1:SGPG. Although ranked 3rd, this marker was not 
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considered further in this study as SGPG is scarcely available and thus 
impractical for routine diagnostic use in most laboratories.  
ROC graphs for GM1, GA1 and GM2, individually and in complex with GalC are 
shown in Figure 4.2 C, and all the individual sample intensity values in Figure 4.2 
D. 
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Figure 4.2. Quantitative and statistical analysis of glycoarray data. 
Panel A. Heat map showing the values (logarithmic scale) of antibody binding intensity to the 40/55 
single glycolipids and complexes that returned a detectable signal for 33 MMN patient sera, 27 
healthy controls and 30 ONDs. The 15 lipids or lipid complexes that returned no signal in any 
samples are excluded from the heat map. The minimal value assigned to any sample was set at 
3.6 IU, corresponding to log 10 ULN (4365 AU). Thus, pale green corresponds to antibody negative 
signals (<4365 AU), darker green and black to mid-range signals and red to high value signals. 
Panel B. ROC analysis was applied to rank signals by sensitivity/specificity ratio as a summary 
measure of assay performance, the highest values representing the best performing glcyolipids 
and lipid complexes. Black bars highlight datasets plotted in Panels C and D. Panel C. Individual 
ROC curves for 3 single glycolipids (GM1, GM2 and GA1) and their complexes with GalC. Panel D. 
Individual glycoarray intensity values for MMN cases and all controls against 3 single glycolipids 
(GM1, GM2 and GA1) and their complexes with GalC.  
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Examining these data, GM1:GalC is the best performing complex for diagnostic 
sensitivity and specificity in this MMN population. Non parametric testing also 
revealed GM1:GalC as the lipid complex most significantly differentiating the 
MMN group from the combined control group (p=6.4x10-17) (Table 4.1). 
Table 4.1. Sensitivity and specificity values for GM1, GM2, GA1 and representative 
complexes. 
Antigen MMN Controls Sensitivity Specificity AUC 
 (n=33) (n=57)    
GM1 19 2 58% 96.5% 0.824 
GM1:GalC 33 4 100% 93.0% 0.979 
GM1:Sulph 22 3 67% 95.0% 0.889 
GM1:SGPG 24 6 73% 89.5% 0.894 
GA1 24 7 73% 87.7% 0.868 
GA1:GalC 31 17 94% 70.2% 0.938 
GA1:Sulph 31 15 94% 73.7% 0.769 
GA1:SGPG 28 15 85% 73.7% 0.838 
GM2 6 0 18% 100% 0.590 
GM2:GalC 28 6 85% 89.5% 0.890 
GM2:Sulph 21 2 64% 96.5% 0.863 
GM2:SGPG 26 6 79% 89.5% 0.868 
 
A characteristic of the glycoarrays as described here are the readily observable 
patterns of enhancement and attenuation seen with different complexes, in 
comparison with antibody binding intensity to the single lipid. Thus, the median 
signal intensity of antibody binding to GM1 in the MMN group was 13394 IU (IQR 
5213 – 28801). When GM1 is in complex with other glycolipids, the signal 
intensity may increase (complex enhanced), decrease (complex attenuated) or 
remain unchanged (complex independent) (Figure 4.3). 
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Figure 4.3. Diagram illustrating Ab binding profiles found in MMN sera. 
A. Illustrative blot from MMN sera. Nerve illustration showing inhibition by GD1a (B) and LM1 (C) of 
GM1 antibody binding. D. GalC mediated enhancement of GM1 antibody binding. E. Complex 
independent antibody binding to GM1. 
These data are quantified in the MMN group for GM1, GM2 and GA1 in complex 
with the 9 other antigens spotted in this glycoarray, where the single glycolipid 
signal intensity is set to zero for each sample as follows: 
Complex A:B  Single A Single B 
A:B-(A+B) 
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Figure 4.4. Patterns of antibody binding in MMN sera. 
GM1 (Panel A), GA1 (Panel C) and GM2 (Panel E) binding for MMN sera showing complex 
enhancement and/or attenuation with other glycolipids. Data are shown as box and whisker plots 
(median and interquartile ranges) depicting signal intensities above (complex enhancement) or 
below (complex attenuation) the intensity value for the single glycolipid which is set at zero. Panels 
B (GM1), D (GA1) and F (GM2) show representative glycoarrays from individual patients binding to 
each of the three glycolipids. For all MMN cases (n=33), datasets were derived in duplicate from 
the boxed coordinates comprising each of the single glycolipids and the 9 possible complexes. 
Most MMN sera bind to more than one complex; thus in Panels B and D, the 2 MMN sera are 
binding strongly to GM1:GalC and GA1:GalC; and in Panel F, the MMN serum is binding strongly 
to GM2:GalC and GA1:GalC. Other complex reactivities are also often seen (e.g. sulphatide:GalC 
and SGPG:GalC in Panels B and F) but were not subjected to further enhancement and 
attenuation analysis. 
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Illustrative arrays from individual patients are shown in the adjacent panels 
(Figure 4.4). From these data sets, it is evident that GalC always provides the 
greatest complex enhancement for GM1, GA1 and GM2. Thus for GM1 in complex 
with GalC, the mean intensity of the GM1:GalC complex was significantly higher 
(paired t-test, p=0.008) by 8797 IU (95% CI, 2538 – 15056), compared with the 
intensity of the sum of each single spot (GM1 single + GalC single). A similar 
pattern was observed for GM2 and GA1. Other enhancing glycolipids for GM1, 
GM2 and GA1 are sulfatide and SGPG, a finding supported by data shown in Table 
4.1. By contrast the complex-inhibiting glycolipids for antibody binding to GM1, 
GM2 or GA1 were LM1, GD1a, and GT1b. 
4.3.3.3 Analysis of Control population 
From visual observation of the heat map for the array data (Figure 4.2 A), (4365= 
3.6 therefore all values represented are positive), it is clear that IgM antibodies 
to certain individual glycolipids and their complexes are present in a proportion 
of both OND and normal controls in addition to MMN samples, GalC:SGPG being 
prominent in this respect. Individual data values in control samples for 6 
antigens shown in Figure 4.2 D indicate that for some glycolipids sensitivity is 
low but specificity is high (e.g. GM2), whereas for others (e.g. GA1:GalC) high 
sensitivity is offset by lower specificity, as summarised in the ROC analyses 
(Figure 4.2 B). Quantified examples for GM1 and GM2 in complex with GalC, 
sulfatide or SGPG are shown in Table 4.1.  
Evaluation of these findings is, by definition, dependent upon the statistical 
methodology used for setting assay thresholds; thus had we used the upper 95% 
confidence interval of the median control value as the ULN in glycoarray, 25/33 
of the MMN population would be positive for anti-GM1 antibodies, equating to 
76%, as opposed to 19/33 (58%), when the ULN of 4365 was applied. By corollary, 
lowering the threshold for sensitivity also decreases the specificity.  
Since the GM1:GalC complex assessed by glycoarray appears from this study to 
be a highly sensitive marker for MMN, careful attention was paid to the 4 
positive samples for this complex in the control population (data points as shown 
in Figure 4.2 D). These data are plotted for the OND group (n=30) in Figure 4.5 
A, for both ELISA and glycoarray in comparison with data for GM1 alone. Of the 4 
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OND samples, one was positive for both GM1 and GM1:GalC by both ELISA and 
glycoarray (sample 1). The remainder were either negative for GM1 by ELISA 
(samples 2, 3, 4) and glycoarray (samples 3, 4) or negative for GM1:GalC by 
ELISA (samples 3, 4). The glycoarray for sample 1 is shown in Figure 4.5 B and 
shows a range of antibodies to single glycolipids and complexes in addition to 
GM1 and GM1:GalC, most notably GA1 and GA1:GalC. Clinically, sample 1 was 
catalogued as having ‘idiopathic peripheral neuropathy’ but on review of the 
clinical notes had presented with multifocal upper limb motor and sensory 
symptoms affected ulnar and radial nerves with median nerve motor conduction 
block in a forearm segment. When previously assayed for anti-GM1 IgM by ELISA 
as part of routine diagnostic workup, this serum sample contained anti-GM1 
antibodies just below the ULN for the assay, and thus had been reported as 
negative at the time. In retrospect, this patient may have fulfilled diagnostic 
criteria for MMN or Lewis-Sumner syndrome but this was not evaluated further, 
and the sample was retained in the OND group. 
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Figure 4.5. Analysis of positive controls. 
Panel A. Analysis of the OND samples registering low positive intensity values for either GM1 
and/or GM1:GalC by either ELISA and/or glycoarray. One sample (numbered 1) is positive for GM1 
and GM1:GalC by both ELISA and glycoarray, and the corresponding glycoarray is shown in Panel 
B. 
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4.3.3.4 Comparative analysis of ELISA and glycoarray data for MMN 
samples  
ELISA and glycoarray values for GM1 and GM1:GalC complex were determined to 
have high correlation coefficients by regression analysis (Figure 4.6 and Figure 
4.7). Thus, comparison of ELISA and glycoarray for determining anti-GM1 IgM Ab 
yields a correlation coefficient of 0.78 (Figure 4.6 A). The correlation 
coefficients for GM1 versus GM1:GalC (Figure 4.6 B-C) were also high, whether 
assaying by ELISA or glycoarray (0.92 and 0.72 respectively). Focusing on samples 
at the lower end of the assay range in ELISA, 7/11 anti-GM1 Ab negative MMN 
samples were either very weakly or borderline positive for GM1:GalC complexes 
(Figure 4.6 B). Using the glycoarray in the same comparative analysis between 
GM1 and GM1:GalC complex (Figure 4.6 C), average IU values were in general 
higher for GM1:GalC than for GM1 alone, and all 33 MMN samples were GM1:GalC 
positive (i.e. above the 4365 IU threshold), compared with 19/33 for GM1 alone. 
Data from more detailed examination of the GM1:GalC complex is shown in 
Figure 4.7.  
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Figure 4.6. Regression analysis of GM1 and/or GM1:GalC for both glycoarray and ELISA. 
Panel A. Correlation coefficient, r=0.78 between ELISA and glycoarray for GM1 antibody binding. 
Panel B. Correlation coefficient, r=0.92, between GM1 and GM1:GalC intensity values for ELISA 
data. Panel C. Correlation coefficient, r=0.71, between GM1 and GM1:GalC intensity values for 
glycoarray data. 
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Using the assay cut-off criteria described above and including all control samples 
(n=57), ROC analysis was used to assess the overall sensitivity and specificity of 
the glycoarray and ELISA techniques and showed no significant difference in 
diagnostic performance (p=0.59) (Figure 4.7 A). Examining the data sets for 
individual MMN sera from both assays (Figure 4.7 B), the correlation coefficient 
is 0.57. Four MMN samples negative for anti-GM1:GalC complex IgM antibodies by 
ELISA were positive by glycoarray (Figure 4.7 C, an expansion of bottom left 
corner of Figure 4.7 B). The corresponding glycoarrays for these 4 samples are 
shown in Figure 4.7 D. In each of these 4 samples, reactivity with other 
glycolipids or complexes are also seen, including GM2, GM2:GalC, GA1 and 
GA1:GalC. 
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Figure 4.7. Comparative data of ELISA and glycoarray performance for MMN serum binding 
to GM1:GalC. 
Panel A. ROC curves show high performance for the two methods, that are insignificantly different 
(p=0.59). Panel B. Correlation analysis shows a coefficient of 0.57 between the 2 methods. Panel 
C. Magnified view of ELISA-negative values (n=4) that were positive by glycoarray. Panel D. 
Individual glycoarray blots of the 4 ELISA-negative, glycoarray- positive MMN samples shown in 
Panel C. 
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4.3.4 Study remarks 
It may be assumed that the strength of the correlation between ELISA and 
Glycoarray methodologies negates the need to replace a well establish 
technique such as ELISA with glycoarray for routine diagnostics for MMN in the 
hospital setting. Whilst ELISA remains an excellent technique for detecting 
antibodies to single or complexed lipids present in serum at medium to high 
titre, our data suggest that the glycoarrary method may be more sensitive at the 
lower end of the detection range. 
Although being equally sensitive and specific than ELISA at medium to high 
titres, this new method has several strong advantages over ELISA: 
 It permits simultaneous screening of an extensive complex ganglioside 
panel with no increment on the amount of sera employed. Containing 
within the same panel an internal duplicate for every epitope. 
 Allows the identification of an antibody binding fingerprint, specific for 
every disease. Being characterised by complex dependent enhancements 
and inhibitions. 
 Visual location of spots facilitates differential analysis of background and 
genuine antibody binding. 
 There is a significant reduction in sample and reagent volume. 
This study provides strong support for the long-standing observation by Pestronk 
and colleagues that a complex of GM1:GalC constitutes a very sensitive antigen 
for screening MMN sera(Pestronk, Choksi, Blume, & Lopate 1997). Indeed, in this 
cohort of 33 MMN cases, all sera were reactive against the GM1:GalC complex in 
glycoarray screening, including those that were not reactive to either GM1 or 
GalC alone. In addition, 4 cases whose sera were negative for antibodies to the 
GM1:GalC complex by ELISA, were positive by glycoarray. These findings need to 
be viewed cautiously until the overall conclusions can be validated in an 
independent, blinded cohort containing a randomised selection of MMN cases 
and appropriate controls.  
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Although the 33 cases from our national area were randomly selected for 
inclusion in this survey, referral bias to both our diagnostic neuroimmunology 
laboratory and clinical service may have been a factor in increasing the 
proportion of antibody positive cases. Moreover, the lack of an automated 
quantification process of spot intensity could somehow contribute to an increase 
on the bias. 
The principle clinical point emerging from this study is that the diagnostic yield 
of the standard anti-GM1 antibody ELISA can be improved upon through use of 
the combinatorial glycoarray.  
The finding of antibodies to GM1 in complex with other glycolipids influences our 
ideas about the immunopathogenesis of MMN by providing further support for an 
antibody-mediated autoimmune hypothesis. What remains unknown is whether 
any complexes that are capable of binding antibody exist in the living nerve 
environment, and where they might be localised. Equally, inhibitory complexes, 
such as GM1:GD1a, may play important roles in attenuating antibody binding and 
subsequent tissue injury, as has been shown experimentally (Greenshields, 
Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, Easton, Roxburgh, 
Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 2009). Further 
information about this will come from isolating anti-complex antibodies for use 
in more detailed pathogenesis studies. 
4.4 Cryptic behaviour of GBS/MMN-derived human 
monoclonal antibodies. 
4.4.1 Study aims 
GBS/MMN-derived human monoclonal antibodies were used to investigate the 
effect of neighbouring lipids to GM1 single binding. 
4.4.2 Results 
The binding pattern of previously cloned GBS/MMN-derived human monoclonal 
antibodies(Willison, Paterson, Kennedy, & Veitch 1994) was first evaluated on 
the lipid panel used in the original SGH MMN study. MAbs BO1 and BO3 were 
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excluded from the current study because of their preferential binding to GA1 
over GM1. 
 
Figure 4.8. Glycoarray binding fingerprint of human mAb SM1 . 
The glycolipid panel comprised GM1, GM2. GD1a, GT1b, GA1, GalC, SGPG, Sulph, LM1 and PS. 
Data corresponding to the SM1 binding fingerprint revealed a similar pattern to 
that observed in SGH MMN patients. GM1 complex binding was characterised by 
GD1a and LM1 inhibition and GalC moderate enhancement (Figure 4.8). In 
addition to this, SM1 presented complex dependent binding to GA1:GalC (Figure 
4.9). GA1 and GM1 molecular structures are identical, except GM1 contains a 
sialic acid group attached to the internal galactose molecule. It is possible that 
binding signal seen for both GM1:GalC and Ga1:GalC represents one or more 
antibodies binding to the same epitope, shared by both heteromeric complexes, 
or different antibody species binding to unique complex dependent epitopes. 
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Figure 4.9. Diagrame ilustrating ganglioside molecular mimicry. 
 
Monoclonal antibodies SM1 (MMN), BR1 (MMN) and DO1 (GBS) were then probed 
against arrays containing different molecular ratios of GM1:GalC, as previously 
done for MMN sera. 
An unexpected finding was that the binding intensity of all three mAb was 
significantly decreased for GM1:GalC complex at a 1:1 ratio, when compared 
with the summed binding intensity of the single lipid components (Figure 4.10 
A). SM1 binding was constant for GM1:GalC ratios between 1:1 and 1:120 (w/w) 
exerting an average intensity of 25954.44 ±1093.8 (Figure 4.10 A). In contrast, 
BR1 and DO1 were unable to bind GM1:GalC complexes at molecular ratios equal 
to or greater than 1:10 and 1:40 (w/w) respectively (Figure 4.10 A). 
Human monoclonal antibody BR1 was derived from a patient included in the SGH 
MMN study previously described. Interestingly, the antibody binding pattern 
described for BR patient serum comprised a strong enhancement of GM1 binding 
in the presence of GalC at a 1:1 w/w ratio (Figure 4.10 B). This data was in 
contrast with the GM1 binding inhibition exerted by BR1 mAb in the presence of 
GalC at any molecular ratio. There are several possible explanations for this 
results, all explained by the polyclonal nature of patient sera. First, the data 
may be explained by the presence of several different anti-GM1 single antibodies 
in BR serum. Among this highly diverse antibody subset some would be binding 
GM1 in the presence of GalC (independent or enhanced) and others would not 
(inhibited). BR1 mAb would belong to the group of anti-GM1 antibodies which 
are inhibited by the presence of GalC. Although BR serum would be representing 
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all the spectrum of GM1 reactivity. A second possible explanation would be the 
presence of complex dependent GM1:GalC (1:1 w/w) antibodies and GM1 single 
specific antibodies. The first antibody subset would recognise GM1 exclusively in 
the presence of GalC but not GM1 alone and the second subset would only 
recognise GM1 when presented as a single epitope. BR mAb would therefore 
have been cloned from a subset of GM1 antibodies which only recognise GM1 
when presented as a single epitope. These findings highlight the fact that in 
polyclonal serum multiple antibodies may be targeted to different epitopes on 
the same molecule and that these antibodies respond differently to the presence 
of a secondary lipid (i.e. enhanced, attenuated or independent).It is these 
unique antibody fingerprints that are is frequently obscured when examining 
whole sera, due to the competing nature of the various antibodies, and can only 
be discriminated when using mAb. 
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Figure 4.10. Human monoclonal antibodies binding profile. 
Panel A. Arrays depicting antibody binding to GM1 single or in complex with increasing amounts of 
GalC (w/w) followed by a graphic representation of antibody binding intensity. Analysis was 
conducted with a one way anova using Tukey’s multiple comparison test (****p value≤ 0.0001) 
Panel B. Ab binding profile of MMN patient sera BR, highlighting the presence of a GM1:GalC 
binding enhancement. 
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4.5 Dutch MMN validation cohort (first screen) 
4.5.1 Results 
Array data from MMN cases and controls, including ALS cases and healthy 
individuals, were subjected to cluster analysis generating a heat map comprising 
spot intensities for 8 single lipid and 28 lipid complex epitopes (Figure 4.11). 
No threshold of positivity was applied to categorise the numerical data thus the 
intensities were expressed as intensity units. 
The strength of each biomarker was then assessed by ROC analysis comparing 
MMN cases (n=100) and controls (n=200). Complex lipids were analysed after 
intensity from each individual component was subtracted from the complex 
intensity. According to this evaluation, the best performing biomarkers were 
GA1:Sulph, GM1, SGPG:GalC, GM1:Sulph, GM2:GalC and GM2 with AUC of 0.807, 
0.775,0.709, 0.654, 0.606 and 0.570 respectively (Figure 4.12 A). 
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Figure 4.11. Quantitative analysis of glycoarray data. 
Heat map showing the values (AU) of antibody binding intensity to the 8 single glycolipids and 28 
complexes for 100 MMN patient sera and 200 controls (100 ALS controls and 100 healthy 
individuals). The minimal value assigned to any sample was set at 0 IU. The rainbow scale was 
applied to categorised the wide range of different intensities. Thus, black corresponds to antibody 
negative signals, with signal intensity increasing from pale blue to red. 
 
Chapter 4  105 
 
Unlike the original SGH MMN cohort, no individual glycolipid or complex was 
identified as a conclusive biomarker of this disease. However, The combination 
of the top biomarkers (overall markers), excluding SGPG:GalC, as diagnostic tool 
significantly improved the sensitivity of the test (84%) with a slight decrease of 
the specificity (81%) yielding an overall AUC of 0.865. The overall markers were 
proven to perform significantly better than GA1:Sulph alone (p=0.05). Although 
accompanied by an improvement of the diagnostic performance, the addition of 
SGPG:GalC to the overall markers was considered not significant (p=0.54)(Figure 
4.12 B). 
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Figure 4.12. Statistical analysis of best performing biomarkers. 
Panel A. Table containing the sensitivity and specificity for the best five performing biomarkers and 
their combined diagnostic efficiency (overall markers). Panel B. ROC analysis depicting the 
differences in assay performance between GA1:Sulph (AUC 0.807), overall markers (AUC 0.865) 
and overall markers plus SGPG:GalC (AUC 0.874). 
The enhancing effect of GalC, when complexed with a secondary lipid which was 
widely documented in my previous study (4.3) was not replicated in this current 
study, exceptfor GM2:GalC. The surprising failure of GalC complex binding 
enhancement when screening this cohort was exemplified by the lack of 
GM1:GalC enhanced reactivity, where only three patient sera measured a 
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significant increase of intensity unexplained by GM1 single reactivity. Out of 
these three MMN patients, only one (IU 8968.70) was above the 4365 AU set as 
positivity threshold on the SGH serology study, the other two presented 
intensities of 1586.60 IU and 1130.00 IU respectively (Figure 4.13 B). 
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A   B 
 
Figure 4.13. Heat map representation of Dutch serology data. 
Highlighting the best performing biomarkers on the Dutch cohort (A) and the previously found on 
the SGH serology study (B). 
Out of the 16 MMN patients negative for the overall markers depicted on Figure 
4.12 A, 7 were positive for SGPG:GalC (Figure 4.14 A). This increase of overall 
sensitivity explains the mild increase of the overall markers AUC after the 
inclusion of SGPG:GalC (from 0.865 to 0.874). However, the specificity for this 
biomarker was seen to be extremely poor, due to 13% of the controls containing 
IgM antibodies againstSGPG:GalC (Figure 4.14 B). 
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Figure 4.14. Analysis of negative patients for overall markers. 
Panel A. Heat map presenting the 16 MMN patients negative for ‘overall markers’. Panel B. Dot 
blot illustrating the antibody reactivity for SGPG:GalC in MMN patients versus controls. Highlighted 
as a red dot is the MMN patient whose glycoarray blot is represented in panel C. 
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Figure 4.15. Representative glycoarray blots. 
Examples of glycoarrays from 8 MMN cases, illustrating the different patterns of binding to 
individual glycolipids and their 1:1(w:w) complexes. Glycoarrays are printed in a grid, with the 
topmost row and far left hand column containing spots of 8 individual glycolipids, and the remaining 
spots comprising the complex formed from the combination of the glycolipids in the corresponding 
row and column. 
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4.5.1.1 Comparison of assay performance between ELISA and Glycoarray 
The sensitivity/specificity ratio of anti-GM1 antibody detection originated from 
ELISA and glycoarray was used to evaluate their assay performance. Sera 
samples were concurrently tested on ELISA (GM1) (screening done by Carolyn 
Watt, Southern General Hospital) and values were correlated with glycoarray 
values. 
The correlation curve with an R2 of 0.84 indicated an extremely robust fit 
between the performances of both techniques, with a slight tendency in favour 
of glycoarray due to its higher sensitivity (Figure 4.16 A). 
Further statistical analysis using ROC highlights a significantly better 
performance of glycoarray (AUC 0.775) compared to ELISA (0.673) (p=0.0016). 
ELISA while maintaining a really high specificity (99.5%) presented a really low 
sensitivity (35%). On the other hand, glycoarray demonstarted improved 
sensitive (58%) with just a slight reduction in specificity (96%) (Figure 4.16 B). 
 
Figure 4.16 Glycoarray and ELISA performance comparison. 
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4.5.1.2 Coefficient of variation (CV) 
A      B 
 
Figure 4.17. Inter-assay variability of a control sera used during a serology study.  
A. depicts the arrays containing GM1, GM2, GM3, GA1, SGPG, LM1, Sulph and GalC and their 
corresponding combinations originated from ten independent studies using a neuropathy control 
sera mainly reactive for GM2:GalC, GM1:GalC, GM2:Sulph and GM1:Sulph. B. shows the 
percentage of variation of GM1 and GM2 single and lipid combinations for ten independent studies. 
A patient previously screened within the SGH MMN study (4.3) was included as a 
positive control in every screening. This serum was selected due to its complex 
dependent reactivity with GM1:GalC and remarkable GalC mediated 
enhancement of GM2 signal. The known median intensities for GM1:GalC and 
GM2:GalC after single reactivity subtraction were 15558 IU and 25802 IU 
respectively. 
Figure 4.17 demonstrates that the inter-assay variability in glycoarray was 
frequently within the normal range of 10% for high and mid reactive lipid 
epitopes such as GM2:GalC, GM2:Sulph and GM1:Sulph. In addition to this, the 
median intensity for GM2:GalC for the current study was insignificantly different 
than the previously established with a value of 24935 IU. Values which would 
support the strength of the results obtained for this biomarker. CV percentages 
exceeding 10% in serology studies have been associated with epitopes presenting 
low antibody binding levels, denoting the detection limit for this technique 
(Reed et al. 2002). 
In our particular case, the high intensity units previously presented by GM1:GalC 
associated binding for this serum would be above the detection limit for this 
technique, previously established between 1000-2000 IU. Therefore, in this case 
the exceedingly high CV (>30 %) presented by GM1:GalC would indicate an 
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unusual fluctuation on the intensity signal for this biomarker which could not be 
explained by limitations on the array technique.  
4.5.2 Summary 
 The enhancing effect of GalC found in the SGH serology study (Chapter 
4.3.3.2) could not be replicated for any ganglioside with the exception of 
GM2 which presented a mild enhancement. 
 The enhancement in this cohort was predominantly mediated by 
sulphatide. 
 Glycoarray showed a better overall performance than ELISA detecting 
anti-GM1 antibodies. 
 The high CV on the house-keeping serum presented by GM1:GalC 
reactivity throughout this study could be due to: 
 A GalC reagent failure exclusively dependent on GM1. 
 An aliquot consistency failure of the house-keeping serum. 
4.5.3 Future recommendations 
 Investigate the integrity of the GalC stock, including: Batch to batch 
variation, stock solubility, difference in branding and molecular 
composition. 
 In order to avoid aliquot inconsistencies, prepare all the house-keeping 
sera with a mix of a minimum of three different aliquots of the same 
serum. 
 The selection criteria used for positive control serum samples is crucial. 
For all future studies three different types of sera controls should be 
used: a control with high antibody titre, one with moderate and one with 
low antibody titres. 
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4.6 GalC investigations 
The main objective of this study was to evaluate any potential change on GalC 
stocks which may explain the loss of GM1:GalC enhancement detected in the 
first screening of the Dutch cohort. The loss of GM1:GalC Ab reactivity in our 
positive control, lead us to believe in the possibility of a GalC reagent failure. 
For this study, sera previously screened in the SGH MMN cohort were used. 
4.6.1 Qualitative differences 
Our initial assumption was that GalC (Sigma) was not fully solubilised when 
resuspended in chloroform/methanol 1:1. This hypothesis was supported by the 
appearance of precipitate in the GalC and GM1:GalC upon preparation of the 
working solutions. For this reason, I will investigate GalC derived from different 
commercial suppliers. In addition to this, I will investigate whether the 
hydroxylation status of GalC stocks has an effect in antibody binding. 
An array containing GalC (Sigma), GalC (Matreya), hydroxylated GalC (Phrenosin) 
and non hydroxylated GalC (Kerasin) was printed and screened using mass 
spectrometry. Filters for Phrenosin and Kerasin were applied in order to 
discriminate between the most abundant species. Mass spectrometry studies 
were performed by Joanna Cappell. This technique allowed us to directly 
identify the presence of the species contained within the array without the need 
of antibody staining. At the same time, we were capable of identifying the 
hydroxylation profile of GalC. 
Contrary to expectations, mass spectrometry confirmed the presence of GalC 
spotted onto the array. Although a slight difference in quantity spotted between 
the stocks could be appreciated, indicated by the slight decrease in brightness of 
the Kerasin containing spots, this technique did not allow any detailed 
quantification (Figure 4.18 A). 
The most striking result to emerge from mass spectrometry data was the 
existence of a significant quantitative difference of Phrenosin and Kerasin 
between the single glycolipid stocks. Thus, GalC Sigma was seen to contain 
mainly Kerasin in both stocks and on the other hand GalC from Matreya was seen 
Chapter 4  115 
 
to contain mainly Phrenosin. Although mass spectrometry data would only give 
an indication of the predominant species, in order to appear as predominant the 
quantitative difference between species needs to be significant (Figure 4.18 A). 
In order to investigate the effect of these GalC species in Ab binding, arrays 
containing these species as single epitopes and in complex with gangliosides 
were printed and probed with MMN patient sera. Results were inconclusive when 
some sera were screened on an array containing the different species of GalC 
(Figure 4.18 B, C and D). It did not show an apparent antibody binding 
correlation between GalC Sigma, which according to mass spectrometry data 
mainly contains Kerasin, and Kerasin and GalC Matreya, which according to mass 
spectrometry data mainly contains Phrenosin, and Phrenosin. Moreover, it did 
not recover the GM1:GalC enhancement previously seen in these samples.  
The only exception was GM2:GalC which seem to maintain the enhancement but 
only when in complex with Sigman GalC (Figure 4.18 B and D). This data partially 
explains why the GM2:GalC enhancement was not lost during the Dutch MMN 
screening which was exclusively performed using Sigma GalC. 
No firm conclusions can be drawn from these results, but it could be postulated 
that the optimum composition of GalC for a GM1 binding enhancement could be 
a specific molecular ratio of both Phrenosin and Kerasin. This might explain the 
lack of correlation between GM2:GalC (Sigma) antibody binding with the binding 
to GM2:Kerasin (Figure 4.18 B). This theory would speculate that the optimum 
antibody binding to GM2 would take place on an environment mainly containing 
Kerasin but including a minor component of Phrenosin.  
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Figure 4.18. Phrenosin and Kerasin content of commercial GalC stocks. 
Panel A. Mass spectrometry data depicting the dominant GalC species, Phrenosin (green) and 
Kerasin (red) within the GalC commercial stocks. Panel B, C and D. Arrays highlighting the 
diversity of Ab binding to complexes containing different GalC species. 
4.6.1.1 Differential antibody binding to complexes containing Phrenosin and 
Kerasin 
It has been previously documented that proteins are selective when binding to 
either hydroxylated GalC (Phrenosin) or non-hydroxylated GalC (Kerasin) 
(Fantini, Maresca, Hammache, Yahi, & Delezay 2000;Hammache et al. 1998;Yahi 
et al. 1992). The presence of the hydroxylated group on the C2 of the fatty acid 
chain induces a conformational change in the molecule through the formation of 
an intra-molecular hydrogen bond network. This alters the orientation of the 
sugar head group from perpendicular to parallel to the membrane surface 
(Fantini, Maresca, Hammache, Yahi, & Delezay 2000). Proteins such as Beta 
amyloid bind preferentially to GalC when presented in the parallel orientation, 
where as some antibodies recognise the perpendicular conformation (Yahi, 
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Aulas, & Fantini 2010) (Figure 4.19). However, the impact of these 
conformational changes on ganglioside complexes has never been explored, but 
it is postulated to have a major impact in the formation of GSL complex 
epitopes. 
 
Figure 4.19. Kerasin and Phrenosin structure. 
Diagram illustrating Phrenosin structure change due to hydrogen bonding network, followed by an 
array probed with a recombinant protein with preferential binding to Kerasin. 
Strong evidence of differential mAb binding to ganglioside complexes containing 
hydroxylated and non hydroxylated GalC species was found after screening of a 
CANOMAD derived human mAb (HA1) on ELISA. As can be seen from Figure 4.20 , 
HA1 bound GM2 only when in complex with Phrenosin. The binding of HA1 to 
GM2:Phre was significantly different from Ab binding to GM2:Ker and GM2:GalC 
sigma (p value≤ 0.0001). As previously demonstrated using mass spectrometry 
(Figure 4.18 A), GalC (Sigma) mainly contains Kerasin. Therefore, the 
resemblance in HA1 binding intensities between GM2:GalC (Sigma) and 
GM2:Kerasin complexes indicates that the dominant species in GalC (Sigma) is 
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Kerasin. After addition of Kerasin in the GM2:Phre complex , a significant 
decrease on HA1 binding intensity was observed (p value≤0.01). In summary, 
these findings indicate that HA1 preferentially binds GM2 when in complex with 
Phrenosin. Thus, it could be postulated that the hydroxylation profile of GalC 
and its subsequent impact in glycolipid structure influences in the formation of 
GSL complexes and that translates in complex specific Ab binding. Therefore, 
these data heightened the need of a more in depth analysis on the impact of 
GalC hydroxylation status in the formation of complex epitopes. 
 
 
Figure 4.20. Monoclonal antibody binding profile on ELISA. 
MAb (HA1) binding profile, at a concentration of 20 µg/ml, to GM1 and GM2 complexes with GalC, 
Phrenosin, Kerasin, GalC sigma and Phrenosin+Kerasin. The assay consisted on two independent 
repeats with two internal duplicates within every repeat. Significance was obtained after one-way 
ANOVA analysis with Tukey’s multiple comparison test (**p value≤0.01 and ****p value≤ 0.0001). 
Horizontal dotted line represents the threshold of positivity set at 0.1 OD. 
4.6.2 Quantitative differences 
As a means to further investigate the potential issues derived from GalC 
solubility, lipids were solubilised both in chloroform:methanol (2:1) and 
chloroform:methanol:water (2:1:0.5). GM1 single concentration remained 
constant at 100 µg/ml and was premixed with GalC (Sigma) at 100, 200, 400 and 
800 µg/ml to form heteromeric complexes, containing half the initial 
concentration of each lipid (Figure 4.21 A). Arrays were then probed with MMN 
sera previously investigated in the SGH MMN study. 
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Data from Figure 4.21 B revealed the recovery of GM1 intensity enhancement, 
but only at increasing concentrations of GalC (Sigma). 1:1 W/W proportion, as 
previously used in the SGH MMN study failed to demonstrate an enhancement. 
The highest enhancement was at a GM1:GalC W/W ratio of 1:8. Moreover, this 
enhancement was partially attenuated when the lipids had been solubilised with 
the addition of water. 
Under these experimental conditions GM1 enhancement is dependent upon 
increased ratio of GalC which may indicate quantitative issues. 
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Figure 4.21. The effect of GalC concentration and solubilisation in GM1:GalC complexes. 
Panel A. Shows the lay out used for this study. Panel B. Presents characteristic fluorescent 
glycoarrays for 4 different MMN patients. 
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To solve this quantitative issue, the concentrations of GM1 as well as GalC were 
increased from 100 µg/ml up to 200 µg/ml, using as a stock solvent 
Chloroform:Methanol (2:1). It is worth pointing out that the W/W ratio between 
GM1 and GalC will be maintained constant and equivalent to the one used for 
the SGH sera screen (1:1 W/W). 
Arrays comparing GM1 at 200 µg/ml and GM1:GalC complexes, both at 200 
µg/ml, showed a significant intensity enhancement for GM1:GalC complexes in 
both ECL (Figure 4.22 A) and fluorescence (Figure 4.22 B). Further analysis 
revealed an insignificant difference between different GalC stocks and between 
stocks at 200 µg/ml and 400 µg/ml. All the data analysis was done using one-way 
ANOVA with Tukey’s multiple comparison test from independent triplicates of 
one single MMN patient sera. 
On a larger data set (n=4), MMN sera was tested against an array containing 
GM1, GM2, GA1 and their complexes with GalC. Both singles and complexes were 
tested at 100 µg/ml and 200 µg/ml. The only complex showing a significant 
increase in intensity enhancement after comparing complexes at 100 µg/ml and 
200 µg/ml was GM1:GalC (two-way ANOVA with Bonferroni correction for 
multiple comparison p value≤0.01). Thus GM1:GalC presented a higher intensity 
enhancement at 200 µg/ml even recovering the signal of borderline negative 
sera (Figure 4.22 C).  
No significant difference was found between GM2:GalC complexes at 100 µg/ml 
and complexes at 200 µg/ml (Figure 4.22 C). This lack of difference might 
explain why during the Dutch cohort first screening the GM2:GalC signal was 
maintained constant throughout the study, presenting a CV within acceptable 
range (Figure 4.17). It is apparent that the GalC mediated GM2 enhancement is 
less sensitive to fluctuations in the GalC content than the GM1:GalC 
enhancement.  
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Figure 4.22. Comparison of different GM1 and GalC concentration. 
ECL (A) and fluorescence (B) array comparing GM1 at 200 µg/ml with GM1:GalC complexes 
containing GalC at 200 µg/ml and 400 µg/ml. (C) evaluation of GM1, GM2 and GA1 antibody 
binding enhancement due to GalC. All single lipids were tested at two different concentrations, 100 
µg/ml and 200 µg/ml. 
4.6.3 Future recommendations 
 All the lipids included within the array will be solubilised using a 
chloroform:methanol (2:1) solution. 
 200 µg/ml will be the working concentration for the lipids included in the 
array. 
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 The four MMN patients characterised in Figure 4.22 C will be used as 
positive controls for the next MMN serology screening. For assay 
validation, positive control must maintain a CV no greater than 20%. 
4.7 Dutch MMN validation cohort (repeat) 
4.7.1 Study design 
 All lipids were reconstituted in chloroform:methanol 2:1 (Future 
recommendations 4.6.3).  
 New coded samples were used. 
 Samples were then screened (n=3) using the lipid panel as follows: GM1, 
GM2, GM3, GA1, SGPG, LM1, Sulph and GalC. 
 The lipid concentration for every lipid was increased up to 200 µg/ml, 
maintaining the molecular proportion used on the SGH screening. 
4.7.2 Results 
4.7.2.1 ROC analysis 
The strength of each biomarker was assessed by ROC analysis comparing MMN 
cases (n=100) and controls (n=200). Complex lipids were analysed after intensity 
from each individual component was subtracted from the complex intensity. 
According to this evaluation, the best performing biomarkers were GM1:GalC, 
GM1, GA1, GM2:GalC and GA1:GalC, as indicated by the AUC value (Figure 4.23 A 
and Table 4.2). GM1:GalC presented a significantly better performance than GM1 
(p=0.0047), the second highest performing biomarker. 
Combinations of various biomarkers increased the sensitivity of diagnosis 
compared to individual biomarkers. However, combined biomarkers resulted in a 
significant decrease in specificity. Due to this decrease in specificity there is no 
significant difference between the diagnostic performance of GM1:GalC and any 
of the different combination of biomarkers (Table 4.2). 
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Table 4.2. Top markers. 
 
4.7.2.2 GM1 and GM1:GalC analysis 
81 MMN patients (81%) contained IgM antibodies against GM1:GalC. Out of the 19 
(19%) GM1:GalC negative patients, there was 3 GM1 positive, 3 GA1 positive, 3 
GA1:GalC positive, 1 GA1:Sulph positive , 3 SGPG:GalC positive and 6 patients 
with no observable antibody reactivity. 23 ALS controls (23%) and 17 Healthy 
controls (17%), adding up to a total of 20% of the overall control population, had 
IgM antibodies against GM1:GalC. Thus GM1:GalC yielded a sensitivity of 81% and 
a specificity of 80% (Table 4.2 and Figure 4.23 B). 
67 MMN patients (67%) contained IgM antibodies against GM1. Out of the 33 (33%) 
GM1 negative patients, there was 17 GM1:GalC positive, 3 GA1 positive, 3 
GA1:GalC positive, 1 GA1:Sulph positive , 3 SGPG:GalC positive and 6 patients 
with no observable antibody reactivity. 24 ALS controls and 15 Healthy controls, 
adding up to a total of 19.5% of the overall control population, had IgM 
antibodies against GM1. Thus GM1 yielded a sensitivity of 67% and a specificity of 
80.5% (Table 4.2 and Figure 4.23 B). 
The addition of 17 GM1:GalC positive MMN patients (Figure 4.23 C and D) which 
were GM1 negative conferred a significant increase in the test sensitivity without 
a detriment on the specificity. The presence of 3 MMN patients positive for GM1 
but negative for GM1:GalC left the sensitivity increase achieved by the addition 
of GalC at a total of 14%. 
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Figure 4.23. Quantitative and statistical analysis of glycoarray data. 
Panel A. Individual ROC curves for 3 single glycolipids (GM1, GM2 and GA1) and their complexes 
with GalC. Panel B. Individual glycoarray intensity values for MMN cases and all controls against 
GM1 and GM1:GalC. Panel C. Heat map in rainbow scale showing the raw intensity values sorted 
through antibody binding to GM1, and corresponding GM1:GalC reactivities. Highlighted are the 17 
MMN patients negative for GM1 and positive for GM1:GalC. The colour scale is as follows: dark 
blue corresponds to antibody negative signals, pale blue and green low to mid-range signals and 
red high value signals. Panel D. Example of a glycoarray depicting patient sera with complex 
dependent GM1:GalC Ab binding.  
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4.7.2.3 First and second screening compared: GM1:GalC enhancement 
recovery 
The repeat screening of MMN positive control sera demonstrated GM2:GalC and 
GM1:GalC reactivities with CVs within the normal range (<20%). The average CV 
for the four MMN positive control sera was 18.35% for GM1:GalC and 12.87% for 
GM2:GalC. This major improvement in the CV of GM1:GalC reactivities would 
suggest a consistent behaviour of GalC epitopes.  
Correlation of data collected for GM1:GalC reactivities for the first and the 
second screening, demonstrated that the GalC mediated enhancement was 
recovered in the second screening (Figure 4.24 B) with a minor variability in the 
GM1 data (Figure 4.24 A). In the repeat screen, 14 MMN patients previously 
described as GM1 negative in the first study were subsequently positive. The 
increase in lipid concentration on the second screen could account for the slight 
increase in GM1 single reactivity (Figure 4.24 A). However, contrary to the 
notion of a generalised increase all lipid reactivities is that 3 patients which 
were GM1 positive on the initial screen, were found to be GM1 negative on 
repeat. 
A     B 
 
Figure 4.24. First and second screening correlation studies. 
GM1 (A) and GM1:GalC (B) data from the first and second screening were compared, obtaining a 
Pearson correlation index of r=0.60 and r=0.49 respectively. 
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4.7.3 Summary 
 CV data confirmed the consistency of our assay throughout the study. 
 Correlation studies between GM1:GalC data from the first and second 
screening, it can be confirmed that GalC mediated GM1 enhancement was 
majorly recovered. 
 Results confirmed the significantly higher sensitivity of GM1:GalC (81%) 
compared to GM1 (67%). 
 This major increase of sensitivity was accompanied by an insignificant 
decrease in specificity (from 80.5% to 80%). 
 Combinations of biomarkers including GM1:GalC did increase the 
sensitivity (from 81% to 86%) but at the cost of a significant decrease in 
specificity (from 80% to 74%). 
4.7.4 Future recommendations 
 The optimum ratio of Phrenosin:Kerasin in GalC preparations needs to be 
further explored. This study could eventually define the antibody profile 
of the 19 MMN patients negative for GM1:GalC. 
 A comparative study between ELISA and glycoarray, focusing on the 
diagnostic strength of GM1:GalC, would be required before adapting this 
test into ELISA-based routine diagnostics in a hospital setting.  
 The ELISA clinical validation sample set could consist on the Dutch cohort 
(300 samples), newly blinded, including the top targets from our previous 
study (GM1, GM2, GA1 and their GalC complexes). 
 Based on our current findings we would strongly recommend the 
introduction of GM1:GalC to the routine serology diagnostic test for MMN. 
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4.8 Discussion 
Initial findings on MMN serology corroborate the ideas of Pestronk and co-
workers (Pestronk, Choksi, Blume, & Lopate 1997), who postulated an enhancing 
effect of GalC in anti-GM1 antibody binding. The idea that GM1:GalC complexes 
compared to single GM1significantly increase the antibody detection sensitivity 
in MMN has been recently confirmed (Nobile-Orazio, Giannotta, Musset, Messina, 
& Leger 2013). Our assay, although similar in principle to those of Nobile-Orazio 
and Pestronk highly differs in methodology. Pestronk’s assay included a complex 
mixture of lipids, which he described as MAG-associated lipid fraction, consisted 
of GM1, GalC, and Cholesterol sulphate (GSC) at a proportion of 1:10:10. The 
initial results, obtained from a cohort including 21 MMN patients and 525 
controls, revealed that 19% of the patients presented elevated titres specific to 
GM1:GSC yielding an overall sensitivity of 62%, in contrast to the 43% of GM1 
alone. The specificity for GM1:GSC was 100%. Under the same principle Nobile-
Orazio tested MMN sera on a panel containing GM1:GalC at a 1:10 ratio. In this 
study, 75% of MMN patients showed a GM1:GalC specific reactivity, a 28% 
increase in sensitivity respect that of GM1 alone. This GM1:GalC increase in 
sensitivity was accompanied by a mild decrease in specificity (8%). The main 
featured differences between our assay and those described above are the array 
platform and the epitope composition. We used glycoarray as opposed to 
conventional ELISA. Our technique by incorporating the combinatorial factor 
allowed the identification of an antibody binding profile common to a majority 
of the MMN samples of the SGH serology test. This MMN antibody binding 
fingerprint consisted on GM1:GalC enhancement and GM1:GD1a/GM1:LM1 cis-
inhibition. Prior studies had already reported the presence of a GD1a cis-
inhibition of GM1 binding in MMN patient sera (Nobile-Orazio, Giannotta, & 
Briani 2010). Another key feature of our assay was the use of GM1:GalC at a 1:1 
weight to weight ratio. Under these conditions, our first study revealed that 
GM1:GalC complexes increased by a 42% the anti-GM1 detection sensitivity with 
just a 3.5% drop in specificity (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013). Our double blinded validation 
study came to confirm the significant increase in MMN diagnostic sensitivity 
conferred by the use of GM1:GalC complexes. 81% of MMN patients had anti-
GM1:GalC antibodies accounting for a 14% increase compared to GM1 alone 
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diagnostic sensitivity. All these preliminary evidence indicate the necessity of 
introducing GalC in partnership with GM1 as a diagnostic test for MMN in a 
clinical setting.  
The comparison of anti-GM1:GalC antibody detection efficiency between ELISA 
and glycoarray during the SGH study, showed a strong correlation between both 
techniques. This comparative study highlights the potential adaptability of 
glycoarray in routine diagnostics. However, further comparisons based on anti-
GM1 detection during the Dutch first screening, indicated a significantly better 
sensitivity/specificity balance for glycoarray. Therefore, the conflicting results 
would be a reflection of the existing inter-laboratory variability and could not be 
accounted as variability between different methodologies. These inconsistencies 
stress the need for a standardised protocol which would strongly benefit from an 
internationally coordinated meta-analysis to identify the source and magnitude 
of inter-laboratory variability. 
In Pestronk’s article, several of the MMN patients presenting high titers for anti-
GM1 Abs had low titers for anti-GM1:GalC Abs (Pestronk, Choksi, Blume, & 
Lopate 1997). This observation was then confirmed by the finding in the Dutch 
cohort, second screening, of three GM1 positive patients which were GM1:GalC 
negative. A more detailed analysis of this apparent paradox has been attempted 
throughout this chapter. An array containing GM1 as a single epitope and in 
complex with increasing amounts of GalC was used to probe neuropathy-derived 
human anti-GM1 IgM monoclonal antibodies. Results from these arrays revealed a 
high binding diversity among these mAbs. Although some antibodies (e.g. SM1) 
bound GM1 independently of GalC presence in any concentration, some mAb 
were unable to bind GM1 when in the presence of specific concentrations of 
GalC, confirming Pestronk’s initial observations (e.g. BR1) (Figure 4.10). 
Furthemore, this binding diversity could be found within the antibody repertoire 
of a single patient.  Interestingly, while the antibody profile of patient BR 
(Figure 4.10 B) was characterised by GM1 single binding followed by a GM1:GalC 
binding enhancement, BR1 the mAb derived from BR was unable to bind GM1 in 
the presence of GalC (Figure 4.10 A). This striking single observation could be 
explained by the presence within the same patient of three different types of 
anti-GM1 antibodies: 
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 Abs which bind GM1 single epitope with or without the presence of GalC 
(cis-independent) 
 Abs which exclusively bind GM1 when in heterodimeric partnership with 
GalC (complex dependent) 
 Abs which do not bind GM1 when in the presence of GalC (cis-inhibited) 
Therefore, when BR1 was cloned from BR patient’s blood (O'Hanlon, Paterson, 
Wilson, Doyle, McHardie, & Willison 1996), the antibody subset which was 
isolated corresponded to the third type, GM1:GalC cis-inhibited. 
This combination of findings provides some support for the conceptual premise 
that GM1 neighbouring lipids play a major role in modulating antibody binding. 
The cryptic nature of these epitopes highlights the enormous diversity of anti-
GM1 antibodies and strengthens the belief that cis-inhibitions and cis-
enhancements could modulate antibody binding in tissue and eventually define 
disease phenotypes. 
The initial finding of a high proportion of GM1:GalC specific patients at 1:1 ratio 
redefined to a great extent the concept of antibody-negative patients. It seems 
apparent from this data that the epitope presentation and thus its composition 
has played a major role in unmasking antibody subsets believed to be involved in 
the development of the disease.  
The past twenty years have seen increasingly rapid advances in the field of 
antibody detection in neuropathy patient sera. Throughout these years of 
development, arrays in PNS neuropathies have conceptually shifted from the 
simplicity of a single epitope to the combinatorial factor introduced by 
heterodimeric ganglisoside complexes. Despite its initial diagnostic success, 
most of these array studies do not conceive antibody epitopes as lipid domains. 
The importance of this chapter relies on proving that by increasing the 
complexity of the epitope, some cryptic antibodies can now be detected.  
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5 Chapter 5. Antibodies to heterotrimeric 
glycolipid complexes in Chronic Inflammatory 
Demyelinating Polyrediculoneuropathy. 
5.1 Introduction 
As outlined in chapter 4, some neuropathy patients present antibodies with high 
specificity for highly cryptic epitopes. These epitopes, characterised by specific 
molecular arrangements and ratios between different glycolipids, have helped to 
unmask reactivities in patients previously described as antibody-negative. In 
order to test the diagnostic potential of these cryptic epitopes, a cohort of 
patients with CIDP, an inflammatory neuropathy where traditionally a small 
proportion of patients show anti-ganglioside antibodies (Hughes et al. 2006), was 
screened using this approach. 
5.2 Aims 
5.2.1 Conceptual aims 
 Investigate the presence of pattern recognition antibodies and antibodies 
against heterotrimeric complexes in CIDP. 
5.2.2 Experimental aims 
The initial experimental aim was to design an array formed by heterotrimeric 
complexes of three different glycolipids. In order to achieve this level of 
molecular complexity I: 
 Look for the optimum molecular ratio between gangliosides and 
glycolipids for enhanced antibody binding. GalC at increasing 
concentrations will be used as the paradigmatic molecule. 
 Compare the Ab binding enhancement properties of different adjuvant 
molecules at a set molecular ratio. 
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 The optimum adjuvant molecule at the set molecular ratio will be 
included into heterodimeric complexes forming arrays containing 
heterotrimeric epitopes. 
 The antibody binding properties of these newly developed arrays will be 
tested onto a cohort comprising CIDP patients and controls. 
5.3 Study design 
 Samples were tested exclusively for IgM reactivities by ECL and 
fluorescence. Numerical analysis was performed using ECL data. 
 Experiments were repeated 3 times with internal duplicates. 
 Pilot studies were performed with 19 CIDP patients randomly selected. 
The arrays on the pilot study were conceived as asymmetrical and 
horizontally laid out. 
 For the definitive screening, 51 CIDP patients and 93 controls (71 multiple 
sclerosis and 22 rheumatoid arthritis) were included. 
 All of the 144 samples were probed against an array consisting of two 
11x11 grids placed next to each other on the same PVDF/PVDF-FL 
membrane. On the left, the grid consisted of single lipids and their 
corresponding heterodimeric complexes at a working concentration of100 
µg/ml each. The grid on the right hand side of the array consisted of the 
same target epitopes but containing in all of them a third glycolipid, 
Phrenosin at a working concentration of 1000 µg/ml. Both 11x11 grids 
where therefore probed simultaneously, as a single array, with the same 
sera (Figure 5.1). 
 The lipids included in the array were as follows: GM1, GM2, GM3, GD1a, 
GD1b, LM1, SGPG, GD3, GT1b and Sulph. 
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Array left (without Phrenosin) Array right (with Phrenosin) 
 
 
Figure 5.1. Array lay out for CIDP cohort screen. 
 
5.4 Results 
5.4.1 Pilot Studies 
5.4.1.1 Determination of the optimum complex molecular ratio 
The initial pilot studies aimed to validate the ratio 1:10 (ganglioside:GalC) as the 
optimum lipid platform for pattern recognition antibody binding. As seen in 
Figure 5.2 the ratio 1:10 (w/w) in CIDP patients revealed a complex dependent 
IgM antibody binding. The use of a complex molecular ratio between gangliosides 
and GalC unmasked Ab reactivity undetected at lower molecular ratios (e.g. 1:1 
or 1:5). 
 
Figure 5.2. Ganglioside complexes containing different GalC ratios. 
The array was printed horizontally and asymmetrically, and contain the GalC singles at different 
concentration on the top first row, and their duplicated complexes with gangliosides on the second 
and third rows. Ganglioside singles were duplicated on the intersection between the first column 
and second and third rows. 
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5.4.1.2 Determination of the optimum adjuvant molecule 
Further analyses were conducted to determine the optimum adjuvant molecule 
to be used in complex with the glycolipid heterodimers on the final CIDP 
screening. The molecular ratio established as the optimal in section 5.4.1.1 for 
GalC was adapted to all the adjuvant molecules. Thus, for this study the 
following molecules were tested in complex with gangliosides at 1:10 ratio 
(ganglioside:adjuvant molecule w/w): GalC, Phre, Ker, GluC, SM, Cer, PC, DGDG 
and Chol. 
Although specific epitope variability was observed, data revealed an increased 
Ab binding to epitopes containing GalC species (Figure 5.3).  
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Figure 5.3 Patterns of antibody binding in CIDP sera. 
CIDP sera binding to GM1, GM3, GD1b, GA1 and SGPG can show complex enhancement and/or 
attenuation with adjuvant molecules. Data are shown as box and whisker plots (median and 
interquartile ranges) depicting signal intensities above (complex enhancement) or below (complex 
attenuation) the intensity value for the single glycolipid which is set at zero. 
Individual analysis of CIDP patients highlighted the presence of patients with 
exclusively Phre dependent reactivities which were GalC complex negative 
(Figure 5.4). This finding, in addition to the fact that all the patients reactive 
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for GalC epitopes were also reactive for Phre complexes, made us choose Phre 
as the adjuvant molecule for the final screen. 
 
Figure 5.4. Galnglioside complexes with different adjuvant molecules. 
Samples were prepared containing gangliosides at 100 µg/ml and adjuvant molecules including 
GalC, SM, Gluc, Cer, Pc, DGDG, Phre, Ker and Chol at 1000 µg/ml. The array was conceived 
horizontally and asymmetrically, containing the adjuvant molecules as single epitopes on the top 
first row, and their duplicated complexes with gangliosides on the second and third rows. 
Ganglioside singles were duplicated on the intersection between the first column and second and 
third rows. 
Therefore, ganglioside complexes and single epitopes will be mixed with ten 
times Phre in a weight to weight proportion. The layout of the grid containing 
two 11x11 arrays (Figure 5.1) will allow direct comparison between arrays with 
and without adjuvant glycolipid. 
5.4.2 CIDP cohort screening 
Array data from all CIDP cases (Figure 5.5) and controls (Figure 5.6) were 
subjected to cluster analysis that yielded a heat map comprising spot intensities 
for all the complexes with and without Phre. Spot intensities were categorised 
according to their arbitrary intensity raw values. 
A significant increase in intensity signal can be seen when including Phre for 
both CIDP and control populations (Figure 5.5 and Figure 5.6). In some cases, the 
increase in signal translated into a saturated signal in ECL. This was later re-
evaluated a descriptive study by fluorescence analysis (Figure 5.7).  
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Figure 5.5. Data from the CIDP population presented as a clustered Heat map. 
Heat maps were created using the raw data recorded for each lipid antigen (rows) depicting serum 
IgM reactivity per patient (columns). The highest intensity value (79266.09 IU) was set as the upper 
limit intensity. Thus, pale green corresponds to antibody-negative signals, darker green and black 
to mid-range signals and red to high value signals  
Chapter 5  138 
 
 
Figure 5.6. Data from the control population presented as a clustered Heat map. 
Heat maps were created using the raw data recorded for each lipid antigen (rows) depicting serum 
IgM reactivity per patient (columns). Lipids are displayed as rows and patients as column headings. 
The highest intensity value (79266.09 IU) was set as the upper limit intensity. Thus, pale green 
corresponds to antibody-negative signals, darker green and black to mid-range signalsand red to 
high value signals.  
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B 
 
Figure 5.7. Representative blots from glycoarray. 
Blots corresponding to two (A and B) representative patients screened using both ECL (above) and 
fluorescence (below). These comparative blots demonstrate the level of saturation existing within 
ECL intensity quantification, which might lead to understating the relevance of complex epitopes in 
Ab binding enhancement.  
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5.4.2.1 CIDP versus Controls 
Further statistical analysis comparing CIDP and control populations, revealed 
that only 9 markers presented higher intensity binding in the CIDP group than in 
the control population prior to the addition of Phre. After the addition of Phre as 
an adjuvant molecule, an extra 12 epitopes presented significantly higher Ab 
binding in the CIDP group (Table 5.1). No epitope lost significance after the 
addition of Phre, suggesting that the specificity was kept constant although the 
sensitivity increased. Sensitivity/specificity data for these 12 epitopes after the 
addition of Phre can be found in Table 5.1.  
Table 5.1. Comparison of CIDP and Control populations. 
Bonferroni’s multiple comparison of markers with or without the addition of Phre. (ns=not 
significant; *p value≤0.05, **p value≤0.01, ***p value≤0.001 and ****p value≤ 0.0001). Sensitivity 
and specificity corresponds to the complexes containing Phre. 
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5.4.2.2 Top markers: GD1b:GT1b:Phre and GD3:GT1b:Phre 
Ranking of markers for diagnostic accuracy using ROC, established 
GD1b:GT1b:Phre and GD3:GT1b:Phre as among the top markers with AUCs of 
0.793 and 0.767 respectively (Figure 5.8 B). Although scoring a higher AUC when 
in complex with Phre, GD1b:GT1b:Phre and GD3:GT1b:Phre were not 
significantly different than their equivalent without Phre (p=0.2880 and 
p=0.1614 respectively) (Figure 5.8 A).  
After combining the diagnostic efficiency of both markers (GD1b:GT1b:Phre & 
GD3:GT1b:Phre), the overall AUC increased up to 0.824. This increase although 
insignificant when compared to GD1b:GT1b:Phre and GD3:GT1b:Phre as 
independent epitopes (p=0.2229 and p=0.1655 respectively), represented a 
significant improvement when compared to both heterodimeric complexes 
without Phre (Figure 5.8 A). 
A 
 
B 
 
Figure 5.8. Statistical analysis of glycoarray data for top markers. 
A. Individual ROC curves for two heterodimeric complexes (GD1b:GT1b and GD3:GT1b), their 
complexes with Phre (GD1b:GT1b:Phre and GD3:GT1b:Phre) and the overall overall diagnosis 
efficiency of both markers together. B. Table summarising the equivalent AUCs, Sensitivity and 
specificity for every each one of the individual ROC curves. 
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5.4.2.3 Antibody binding fingerprint: GM3:Sulph:Phre 
After individual analysis of patient arrays, a marker which did not rank among 
the most efficient diagnostic epitopes was considered for multivariable 
fingerprint profiling. 22% of the patients presented GM3:Sulph:Phre complex 
enhanced binding, 4 % of those binding exclusively to GM3:Sulp:Phre, suggesting 
the potential use of this marker as part of a larger biomarker fingerprint for CIDP 
(Figure 5.9). In addition to this, the presence of Ab binding to GM3:Sulph:Phre 
heterotrimeric complexes but not to GM3, Sulph, Phre, Sukph:Phre, GM3:Sulph 
or GM3:Phre suggests the presence of an antibody subset specific for epitopes 
composed of three different glycolipids. 
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Figure 5.9. Characteristic blots depicting enhanced or complex specific GM3:Sulph:Phre 
reactivities. 
11x11 grids placed next to each other within the same PVDF membrane. On the left, the grid 
consisted of single lipids and their corresponding heterodimeric complexes at a working 
concentration of100 µg/ml. The grid on the right hand side of the array consisted of the same target 
epitopes but containing in all of them a third glycolipid, Phrenosin.  
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The addition of GM3:Sulph:Phre to GD1b:GT1b:Phre and GD3:GT1b:Phre 
marginally improved the AUC, from 0.824 to 0.853. A more in depth analysis 
revealed a 4% increase in sensitivity with a 0.9% decrease in specificity (Figure 
5.10 and Figure 5.11 B). 
 
Figure 5.10. Heat map depicting the top markers. 
Heat map representing the Ab binfing fingerprint for the CIDP and control population (rows). The 
rainbow scale representation has been adapted to a maximum threshold of 20000 intensity units. 
Under this scale the CIDP patients for the three markers together have been classified as: low 
intensity (n=17), mid intensity (n=6) and high intensity (n=19).  
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Although this slight improvement did not prove significant after ROC analysis 
(p=0.1236), the 4% increase in sensitivity and the stability of specificity 
highlights the beneficial effect of adding GM3:Sulph:Phre as a test marker for 
CIDP (Figure 5.11 A). 
A 
 
B 
 
Figure 5.11. Statistical analysis of glycoarray data for overall markers. 
A. Individual ROC curves for the diagnosis efficiency of GD1b:GT1b+GD3:GT1b and , 
GD1b:GT1b+GD3:GT1b+GM3:Sulph:Phre. B. Table summarising the equivalent AUCs, Sensitivity 
and specificity for every each one of the individual ROC curves. 
After establishing GD1b:GT1b:Phre + GD3:GT1b:Phre+ GM3:Sulph:Phre as the 
most efficient biomarker fingerprint for CIDP, the significance of Phre within the 
complexes was evaluated using ROC analysis. 
The comparison between the heterodimeric complexes with and without Phre, 
demonstrated the relevance of Phre as a potent adjuvant for antibody binding. 
The markers conforming the CIDP fingerprint without Phre scored an AUC of 
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0.730, being significantly lower than the AUC of 0.853 for the same markers 
including Phre (p=0.0065) (Figure 5.12).  
Although the addition of Phre to these markers decreases the specificity by a 
5.4%, the sensitivity experiences a significant 25.5% increase. Therefore, the 
overall diagnostic efficiency depends to a great extent on the epitope content of 
Phre. 
 
 
Figure 5.12. Ab binding fingerprint after the inclusion of Phre. 
Individual ROC curves comparing the Ab binding fingerprint for CIDP 
(GD1b:GT1b:Phre+GD3:GT1b:Phre+GM3:Sulph:Phre) with and without Phre. 
5.5 Future work 
 Look for characteristic clinical correlations between the IgM markers 
identified and disease phenotypes. 
 Investigate the IgG reactivity present within this cohort of patients and 
controls. 
 Include another control group consisting of healthy subjects. 
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 Validate the markers found in this study on a double blinded cohort of 
CIDP patients and controls. 
5.6 Discussion 
42 of 51 CIDP patients demonstrated IgM binding to glycolipid antigens defined 
by a cluster of three different reactivities: GD1b:GT1b:Phre, GD3:GT1b:Phre and 
GM3:Sulph:Phre. The remaining 9 CIDP patients did not present any glycolipid 
binding, and were classified as antibody-negative for this study. 16 of 93 
controls demonstrated IgM binding to the cluster of three different epitopes 
specified above. The rest of the controls were either antibody-negative or 
presented low levels of GM1:Phre and mid to high levels of Sulph:Phre. 
Reactivities found in previous serology studies with CIDP patients, such as anti-
SGPG IgM antibodies (Yuki et al. 1996) were slightly underrepresented in our 
test. In our study 13% of CIDP patients presented antibodies against SGPG in 
contrast to the 40% reported by Yuki and co-workers (Yuki, Tagawa, & Handa 
1996). LM1, a myelin glycolipid with similar structure to that of SGPG, differing 
only in the presence of a sialic acid as opposed to a 3-sulfated glucuronic acid, 
was also marginally represented by a 6% antibody binding. 
In order to generate an animal model of CIDP, rabbits have been traditionally 
immunised with galactocerebroside (Saida, Saida, Brown, & Silberberg 1979). 
Therefore, a hypothesis from this study would be that antibodies to this 
glycolipid could be involved in the development of the disease and thus found in 
high titres in CIDP patients. In agreement with previous findings (Hughes et al. 
1984;McCombe et al. 1988), our study did not find IgM reactivity against single 
galactosilceribrosides or its sulphated form. 
The addition of complexity within the epitope, after incorporating Phre, 
considerably improved IgM antibody binding in this study. Phrenosin has been 
proven to increase the sensitivity of the arrays at the same time as maintaining 
the specificity. One representative case of the cryptic behaviour of antibodies 
has been the discovery of antibodies against GM3:Sulph:Phre. This subset of 
antibodies found in a greater proportion and higher levels in CIDP patients, 
exclusively bound GM3 when in complex with Sulphatide and Phrenosin. This 
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antibody binding to heterotrimeric complex is the first description to date of an 
antibody binding to 3 different lipids but not the singles or the heterodimers 
alone. IgM antibodies are known for their intrinsic capability to form multivalent 
interactions. As it has been previously demonstrated (Niedieck & Kuck 
1976;Oyelaran, Li, Farnsworth, & Gildersleeve 2009a), the use of a complex lipid 
platform for antibody detection enhances the affinity and avidity of these 
antibodies which are per se low affinity. Although, little is understood about the 
molecular rearrangement which takes place within the epitope, the generation 
of these cryptic domains has shown a promising testing improvement for CIDP 
serology diagnostics. After the discovery of heterodimers as Ab epitopes (Kaida, 
Morita, Kanzaki, Kamakura, Motoyoshi, Hirakawa, & Kusunoki 2004), much has 
been speculated on the possibility of a more complex scenario. This new 
GM3:Sulph:Phre heterotrimer moves the epitope complexity a step forward and 
sets the final goal for array screening on developing a dynamic membrane-like 
platform for HTS. 
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6 Chapter 6. Discussion 
6.1 Modulation of antibody binding to GM1 
Anti-GM1 antibodies have been previously described as having a highly diverse 
binding profile in tissue (O'Hanlon, Paterson, Wilson, Doyle, McHardie, & Willison 
1996;O'Hanlon et al. 1998) and arrays (Greenshields, Halstead, Zitman, Rinaldi, 
Brennan, O'Leary, Chamberlain, Easton, Roxburgh, Pediani, Furukawa, 
Furukawa, Goodyear, Plomp, & Willison 2009). This diversity, present even 
within antibodies derived from the same patient (e.g. BO1 and BO3), cannot be 
solely explained by differences in epitope distribution. Therefore, it seems 
apparent that factors other than single presentation of GM1clusters might be 
influencing the binding diversity of this highly cryptic epitope. 
In Chapter 3 we have seen how anti-GM1 Abs can be modulated by the presence 
of neighbouring molecules. The presence of Cholesterol in complex with GM1, 
allowed Ab recognition in a complex-dependent manner. Ab in BTN sera 
recognised GM1 in liposomes containing cholesterol (1:5 M/M) and exclusively 
bound GM1 when in complex with cholesterol. The array binding data also 
revealed the importance of molecular ratios in Ab binding. Isolated anti-GM1 Ab 
from BTN serum started binding GM1:Chol in molecular ratios of 1:5 and greater. 
As previously discussed, the formation of this epitope could be induced by a GM1 
conformation change. The change induced by cholesterol through a hydrogen 
bond network with GM1, would modify GM1’s sugar moiety to a more planar 
conformation, closer to the membrane surface (Lingwood 1996;Mahfoud, Manis, 
Binnington, Ackerley, & Lingwood 2010). 
This chapter also highlights the relevance of GD1a in forming complexes with 
GM1. Antibodies against GM1:GD1a complexes were first described in 2004 
(Kaida, Morita, Kanzaki, Kamakura, Motoyoshi, Hirakawa, & Kusunoki 2004) and 
later characterised as a 1:1 molecular complex (Mauri, Casellato, Ciampa, 
Uekusa, Kato, Kaida, Motoyama, Kusunoki, & Sonnino 2012). Our study using JK 
sera also determined GM1:GD1a 1:1 as the optimal molecular ratio for antibody 
binding. 
Chapter 6  150 
 
Chapter 4 first describes data from a local cohort of MMN patients. In this study, 
19/33 contain Ab against GM1 alone however 33/33 MMN patients exhibited Ab 
reactivity against GM1:GalC (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013). These results support those of 
Pestronk and co-workers (Pestronk, Choksi, Blume, & Lopate 1997) where they 
found a significant enhancement of GM1 Ab binding in the presence of a GalC 
mix. Recently, these observations have been further confirmed demonstrating a 
27% increase in anti-GM1 Ab detection when in complex with GalC (Nobile-
Orazio, Giannotta, Musset, Messina, & Leger 2013). 
The initial validation cohort study revealed the complete disappearance of 
GM1:GalC reactivity. Further investigations identified a quantitative and 
qualitative failure of our GalC reagent. We discovered a decrease in the 
solubility of our GalC stock. That decrease in solubility accompanied the 
disappearance of the GalC enhancing effect over GM1 reactivity. After re-
adapting the solubilisation methodology, by increasing the chloroform content in 
the solvent mix, and increasing the lipid concentration from 100 µg/ml to 200 
µg/ml, the enhancing effect was recovered. At the same time, mass 
spectrometry data suggested a qualitative difference between the commercially 
procured GalC stocks. Each lot contained variable proportions of different GalC 
species. According to GalC’s hydroxylation profile, there are two different 
species: Phrenosin (HFA-GalC) and Kerasin (NFA-GalC). The hydroxylation of 
GalC has been seen to affect the conformation of its sugar moiety that 
ultimately alters anti-GalC Ab binding (Chapter 4.6.1). Studies based on HIV’s 
mechanism of cell anchoring proved how the anchor protein gp120 preferentially 
bound Phrenosin but not kerasin due to a preference for the kinked 
conformation of Phrenosin’s galactose (Coffin et al. 1997;Hammache, Pieroni, 
Yahi, Delezay, Koch, Lafont, Tamalet, & Fantini 1998;Yahi, Baghdiguian, 
Moreau, & Fantini 1992). The structural constraints of GalC could influence the 
way they form complexes with GM1. The qualitative variability in GalC stocks 
translated into a differential Ab binding when in complex with GM1 and/or GM2 
(Chapter 4.6.1). 
A validation study, using a blinded cohort of MMN patients and controls, 
confirmed the anti-GM1 Ab detection enhancement conferred by the addition of 
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GalC. This study detected antibodies against GM1:GalC in 81/100 MMN patients, 
a 14% increase in Ab detection compared to GM1 alone. However, the 100% 
sensitivity could not be replicated in this study. One issue which needs to be 
addressed is the affect Phrenosin/Kerasin molecular ratios have on Ab binding to 
GM1:GalC complexes. The difference in Phrenosin/Kerasin ratios between GalC 
stocks could explain the variability between the SGH study and the Dutch 
validation cohort of MMN patients positive for GM1:GalC Abs. Similarly, this 
variability could account for the inter-assay and inter-laboratory variability of 
the GM1:GalC assay. In order to find the optimum GalC reagent for this Ab test, 
an array should be designed containing GM1 as a single epitope and in complex 
with different Phrenosin/Kerasin molecular ratios. The Dutch cohort could then 
be re-screened and each of the GM1:GalC complexes evaluated for sensitivity 
and specificity. 
Several studies have singled out the inhibitory effect of GD1a over GM1 Ab 
binding (Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, 
Chamberlain, Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, 
Plomp, & Willison 2009;Nobile-Orazio, Giannotta, & Briani 2010). In our SGH 
MMN screening a significant majority of the patients presented cis-inhibition of 
GM1 Ab binding in the presence of GD1a and LM1 (Chapter 4.3.3). The existence 
of anti-GM1 Abs with enhanced or cis-inhibited binding to the same epitope 
(GM1:GD1a) reflects the wide diversity existing among these antibodies. The 
Dutch validation cohort further confirmed the inhibitory effect of GM1:LM1 
complexes over GM1 Ab binding. 
Contrary to expectations, when we analysed anti-GM1 mAb binding to GM1:GalC 
complexes, GalC was found to be detrimental to Ab binding in a concentration 
dependent manner. Anti-GM1 mAbs DO1 and BR1 did not bind GM1 when in 
complex with GalC while at the same time SM1 GM1 binding remained unaltered 
in the presence of GalC (Chapter 4.4.2). In support of this data, Pestronk and co-
workers found several patients with high titres of anti-GM1 abs with a significant 
titre reduction when GM1 was in complex with GalC (Pestronk, Choksi, Blume, & 
Lopate 1997). A similar observation was noted in the second screening of the 
Dutch validation cohort (Chapter 4.7.2). In this screening three MMN patients 
with anti-GM1 Abs had cis-inhibition of Ab binding when GM1 was in complex 
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with GalC. This phenomenon highlights, once again, the high reactivity diversity 
among anti-GM1 antibodies and the major role played by adjacent molecules in 
GM1 Ab binding. 
As previously discussed, BR1, the MMN-derived human anti-GM1 mAb, was 
inhibited from binding GM1 in the presence of GalC. Initial serology data from 
BR, the patient origin of the BR1 mAb clone, revealed the presence of anti-
GM1:GalC Abs within the patient serum (Chapter 4.4.2). These findings may help 
us to have a deeper understanding of the polyclonal nature of patient sera and 
the huge diversity existing among antibodies against the same target. Although, 
the diversity of a patient’s anti-GM1 Ab repertoire can be determined by the 
way these antibodies behave in the presence of neighbouring lipids such as GalC, 
their individual contribution to GSLs complex binding can only be fully dissected 
by the use of mAb.  
6.1.1 GM1:GD1a complex inhibition as potential modulator of 
clinical phenotypes 
Serology studies detecting anti-GM1 antibodies have been used for many years as 
a diagnostic tool for several neuropathies (Kaida, Morita, Kanzaki, Kamakura, 
Motoyoshi, Hirakawa, & Kusunoki 2004;Kaida, Sonoo, Ogawa, Kamakura, Ueda-
Sada, Arita, Motoyoshi, & Kusunoki 2008;Latov, Hays, Donofrio, Liao, Ito, 
McGinnis, Konstadoulakis, Freddo, Shy, & . 1988;Pestronk, Cornblath, Ilyas, 
Baba, Quarles, Griffin, Alderson, & Adams 1988). Even though the techniques 
employed have ranged from ELISA-based studies (Adams, Kuntzer, Burger, 
Chofflon, Magistris, Regli, & Steck 1991;Willison, Veitch, Swan, Baumann, Comi, 
Gregson, Illa, Zielasek, & Hughes 1999) to surface Plasmon resonance (Alaedini 
and Latov 2001) and more recently a methodology based on combinatorial 
glycoarrays (Brennan, Galban-Horcajo, Rinaldi, O'Leary, Goodyear, Kalna, 
Arthur, Elliot, Barnett, Linington, Bennett, Owens, & Willison 2011;Galban-
Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & 
Willison 2013;Rinaldi, Brennan, Goodyear, O'Leary, Schiavo, Crocker, & Willison 
2009), the objective has always been to link the antibody reactivity to clinical 
phenotype allowing a more accurate diagnosis followed by a more precise 
treatment than relatively non-specific treatments such as plasma exchange or 
intravenous immunoglobulin (IVIG).  
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Serology does not necessarily infer clinical indicators, for example with 
antibodies targeting the same ganglioside, GM1, clinical features can be variable 
depending on antibody specificity and affinity (Lardone et al. 2010;Lopez et al. 
2010) and in many cases can be reversible (Koga et al. 2003). Various studies 
have attempted to link a specific antibody reactivity profile to clinical features 
in many cohorts of patients suffering from a wide range of neuropathies 
(Kinsella, Lange, Trojaborg, Sadiq, Younger, & Latov 1994), based exclusively on 
multi-focal motor neuropathy (MMN) patients (Cats, Jacobs, Yuki, Tio-Gillen, 
Piepers, Franssen, van Asseldonk, van den Berg, & van der Pol 2010b) or on cases 
of Guillain–Barré syndrome (GBS) (Kuwabara et al. 1998a;Kuwabara et al. 
1998b). The first two studies reported a significant correlation between high 
anti-GM1 antibody titres and a clinical phenotype characterized by a more 
severe weakness. Kuwabara and co-workers (Kuwabara, Yuki, Koga, Hattori, 
Matsuura, Miyake, & Noda 1998b) reported the main feature consisting of 
conduction failure and axonal degeneration. This evidence shows a possible 
correlation between anti-GM1 antibodies and the presence of certain clinical 
features in a range of neuropathies; however it does not entirely explain the 
nature of the difference in clinical phenotypes. 
In the case of MMN, neuropathy of peripheral nerves characterized by the 
presence of asymmetric distal weakness, conduction block along motor axons 
and often the presence of IgM anti-GM1 antibodies, the clinical features 
correspond to an exclusive motor nerve disorder leaving the sensory nerves 
unaffected (Pestronk, Cornblath, Ilyas, Baba, Quarles, Griffin, Alderson, & 
Adams 1988) (Parry & Clarke 1988) surprisingly both motor and sensory nerves 
contain a similar proportion of GM1 ganglioside (Svennerholm 1994;Svennerholm 
et al. 1994). In 1994, and later in 1998 published as a review article, Ogawa-
Goto brought attention to differences in GM1 ganglioside structures as 
determinants of antibody binding in patients with GBS. In his article Ogawa-Goto 
postulated that it was the difference in the carbon length of the fatty acid 
containing ceramide of GM1 which determined the differences in anti-GM1 
antibody binding. The results showed decreases in binding respectively in the 
presence of motor nerve GM1, sensory nerve GM1 and brain GM1(Ogawa-Goto et 
al. 1992;Ogawa-Goto & Abe 1998).This finding, while preliminary, suggests that 
slight differences in ganglioside structure could lead to high affinity antibody 
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binding in certain regions of the peripheral nervous system (PNS), such as motor 
nerves, where a specific form of GM1 is more abundant, causing motor 
neuropathies with no clinical sensory features (eg.MMN and acute motor axonal 
neuropathy (AMAN)).  
One question to be addressed, however, is whether the membrane environment 
is going to play a role in the way the GM1-epitope will be presented for antibody 
recognition (Li and Pestronk 1991;Marcus et al. 1989). Perhaps the most serious 
disadvantage of the methods employed by Ogawa-Goto and co-workers is that 
solid-phase assays do not take into account the complexity of a cryptic 
membrane environment. Strong evidence of the complexity of the GM1-epitope 
was found when antibodies from MMN patients which were unreactive to either 
GM1 ganglioside or galactocerebroside (GalC) as single lipid epitopes were shown 
to be reactive to a complex mixture (GM1:GalC) and that the detection 
efficiency was significantly increased when cholesterol was introduced to the 
lipid complex mixture (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Nobile-Orazio, Giannotta, 
Musset, Messina, & Leger 2013;Pestronk, Choksi, Blume, & Lopate 1997). 
Supporting these findings, antibody binding to complex gangliosides was found in 
patients suffering GBS (Kaida, Morita, Kanzaki, Kamakura, Motoyoshi, Hirakawa, 
& Kusunoki 2004;Kaida, Sonoo, Ogawa, Kamakura, Ueda-Sada, Arita, Motoyoshi, 
& Kusunoki 2008) and antibodies targeting GM1 mediated lipid complexes 
(eg.GM1:GalNac-GD1a) could be playing an important role in the development of 
pure motor GBS (Kaida, Sonoo, Ogawa, Kamakura, Ueda-Sada, Arita, Motoyoshi, 
& Kusunoki 2008;Kaida & Kusunoki 2010). Difficulties arise, however, when an 
attempt is made to extrapolate these findings to the “living membrane”. 
Recently, studies in tissue and solid-phase immunoassays have revealed that the 
GM1-epitope can be inaccessible for antibody binding due to a masking effect 
exerted by neighbouring gangliosides such as GD1a (Complex mediated cis-
inhibition)(Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, 
Chamberlain, Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, 
Plomp, & Willison 2009;Nobile-Orazio, Giannotta, & Briani 2010). The most 
striking conclusion to emerge from the data is that unless the GM1-epitope is 
topologically available for antibody binding no axonal damage or conduction 
block would be induced due to a lack of antibody bound complement activation 
Chapter 6  155 
 
(Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, 
Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 
2009).  
It can thus be suggested that lipid complexes containing GM1 could be 
modulators, either enhancing or inhibiting antibody binding, and play a key role 
in producing different clinical phenotypes within the same neuropathy. For 
example, the presence of antibodies which exclusively bind lipid complexes 
formed by GM1, a major ganglioside of axons of both the motor and sensory 
spinal roots (Gong, Tagawa, Lunn, Laroy, Heffer-Lauc, Li, Griffin, Schnaar, & 
Sheikh 2002;Kusunoki et al. 1993;O'Hanlon, Paterson, Veitch, Wilson, & Willison 
1998) and GalC, a major component of myelin (Garbay et al. 2000), could 
conceivably indicate a more nodal lesion, the specialised area where this 
complex is more likely to be found. 
If we now turn our attention to the capability of some gangliosides, such as 
GD1a, to inhibit antibody binding to GM1 in MMN (Cats, Jacobs, Yuki, Tio-Gillen, 
Piepers, Franssen, van Asseldonk, van den Berg, & van der Pol 2010b;Galban-
Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & 
Willison 2013;Nobile-Orazio, Giannotta, & Briani 2010) and IgG monoclonal 
antibodies (Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, 
Chamberlain, Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, 
Plomp, & Willison 2009) we might be able to find a possible explanation for what 
seems an apparent inconsistency between GM1 distribution in PNS and the 
existence of exclusively motor neuropathies. According to previous reports there 
are no quantitative differences in the distribution of GD1a between dorsal 
(containing afferent sensory axons) and ventral (containing efferent motor 
axons) roots (Svennerholm et al. 1992;Svennerholm, Bostrom, Fredman, 
Jungbjer, Lekman, Mansson, & Rynmark 1994). However, qualitative differences 
in GD1a structure, possibly consisting of differences in fatty acid chain length, 
between motor and sensory nerves have been reported. Two forms of GD1a are 
expressed in motor nerves as opposed to sensory nerves which just contain one 
variant of GD1a ganglioside. These results suggest the presence of an alternative 
form of GD1a strictly expressed in motor nerves (Gong, Tagawa, Lunn, Laroy, 
Heffer-Lauc, Li, Griffin, Schnaar, & Sheikh 2002). It could be hypothesized then 
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that in motor nerves the alternative form of GD1a would be unable to cis-inhibit 
antibody binding to GM1 or could form a complex with GM1 which would 
compete with the conventional inhibitory GM1:GD1a complex, enhancing 
antibody binding and giving the disease a pure motor phenotype. Another 
plausible explanation for the appearance of two different forms of GD1a in the 
previous study is the presence of GalNac-GD1a in peripheral nerves (Ilyas et al. 
1988a;Ilyas, Willison, Quarles, Jungalwala, Cornblath, Trapp, Griffin, Griffin, & 
McKhann 1988b), which would only be expressed by motor neurons and axons 
(Gong, Tagawa, Lunn, Laroy, Heffer-Lauc, Li, Griffin, Schnaar, & Sheikh 2002). 
Together this data suggests that in motor nerves GalNac-GD1a would not exert 
an inhibitory effect on antibody binding to GM1 when in complex, and could be 
targeted by IgM antibodies as a single epitope or in complex with GM1 
(Tatsumoto et al. 2006) causing the profile of a pure motor neuropathy whereas 
GM1:GD1a has a cis-inhibitory effect in sensory nerves. Although this theory can 
be supported in the case of MMN, caution must be applied when considering pure 
motor forms of GBS (AMAN). In patients suffering AMAN, GM1:GalNac-GD1a lipid 
complexes have been identified as a main target for high affinity antibodies 
(Kaida, Sonoo, Ogawa, Kamakura, Ueda-Sada, Arita, Motoyoshi, & Kusunoki 
2008). Although this could again indicate the role of complex cis-
enhancement/inhibition in modulating a disease phenotype, it cannot be 
forgotten that in GBS GD1a, present in both motor and sensory nerves, has not 
been reported as inhibiting antibody binding to GM1 when in lipid complex form 
in vitro (Kaida, Morita, Kanzaki, Kamakura, Motoyoshi, Hirakawa, & Kusunoki 
2007) although there is some conflicting in vivo data (Greenshields, Halstead, 
Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, Easton, Roxburgh, Pediani, 
Furukawa, Furukawa, Goodyear, Plomp, & Willison 2009).  
6.1.2 Molecular ratios of GalC as modulators of antibody binding 
to GM1 
Chapter 4 has given an account of the high diversity existing among anti-GM1 
antibodies in MMN. It has also described how neighbouring lipids can 
substantially affect antibody binding to GM1 ganglioside. The results of this work 
contribute to the existing knowledge that the binding of anti-GM1 antibodies can 
be inhibited by the presence of GD1a and LM1. It also contributes additional 
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evidence that suggests the key role played by GalC in enhancing antibody 
binding to GM1 epitopes in a clinical cohort. 
Whilst confirming the effect of neighbouring lipids on modulating antibody 
binding to GM1, this study partially substantiates the idea that molecular ratios 
between lipid complexes could also be a key factor. These molecular patterns 
defining GM1 epitopes would potentially form highly specific antibody binding 
platforms. This newly described antibody behaviour would be capable of 
unmasking anti-GM1 antibodies in patients previously described as antibody-
negative.  
Despite its exploratory nature, work with MMN-derived human monoclonal 
antibodies offers some insight into the inhibitory effect which GM1:GalC driven 
molecular patterns might have on anti-GM1 antibodies. This apparent paradox, 
where GM1 antibodies in patient sera see their binding enhanced in the presence 
of GalC and in contrast MMN-derived monoclonal antibodies are potentially 
inhibited by GalC molecular patterns, emphasises the diverse and obscure nature 
of these antibodies. 
In studies using rodent and human tissue, binding diversity in vitro translated 
into differential tissue binding profiles for each of these human monoclonal 
antibodies (O'Hanlon, Paterson, Wilson, Doyle, McHardie, & Willison 
1996;O'Hanlon, Paterson, Veitch, Wilson, & Willison 1998). SM1 and WO1 for 
example, were the only mAb presenting nodal staining in human teased fibre 
preparations. When comparing this observation with array studies where SM1 is 
the only antibody that binds GM1 in the presence of high concentrations of GalC, 
it could be hypothesised that exclusive binding of SM1 in certain nerve regions 
could indicate the presence of GalC enriched GM1 domains. Array data on WO1 
has not been acquired for this study due to antibody availability. In order to 
further support this theory, the GM1 binding behaviour of WO1 in the presence 
of high concentrations of GalC should be tested on array to ascertain if it mimics 
SM1 behaviour. 
Cautious interpretation must be applied when translating concepts from solid-
phase assays onto tissue and vice versa. This merely speculative work should be 
further tested on a definitive in vivo platform. The relevance of GalC as binding 
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modulator of GM1 could be tested using PC12 cells containing GalC. PC12, a cell 
line derived from rat adrenal medulla allows easy modification and engineering 
of its lipid membrane profile (Mutoh et al. 1998). The role played by GD1a on 
antibody binding could be elucidated by regulating its presence by treating the 
tissue with sialidases. This family of enzymes hydrolyse terminal sialic acid 
residues converting GD1a into GM1 (Monti et al. 2010). If our initial hypothesis 
was correct, and GM1 was found in complex with GalC on a living membrane, the 
only mAb staining PC12 cells containing GalC would be SM1 and/or WO1. Further 
studies for confirmation could be done on murine tissue lacking GalC. 
6.1.3 Cholesterol as potential modulator of GM1 antibody binding 
So far we have hypothesised how GM1:GalC clusters can determine tissue binding 
of certain mAb but not others. This would potentially determine the distribution 
of SM1 staining in specific tissue preparations. Although GM1 complexes with 
GD1a could explain the absence of SM1 binding in certain tissue samples 
(Greenshields, Halstead, Zitman, Rinaldi, Brennan, O'Leary, Chamberlain, 
Easton, Roxburgh, Pediani, Furukawa, Furukawa, Goodyear, Plomp, & Willison 
2009), it could not explain the binding difference between SM1 and other human 
mAb (O'Hanlon, Paterson, Wilson, Doyle, McHardie, & Willison 1996;O'Hanlon, 
Paterson, Veitch, Wilson, & Willison 1998), being as they are all equally 
inhibited by the presence of GD1a according to array data. 
In light of the capability of Cholera Toxin (CT) to inhibit the binding in human 
tissue of these mABs, they were broadly classified into two groups: CT like (SM1, 
WO1 and BO3) and CT unlike (BR1, DO1 and BO1) (O'Hanlon, Paterson, Veitch, 
Wilson, & Willison 1998). As described in chapter 3, the binding of CT to GM1 is 
affected by the presence of cholesterol enriched domains. These domains would 
induce a conformational change upon GM1 making it unavailable for CT 
recognition (Lingwood, Binnington, Rog, Vattulainen, Grzybek, Coskun, 
Lingwood, & Simons 2011;Mahfoud, Manis, Binnington, Ackerley, & Lingwood 
2010). If one assumes cholesterol as the only modulator of GM1-CT binding, the 
degree of correlation of CT binding with the binding of these human mAb could 
then suggest the presence of GM1:Cholesterol domains in human tissue. 
Therefore, mAbs such as SM1 characterised as CT like would be unable to 
recognise the crooked form of GM1 found in the presence of cholesterol, and by 
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corollary CT unlike mAbs would mainly bind the GM1 form found within 
cholesterol clusters. 
Although it could offer an alternative explanation for differential tissue binding 
due to anti-GM1 antibody diversity, the above is merely hypothetical. 
Preliminary studies on arrays containing GM1:Cholesterol probed with MMN-
derived mAbs would need to be conducted to confirm the validity of this 
hypothesis on solid-phase platforms. Further investigations using cyclodextrin 
treated tissue could be performed to confirm the extent of cholesterol 
involvement in the modulation of Ab binding to GM1. 
6.1.4 Standardisation of the GM1:GalC assay 
The final goal of a diagnostic marker is to contribute to the definitive clinical 
diagnosis of a patient. The high variability in results for anti-GM1 Abs has in 
effect devalued its use as diagnostic test for MMN. Since the first description of 
anti-GM1 Abs as potential biomarkers for MMN (Pestronk, Cornblath, Ilyas, Baba, 
Quarles, Griffin, Alderson, & Adams 1988) there have been a huge number of 
publications reporting different diagnostic potentials for anti-GM1 in MMN. These 
studies have differed methodologically and conceptually from each other. The 
techniques vary from ELISA (Carpo, Allaria, Scarlato, & Nobile-Orazio 1999) to 
dot-blot (Chabraoui, Derrington, Mallie-Didier, Confavreux, Quincy, & Caudie 
1993) and most recently to glycoarray (Galban-Horcajo, Fitzpatrick, Hutton, 
Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & Willison 2013). The controls 
used within the assays also differ and include ALS (Carpo, Allaria, Scarlato, & 
Nobile-Orazio 1999), CIDP and Healthy controls (Nobile-Orazio, Giannotta, 
Musset, Messina, & Leger 2013), undiagnosed neurological disorders and multiple 
sclerosis (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, 
Yu, Goodyear, & Willison 2013). Over the years, there has been little attempt to 
methodologically standardise anti-GM1 testing. This has created confusion within 
clinical practice and has substantially diminished the strength of anti-GM1 Abs as 
a possible marker for MMN diagnosis. Although there have been attempts to 
identify patterns among the various studies by the use of metanalysis (van Schaik 
et al. 1995), no simultaneous inter-laboratory study on assay variability has been 
attempted.  
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With GM1:GalC as a recently emerging marker for MMN, and the existence of 
only three publications to date (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, 
Kalna, Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Nobile-Orazio, 
Giannotta, Musset, Messina, & Leger 2013;Pestronk, Choksi, Blume, & Lopate 
1997), the same questions arise once again: What is the inter-
laboratory/methodology testing variability, which is the optimal method for 
testing and therefore what is the real diagnostic value of GM1:GalC antibodies in 
MMN. 
Among the existing studies on GM1:GalC Ab testing, the methodological 
discrepancies are already significant: 
 The use of ELISA (Nobile-Orazio, Giannotta, Musset, Messina, & Leger 
2013;Pestronk, Choksi, Blume, & Lopate 1997) and Glycoarray (Galban-
Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, 
Goodyear, & Willison 2013). 
 The solubilisation of the working lipid solutions using methanol (Galban-
Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, 
Goodyear, & Willison 2013;Pestronk, Choksi, Blume, & Lopate 1997) and 
ethanol (Nobile-Orazio, Giannotta, Musset, Messina, & Leger 2013). 
 Potential solubilisation of the lipid stocks using chloroform:methanol 1:1 
(Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, 
Goodyear, & Willison 2013) and 2:1 (Chapter 4, Dutch cohort repeat). 
 The use of GM1:GalC at w/w ratios of 1:10 (Nobile-Orazio, Giannotta, 
Musset, Messina, & Leger 2013;Pestronk, Choksi, Blume, & Lopate 1997) 
and 1:1 (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, Brennan, 
Rinaldi, Yu, Goodyear, & Willison 2013). 
 The use of Cholesterol sulphate as part of the GM1:GalC mix (Pestronk, 
Choksi, Blume, & Lopate 1997)or GM1:GalC alone (Galban-Horcajo, 
Fitzpatrick, Hutton, Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & 
Willison 2013;Nobile-Orazio, Giannotta, Musset, Messina, & Leger 2013). 
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 Secondary antibody dilutions 1:20000 (Pestronk, Choksi, Blume, & Lopate 
1997) and 1:25000 (Galban-Horcajo, Fitzpatrick, Hutton, Dunn, Kalna, 
Brennan, Rinaldi, Yu, Goodyear, & Willison 2013). 
Before the volume of research on GM1:GalC Abs in MMN expands and the overall 
message on any anti-GM1:GalC predictive value becomes diluted by data 
inconsistency, an international multi-centre cooperative study would be 
necessary to standardise and validate this test. 
The design of the aforementioned international GM1:GalC predictive value 
validation study in MMN could consist of: 
 International collection of sera samples from MMN patients and controls 
(including other neurological diseases and healthy controls) and creation 
of a centralised sera bank. The MMN patients included in the study would 
have been diagnosed using clinical criteria other than their GM1 Ab 
reactivity in sera. This cohort of serum samples will then be coded and 
double-blinded. 
 Aliquots from this sera cohort would then be distributed to all the 
international laboratories collaborating in the study.  
The screening of these samples would comply with several requirements: 
 All participating laboratories would use ELISA, as it is currently the 
standard technique for sera screening within a hospital setting. 
 The sera dilutions for titration should be standardised and agreed 
between all participating laboratories prior to commencement of 
screening. 
 Sera screening would be repeated a minimum of three times (n=3) to 
account for the intra-assay variability. 
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 Lipid samples (e.g. GM1 and GalC) and HRP labelled secondary Ab would 
be sourced from the same commercial supplier and consist of the same 
batch, if possible. 
 The totality of the data would be analysed by one laboratory designated 
as the data coordination centre. 
These data, originating from the same set of samples, would allow a meta-
analysis where the only inter-assay variability would originate from 
methodological divergences. Identifying these divergences would allow the 
optimal conditions for GM1:GalC Ab testing to be determined and finally 
elucidate the real diagnostic value of these Abs in MMN. 
6.2 Antibodies to heterotrimeric glycolipid complexes in 
CIDP 
Chapter 5 introduced a new methodology for Ab screening. It combined the 
concepts of pattern recognition antibodies (Dam and Brewer 2010a;Dam and 
Brewer 2010b) and heterotrimeric lipid complexes. The results, from initial pilot 
studies, suggested Phre at a ratio of 1:10 (GSL:Phre w/w) as the ideal adjuvant 
molecule for Ab-GSL binding enhancement. A first crude analysis of the data 
proved a significant overall sensitivity improvement for complexes containing 
Phre (Chapter 5.4.2.1). 
ROC analysis ranked GD1b:GT1b:Phre and GD3:GT1b among the top diagnostic 
markers with an overall sensitivity ranging from 65% to 69% and the specificity 
from 85% to 87%. The use of both GSL epitopes as a composite disease marker 
increased the test’s sensitivity up to 78% with a marginal specificity decrease. In 
this case, the addition of two markers strengthened the sensitivity of the assay 
and indicated the beneficial effect of using multivariable array analysis in CIDP 
diagnosis. 
22% of all the CIDP patients showed an Ab binding enhancement with 
GM3:Sulph:Phre, 4% of which had complex specific Ab binding. Upon the 
inclusion of GM3:Sulph:Phre to the overall markers specified above, the test 
sensitivity was raised to 82.4% with an insignificant decrease in specificity. 
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60% of the CIDP patients positive for the addition of the three markers yielded 
mid to high Ab binding intensities (12709-79266 IU), the other 40% rendered low 
to mid intensities (900-5976 IU). 
In conclusion, the introduction of epitope complexity has helped unmask Ab 
reactivities previously undetected in neuropathy patients. This chapter first 
describes the diagnostic potential of a novel screening methodology based on a 
complex lipid landscape as Ab epitope. 
6.3 Final remarks 
Through the use of glycoarray, previously developed by Rinaldi and co-workers 
(Rinaldi, Brennan, & Willison 2012), this thesis has explored and extended the 
concept of complex glycolipid landscapes in the context of neuropathy 
associated antibodies. Using the well-established concept of anti-glycolipid 
complex antibodies, where the Ab binding intensity to a single glycolipid 
element is lower than the binding intensity to a complex of epitopes, we have 
demonstrated the presence and diagnostic relevance of highly cryptic antibodies 
in GBS, MMN and CIDP.  
Although no inference could be made between clinical phenotype and serological 
Ab profiling, the decay of Ab titres in convalescent GBS patients would suggest 
an Ab drive of the disease. In support of this notion several serological studies 
have associated severe weakness to high titres of anti-GM1 antibodies (Cats et 
al. 2010a) and the presence of severe disability with anti-GD1b:GT1b antibodies 
(Kusunoki and Kaida 2011). However, to date there is no direct evidence linking 
anti-glycolipid complex antibodies and the development of the disease.  
The origin and development of these neuropathy associated antibodies is far 
from clear. Several studies have suggested the role played by viral and bacterial 
infections in the development of GBS. Infections such as mycoplasma 
pneumoniae and campylobacter jejuni have been seen to precede cases of GBS 
(Yuki and Hartung 2012).  These infections induce an IgA Ab response against the 
bacterial lipo-oligosaccharides (LOSs) and due to a phenomenon known as 
molecular mimicry the Abs target gangliosides, present in nerve, due to their 
structural similarities with LOSs (Young et al. 2007). Recognition of membrane 
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structures by self Ab implies that a break in the immune tolerance needs to take 
place (Bowes et al. 2002). Research to date highlights the interaction of 
bacterial LOSs with toll like receptors, dendritic cell stimulation and subsequent 
B cell proliferation as the most plausible mechanism inducing an Ab response 
targeting sialic acid containing glycolipids (Geleijns et al. 2004;Huizinga et al. 
2012;Kuijf et al. 2010). 
If we accept post-infectious molecular mimicry as the causal factor for GBS and 
assume the involvement of complex antibodies in the development of the 
disease, there has to be an LOS structure mimicking ganglioside complexes. 
Addressing this paradigm, studies using sera with GM1:GD1a complex Abs were 
found to bind campylobacter jejuni preparations containing GM1-like and GD1a-
like LOSs (Kuijf et al. 2007). This finding suggested the presence of complex 
oligosaccharide structures mimicking ganglioside complexes, strengthening the 
notion of GBS as a post-infectious disease. However, it has yet to be 
demonstrated whether complex ganglioside structures, such as the ones 
described throughout this thesis, have an equivalent LOS mimic.   
This thesis has attempted to replicate a membrane-like environment, in a solid-
phase assay, in an endeavour to unmask self-antibodies. To date these complex 
Ab platforms had only been reproduced by the use of liposomes (Townson, 
Boffey, Nicholl, Veitch, Bundle, Zhang, Samain, Antoine, Bernardi, Arosio, 
Sonnino, Isaacs, & Willison 2007). Although liposomes are an efficient approach 
to generate membrane domains, they prove challenging to work with and 
extremely time costly. The use of combinatorial arrays, containing complex 
glycolipid platforms, has most definitely enhanced the exploratory nature of 
these assays. The relevance of combinatorial glycoarrays has proven important 
in diseases such as AIDP where self-Ab detection rates have traditional yielded 
very low sensitivity. A recent study, using complex epitopes immobilised on a 
combinatorial array platform, identified antibodies targeting complex glycolipids 
in more than 60% of AIDP cases (Rinaldi et al. 2013;Rinaldi 2013). These new Ab 
targets formed by gangliosides and the neutral lipids contained in myelin 
significantly increased Ab detection.  
In an attempt to shed light over the so called “antibody-negative” GBS and MMN 
cases, this thesis has demonstrated the diagnostic value of Abs to complex 
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glycolipid epitopes; Thus narrowing the gap between the association of clinical 
phenotypes and serological screenings. Further technique standardisation studies 
need to take place to fully understand the clinical application of combinatorial 
glycoarrays, however, we can now confirm the enormous potential that complex 
glycolipid platforms have in the context of self-Ab detection. 
6.4 In conclusion 
This thesis has attempted to explore the extent and relevance of Abs to complex 
GSL epitopes as diagnostic markers for PNS neuropathies. In the case of MMN, a 
great proportion of patients have been identified as bearing Abs to the novel 
target GM1:GalC, although several questions, such as the influence of GalC 
hydroxylation profile on complex formation and Ab binding, still remain 
unanswered, combinatorial array research has facilitated a substantial 
improvement in MMN diagnosis. This diagnostic improvement could eventually 
lead to a more refined treatment intervention. The ultimate goal of GM1:GalC 
testing is to become an internationally standardised highly robust diagnostic tool 
directly influencing treatment decision-making. 
Furthermore, the increase in array complexity has permitted identifying two 
classes of Abs to GSL: pattern recognition Abs and Abs to heterotrimeric lipid 
complexes. The construction of arrays containing a combined approach of 
molecular patterns and heterotrimeric epitopes has allowed us to substantially 
improve CIDP diagnosis. The combination of three different complex biomarkers 
led to significant Ab detection enhancement. 
As part of a larger effort to improve prognosis and treatment course, Abs against 
complex GSLs have been proven specific markers for differential diagnosis and 
have pushed forward the notion of PNS neuropathies as Ab driven diseases. 
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7 Appendices 
7.1 Buffers and solutions 
PBS 10X 
NaCl   80g 
KH2PO4  2g 
Na2HPO4.12H2O 29g 
KCl   2g 
 
Make up to 1000ml with dH2O. 
 
Dilute 1:10 to use. pH to 7.4. 
 
1% 2% 3% BSA 
Add 1g, 2g or 3g bovine serum albumin in 100ml PBS 
 
ELISA detection buffer 
14ml 0.1M Citrate (10.507g to 500ml dH2O) 
16ml 0.2M Na2HPO4 (14.196g to 500ml dH2O) 
30ml dH2O 
1x OPD tablet (Sigma) 
20µl H2O2 
 
ELISA stop solution  
4M H2SO4 (54ml to 500ml dH2O, perform in hood, add acid slowly to water) 
 
Binding Buffer  
A.0.2M NaH2PO4 2H2O (31.2g/L), pH 7.0 
B. 0.2M Na2HPO4 (28.39g/L) 
 
Elution buffer 
0.1M glycine-HCl pH 2.7 (3.75g glycine to 500ml dH20)  
Tris-HCl pH 9.0 (30.285g +250ml dH20) 
 
10% RPMI-FBS 
500ml RPMI with L-glutamine 
100ml / 50ml foetal bovine serum 
10ml penicillin / streptomycin solution
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7.2 Methodological development 
7.2.1 Fluorescent slides development 
In order to test the most suitable spray glue to be used for fluorescent staining, 
two different 3M models were used. Three independent studies were conducted, 
generating arrays containing a full panel of gangliosides plus secondary antibody 
control spots. These arrays were probed with an antibody-negative serum from a 
healthy control and the auto fluorescence of the glue was evaluated after the 
images were scanned. 
 
Figure 7.1. Arrays showing the differential auto fluorescent profile of two commercial 3M 
glues. 
Panel 1 represent three independent studies using 3M commercial glue A. Panel 2 represent three 
independent studies using 3M commercial glue B. 
The only methodological difference between the assays presented in panel 1 and 
panel 2 was the use of different commercial glue. As can be seen in Figure 7.1, 
3M commercial glue B presented a cleaner array surface due to the lower auto 
fluorescence background originating from the glue. The signal to noise ratio of 
3M commercial glue B was significantly higher (2-fold) than the ratio resulting 
from 3M commercial glue A.  
7.2.2 Fluorescence-ECL comparison 
The detection system employed on a serology study is going to influence to a 
great extent the interpretation of antibody binding enhancements and cis-
inhibitions. In glycoarray, the commonly used ECL detection system (Brennan, 
Galban-Horcajo, Rinaldi, O'Leary, Goodyear, Kalna, Arthur, Elliot, Barnett, 
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Linington, Bennett, Owens, & Willison 2011;Galban-Horcajo, Fitzpatrick, Hutton, 
Dunn, Kalna, Brennan, Rinaldi, Yu, Goodyear, & Willison 2013;Rinaldi, Brennan, 
Goodyear, O'Leary, Schiavo, Crocker, & Willison 2009) has as limiting factors the 
capacity of the photographic film to absorb light and the availability of substrate 
to enable the chemo luminescent reaction. Therefore the plateau of intensity 
saturation will be reached for reasons other than antibody binding affinity and 
avidity. In the case of detection by fluorescently labelled secondary antibodies 
the detection directly depends on reading antibody binding and sensitivity of the 
fluorescence signal. This detection method offers a greater linear dynamic range 
of variation on the upper scale of intensity, allowing discriminating between 
high intensity signals. 
 
Figure 7.2. Experimental outline of combinatorial arrays using Chemoluminescence or 
Fluorescence as detection systems. 
GA1 ganglioside is attached to the PVDF hydrophobic membrane. Primary antibody recognises the 
lipid. Secondary antibody HRP labelled or fluorescently labelled will then bound the primary 
antibody. In the case of fluorescent arrays, the array will be ready to be read after application of 
secondary antibody. For HRP arrays, slides will need to be incubated with ECL substrate to obtain 
a chemiluminescent reaction which will develop a radiographic film. 
Using inter and intra-assay variability calculations allows to illustrate how 
fluorescence detection presents a wider range of intensities, translated into a 
higher coefficient of variation in contrast to ECL detection.  
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A      B 
 
Figure 7.3. Fluorescence and ECL assay variability. 
Glycoarrays containing GM1 ganglioside spots probed using the same patient sera of known 
reactivity. A was probed using Alexa647 labelled anti-Human IgM antibodies and B was probed 
using HRP labelled anti-Human IgM antibodies detected using ECL. 
Table 7.1. Coefficient of variation (CV) for Fluorescence and ECL.  
 Fluorescence 
(AlexaFluor 647) 
 
ECL 
 
Intra-assay variability (%) 14.58 9.54 
Inter-assay variability (%) 12.81 9.98 
 
The only difference between the arrays in Figure 7.3 is the detection method 
employed; therefore the differences in assay variability between both arrays are 
due to the nature of the probe. As seen in Table 7.1, fluorescently labelled 
antibodies as detection probes present a significantly higher intra and inter-
assay variability. This difference comes to illustrate the wider spectrum of 
detection in the upper limit of the intensity scale presented by fluorescent 
probes in contrast to ECL dependent probes.  
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Figure 7.4 Detection methods employed in combinatorial glycoarrays.  
Secondary antibodies conjugated to either HRP, which catalyses the ‘ECL plus’ reaction, or 
fluorophore have both been employed to visualise antibody binding on combinatorial glycoarrays. 
In this example binding of the same N-Ab containing sera was quantitatively compared using either 
detection method. Heatmaps are scaled to the highest intensity value of an individual spot in any 
one array. Panel A ECL autoradiography is a very sensitive detection system; however it has a 
narrow linear dynamic range and thus does not easily facilitate comparative analysis, as 
demonstrated here by the saturation of intensity measurements of GA1 and its complexes (black 
boxes). Panel B. Fluorophore-labelled secondary antibodies for N-Ab detection accommodate 
multiplexed analysis (different antibody classes and subclasses can be assessed in a single 
assay), resulting in increased experimental throughput, with improved linearity during quantitative 
analysis. This is demonstrated here by the range of intensity measurements of GA1 and its 
complexes (white boxes). 
7.3 Publications 
Antibodies to GM1: galactocerebroside complexes in multifocal motor 
neuropathy: it takes two to tango. 
 
Willison HJ, Galban-Horcajo F, Halstead SK. 
 
Institute of Infection, Immunity and Inflammation, College of Medical, 
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Anti-GM2 ganglioside antibodies are a biomarker for acute canine 
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